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Abstract
Proteolysis inducing factor (PIF) is a pro-cachectic glycopeptide purified
from the urines of mice innoculated with the MAC 16 tumour and from the urines of
weight losing patients with pancreatic carcinoma. It arises from the dermcidin gene
which produces 2 other peptides, Y-P30, an unglycosylated neuronal survival factor
with homology to the PIF peptide core and DCD-1, an antibiotic peptide secreted by
eccrine sweat glands which has no homology with PIF. We sought to investigate PIF
/ dermcidin expression in cell lines and pancreatic carcinoma tissue, the role of
proteolysis inducing factor as a growth and survival factor in tumour cells and the
influence on these effects of the structural features known to be important to the
induction of cachexia by PIF and the functions ofY-P30 and dermcidin.
In vitro expression was assessed by PCR, Western blotting, in vitro
translation and immunocytochemistry. In vivo expression was assessed using laser
capture microdissection, PCR, real-time PCR, Western blotting, immunoprecipitation
and the analysis ofurine by mass spectrometry. Growth and survival functions were
assessed in the HuH7 cell line with immunocytochemistry and flow cytometry. Cells
were treated with a synthetic PIF peptide or stably transfected with PIF / dermcidin
expression vectors. Site-directed mutagenesis of these vectors was used to assess
glycosylation and the role of different sequences within the polypeptide.
Dermcidin was expressed by pancreatic carcinoma cell lines and primary
human hepatocytes but not by the HuH7 cell line. In HuH7 cells induced expression
promoted cell growth and improved survival following oxidative stress. The YP-30 /
PIF core peptide sequence was sufficient to induce cell growth. Survival promotion
did not require glycosylation but was prevented by mutagenesis of the asparagine
residues of the PIF core peptide. Analysis ofmRNA expression suggested dermcidin
was expressed in a low number of pancreatic carcinomas. Non-specific antibody
binding prompted the development ofmass spectrometry for detection ofPIF in
urine samples of patients with these tumours. This did not reveal PIF but did
demonstrate other proteomic changes.
We have demonstrated growth and survival functions ofPIF / dermcidin
which may be relevant in a range of physiological and pathological processes
including cachexia and neoplasia. The PIF core peptide sequence appears to be
important for these effects but its glycosylation does not appear to be required.
However, differential glycosylation may account for PIF's cachectic affects and the
difficulty in its immunological detection. Further investigation using techniques such
as mass spectrometry may cast further light on the structure ofPIF and its
relationship to disease processes.
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Summary
The work presented in this thesis explores the cellular functions of proteolysis
inducing factor (PIF) / dermcidin. The structural features ofPIF / dermcidin
suggested to be important for these functions have also been investigated.
The PIF molecule is a highly glycosylated, pro-cachectic polypeptide which
arises from the dermcidin gene. Dermcidin also produces Y-P30, an unglycosylated
neuronal survival peptide ofwhich the unglycosylated PIF core peptide forms a part
and DCD-1, a C-terminus peptide with antibiotic properties which does not overlap
with the sequence of the PIF core peptide. We examined the expression pattern of
PIF / dermcidin mRNA, its effects on cells known to respond to the cachectic effects
of glycosylated PIF and the regions of the PIF / dermcidin sequence which may be
important for these functions. We also attempted to relate these findings to the in
vivo situation by examining PIF / dermcidin expression in tumours resected from
patients with pancreatic carcinoma.
Several pancreatic carcinoma cell lines, a hepatic carcinoma cell line and
primary cultures of adult and fetal liver cells were screened for PIF / dermcidin
expression. Expression was observed in all of the pancreatic carcinoma cell lines but
not in the HuH7 hepatic carcinoma cell line (Chapter 3). The latter cell line was
therefore selected as a model in which to study the effects PIF / dermcidin
expression. This was achieved by the transfection ofHuH7 cells with the full-length
PIF / dermcidin cDNA in a mammalian overexpression vector (Chapter 4). PIF /
dermcidin produced from this vector contained a signal peptide and was targetted to
the secretory pathway in HuH7 cells. Site-directed mutagenesis of the expression
vector was employed to remove potential N-glycosylation sites, introduce premature
1
STOP codons and alter the domain predicted to be critical for PIF / dermcidin to
function as a phosphatase.
In order to study the effect ofPIF / dermcidin expression on survival
transfected cells were subjected to oxidative stress (Chapter 5). This resulted in cell
necrosis. Cells transfected with PIF / dermcidin exhibited improved survival in
comparison with untransfected cells. This was abrogated by mutation of both
potential N-glycosylation sites in combination but not individually. However, PIF /
dermcidin glycosylation was not demonstrable in these cells or using an in vitro
translation system. Both of the potentially glycosylated asparagine residues lie within
the phosphatase domain, raising the possibility that this may be of relevance to the
survival benefits.
The effect ofPIF / dermcidin on cell proliferation was explored. Transfected
cells were assayed for cell cycling by bromodeoxyuridine staining (Chapter 6). Cells
transfected with native PIF demonstrated a significant increase in cell proliferation
which was not inhibited by the introduction of a STOP codon 5' to the DCD-1
peptide sequence. In contrast with this, the use of a STOP codon to prevent
translation of the PIF core peptide prevented PIF / dermcidin -induced cell
proliferation. A similar effect was observed on mutation ofwhat analysis of
homologous phosphatases suggests is the most highly conserved residue in the PIF /
dermcidin phosphatase domain. These results were shown to be relevant at the
peptide level by the induction of proliferation by a synthetic peptide corresponding to
the PIF core peptide. Thus, PIF / dermcidin appears to have effects on both cell
proliferation and survival. Our results also suggest that the same peptide sequence
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may be responsible, raising the possibility that the same signalling mechanism may
exert both effects.
The survival and proliferation benefits ofPIF / dermcidin suggest that
expression may be of benefit to cells within the abnormal microenvironment of a
tumour. We aimed to investigate this by relating the production of urinary PIF,
believed to be a marker of cachexia, to the expression ofPIF / dermcidin in tumours
of the pancreas. Urine samples and tissue specimens were obtained from patients
undergoing surgery for pancreatic carcinoma. Unfortunately, we were unable to
detect urinary PIF by immunological methods and testing revealed non-specific
reactions of anti-PIF antibodies. We subsequently developed MALDI-TOF mass
spectrometry as an alternative means ofurinary analysis. This sensitive technique
was similarly unable to detect urinary PIF, but did demonstrate the presence of
MEKK-3 and APC-binding protein EB1, proteins not present in normal urine.
Further development of this technique may reveal important clues as to the
pathogenesis of pancreatic carcinoma and cachexia.
Our analysis of tumour PIF expression was similarly limited by the lack of a
reliable immunological method of detection. However, only one of the 19 tumour
samples demonstrated expression ofPIF / dermcidin mRNA. This is consistent with
the lack of urinary PIF on assessment by mass spectrometry and suggests that
expression may be of low frequency in these tumours. In contrast, all three of the
pancreatic carcinoma cell lines which we screened demonstrated PIF / dermcidin
expression. One explanation for this difference is that an influence of the in vitro
environment is capable of inducing PIF expression.
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PIF / dermcidin expression therefore appears to confer survival and
proliferation benefits on cells which may be relevant in a subset of pancreatic
carcinomas. It is feasible that these effects may result in the positive selection of
expressing cells, thereby contributing to the development of cachexia. In the liver,
these effects may render PIF / dermcidin relevant as a pre-conditioning agent.
The effects ofPIF / dermcidin may be mediated separately or in concert. In
favour of the latter, the phosphatase domain appears to be important in both survival
and proliferation. Future studies will aim to further investigate this mechanism and to
resolve the difficulties surrounding in vivo assessment ofPIF / dermcidin expression.
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1. Introduction
Proteolysis inducing factor / dcrmcidin
Identification of proteolysis inducing factor / dermcidin
Proteolysis inducing factor is a novel pro-cachectic glycopeptide which was
first definitively isolated by affinity chromatography of antigenic material from the
MAC 16 murine adenocarcinoma (Todorov et al. 1996a). This tumour was known to
induce cachexia via the secretion of circulatory catabolic factors (Bibby et al. 1987,
Beck and Tisdale 1987) and the monoclonal antibody used to purify PIF had been
developed by the fusion ofmyeloma cells with splenocytes from MAC 16-bearing
mice demonstrating delayed cachexia (McDevitt et al. 1995). PIF eluted as two
species of molecular mass 69kD and 24kD (Todorov et al. 1996a). On re-injection
into mice the 24kD species induced rapid weight loss which could be prevented by
prior administration of the monoclonal antibody (Todorov et al. 1996a). In vitro, the
24kD species was capable of inducing proteolysis in isolated gastrocnemius muscle
leading it to be termed 'proteolysis inducing factor' (PfF)(Todorov et al. 1996a). PIF
was subsequently identified in the urines ofweight-losing patients with carcinomas
of the pancreas, lung, ovary and breast, but not in non-weight losing patients with the
same tumours or in weight-losing patients with non-malignant disease (Todorov et
al. 1996a, Cariuk et al. 1997).
Amino acid sequencing of the 24kD species of PEF from the MAC 16 tumour
revealed a 20 amino acid N-terminus sequence. An identical 14 amino acid sequence
was obtained from 24kD PIF obtained from the urine of a weight-losing patient with
pancreatic carcinoma (Todorov et al. 1996a). The sequence showed no homology to
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any known cytokine or eukaryotic protein sequence, but 11 of the 13 N-terminus
amino acids did show homology with a streptococcal preabsorbing antigen involved
in the pathogenesis of post-streptococcal glomerulonephritis (Yoshizawa et al. 1992).
At this point it was not possible to identify PIF's parent gene using the available
techniques of Southern and Northern blotting due to the high degree of degeneracy of
the codons encoding the terminal seven amino acids.
Structure and homologues of proteolysis inducing factor / dermcidin
Structural analysis ofMAC16-derived PIF demonstrated the presence of
carbohydrate in the 24kD species, with N- and O-deglycosylation suggesting it
consisted of a short core peptide with one O-linked sulphated oligosaccharide of
molecular mass 6kD and one N-linked sulphated oligosaccharide of molecular mass
lOkD (figure 1.1) (Todorov et al. 1996a, Todorov et al. 1997). The molecular weight
of the core peptide was initially placed at 2kD in correspondence with the predicted
weight of the sequenced N-terminus peptide (1.9kD) (Todorov et al. 1996a).
However, more detailed structural analyses suggested it to be closer to 4kD (Todorov
et al. 1997, Todorov et al. 1999), suggesting a longer core peptide of approximately
30 amino acids. The deglycosylated peptides did not induce gastrocnemius muscle
proteolysis, suggesting that glycosylation is essential for PIF's pro-cachectic effects
(Todorov et al. 1997). Deglycosylation with peptide A-glycosidase F or O-
glycosidase also prevented detection ofPIF with the monoclonal antibody. Similar
results were obtained with human PIF purified from the melanoma cell line G361
(Todorov et al. 1999).
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Shortly before the latter study, in 1997 and 1998, two patents describing the
human cachexia associated protein (HCAP) gene encoding PIF and its putative
peptide products were published (Genbank accession number AR053250, US patent
5834192). However, it was with the identification ofPIF homologues that the cDNA
and genomic sequences first entered the literature. Initially, a 30 amino acid peptide
which showed a high degree of homology with the 20 sequenced amino acids of the
PIF core was purified from the media of oxidatively-stressed neuronal cells (figure
1.1) (Cunningham et al. 1998). This peptide was named Y-P30. The cDNA encoding
Y-P30 was subsequently identified in a search of the 'LifeSeq Gold' database of
Incyte genomics, the authors of the 1997 PIF patent (Cunningham et al. 2002). The
translated sequence of this cDNA (Genbank accession number AY044239) showed
alignment with 18 of the 20 residues of the murine PIF core peptide sequence and 29
of 30 residues ofY-P30. However, the first group to publish this cDNA sequence
had in fact independently identified it as a transcript differentially expressed by
melanomas and melanocytic naevi (Hipfel et al. 2000). The parental gene was named
dermcidin (DCD) following the discovery that it encoded a 47 amino acid peptide,
termed DCD-1, secreted by eccrine sweat glands (Schittek et al. 2001). Although
DCD-1 showed no homology to either PIF or Y-P30, translation ofDCD suggested
that they arose from the same transcript. The gene encoding DCD was mapped to
chromosome 12ql3 and consisted of 5 exons and 4 introns (Schittek et al. 2001).
7





Figure 1.1. Predicted peptide products ofPIF / dermcidin.
S - Potential O-glycosylation site
N - Potential N-glycosylation site
It is possible to construct a map of the nascent polypeptide by assimilating the
data on the sequences of the PIF, Y-P30 and DCD-1 peptides (figure 1.1). The
presence of an N-terminus signal peptide was first suggested on the discovery of
dermcidin (Schittek et al. 2001) but its production has yet to be confirmed
experimentally. Certainly, the sequence is that of a signal peptide which would be
expected to target the polypeptide to the secretory pathway
(http://www.cbs.dtu.dk/sevices/SignalP). It has been suggested that proteolytic
processing may account for the production of the other peptides, but this has also to
be confirmed and may potentially occur either intracellularly or extracellularly
(Schittek et al. 2001).
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Function of proteolysis inducing factor / dermcidin
Subsequent studies ofPIF, Y-P30 and DCD-1 have provided further insight
into the function of the dermcidin gene products. Following the initial discovery of
the proteolytic effects ofPIF on skeletal muscle (Todorov et al. 1996a, Todorov et al.
1996b, Todorov et al. 1997), an in vitro assay was developed using C2C12 murine
myoblast 3H-phenylalanine uptake and release to assay protein synthesis and
degradation (Smith et al. 1999). This confirmed a stimulatory effect ofPIF on
protein degradation and also an ability to inhibit protein synthesis. Interestingly, the
effect on degradation but not synthesis was inhibited by treatment with the
polyunsaturated fatty acid, eicosapentanoic acid (EPA), suggesting that these effects
are mediated by different mechanisms. It was subsequently demonstrated that
degradation involved expression of 20S proteasome subunits and downregulation of
IkB, which was attenuated by EPA (Whitehouse and Tisdale 2003) and potentially
mediated by phospholipase A2 and phospholipase C-induced arachidonic acid release
leading to mitosis activating protein kinase activation (Smith and Tisdale 2003).
The influence ofPIF on hepatic protein metabolism was investigated using
cultures of primary hepatocytes and the hepatoma cell line HepG2 (Watchorn et al.
2001). Flere, it was again found that PIF had in vitro effects consistent with a role as
a cachectic factor, activating the transcription factors NF-kB and STAT3 and
subsequently stimulating IL-8, IL-6 and CRP production and inhibiting transferrin
production. PIF was subsequently found to induce the expression ofNF-kB, IL-6, IL-
8, ICAM-1 and VCAM and the shedding of syndecans in the liver endothelial cell
line SK-HEP-1 and human umbilical vein endothelial cells but not in pulmonary
artery endothelial cells (Watchorn et al. 2002). These results confirmed the
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specificity ofPIF's effects, demonstrating differential effects on endothelial cell
subtypes. In addition, the roles of ICAM-1, VCAM and syndecans in development,
inflammation, tissue repair and host defence (Collins et al. 1995, Attar et al. 1999,
Park et al. 1999, Zimmermann and David 1999) suggested for the first time that the
glycosylated PIF peptide may have a role outwith the cachectic process.
Data on DCD-1 indicate that its primary function may be as an antibiotic
peptide. This was initially suggested by its size and location at the COOH terminus
of the protein, which are consistent with those of proteolytically-processed antibiotic
peptides (Bals 2000), and confirmed by the finding of a high degree of antimicrobial
activity against e. coli, s. aureus, e.faecalis and c. albicans (Schittek et al. 2001). Of
note, Y-P30 did not have any effect on the same organisms.
The first function ofY-P30 to be identified was that of a survival factor for
neuronal cells (Cunningham et al. 1998). Synthetic Y-P30 increased the survival of
neuronal cells on treatment with H2O2 in vitro and was capable of sustaining the
cortical neurons of rats following surgical injury in vivo (Cunningham et al. 1998). It
was suggested that the in vitro effect may be due to cation-dependent phosphatase
activity of the peptide, which contains a motif similar to the catalytic region of
calcineurin-type phosphatases and this was subsequently confirmed (Zhuo et al.
1994, Mertz et al. 1997, Cunningham et al. 2002). The protective effect ofY-P30
was also found to be associated with binding to calreticulin (Cunningham et al.
2000). Transfection of the full-length dermcidin cDNA (termed DSEP for diffusible
survival evasion peptide) into mouse and human neuronal cells resulted in increased
resistance to H2O2 and /ram-retinoic acid (Cunningham et al. 2002), and it is feasible
that this effect may be mediated via calreticulin given its ability to downregulate
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transcription of retinoic acid-responsive genes (Dedhar et al. 1994, Desai et al. 1996,
Shago et al. 1997). More recently, it has been suggested that the survival function of
Y-P30 may be important in its action as an oncogene in breast cancer (Porter et al.
2003). This hypothesis is based on the finding that DCD is overexpressed in -10% of
breast cancers and promotes the growth and survival of breast cancer cells in vitro.
However, these studies were based on the overexpression of the full length DCD
cDNA and the peptide responsible for oncogenesis has not been definitively
identified. The fact that synthetic Y-P30 peptide has survival benefits in neuronal
cells (Cunningham et al. 1998) supports its promotion of tumour cell survival, but
there is as yet no evidence to suggest it induces cell growth.
Recently, data has been published which raises important questions about the
role ofPIF in cancer cachexia. Using PCR and real-time PCR, Monitto et al (2004)
demonstrated DCD expression in a subset of breast tumours but not in the MAC 16
murine adenocarcinoma cell line or in human pancreas. Protein expression was also
not detected using an antibody raised to amino acids 44-62 of the polypeptide.
Furthermore, although a secreted protein was produced on transfection of several
murine and human cell lines with the full-length DCD cDNA in an overexpression
vector, no glycosylation was apparent. Xenografting of overexpressing tumours into
nude mice also did not result in cachexia. These results are consistent with the lack
of a consensus N-glycosylation sequence in the PIF sequence, although tumours are
known to demonstrate abnormal glycosylation patterns (Kannagi et al. 2004). The
glycosylation ofPIF may therefore be critical in determining its biological activity
although the mechanisms by which it is glycosylated remain unknown.
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Protein glycosylation
Glycosylation is the process by which glycoproteins are created through the
covalent addition of sugars to proteins. The majority of soluble and membrane-bound
proteins destined for the Golgi apparatus, lysosomes, cell membrane or extracellular
space are glycosylated.
Mechanisms of glycosylation
Glycosylation occurs both co- and post-translationally. Most proteins
synthesised in the rough endoplasmic reticulum (ER) are initially co-translationally
glycosylated by the addition of an N-linked oligosaccharide. This reaction is
catalyzed by oligosaccharyl transferase, a membrane bound ER enzyme with its
active site on the lumenal side of the ER membrane (Alberts et al. 2002a).
Oligosaccharyl transferase is specific and acts preferentially on asparagine residues
contained in the consensus sequence Asn-X-Ser / Thr, where X is any amino acid
other than proline (Lau et al. 1983, Welply et al. 1983). It has been proposed that the
importance of the Ser / Thr residues lies in their ability to act as donors in hydrogen
bond formation with oligosaccharyl transferase, a function which reduced cysteine
may also fulfill creating the atypical glycosylation site Asn-X-Cys (Sato et al. 2000,
Spiro 2002). As the asparagine residue of the nascent polypeptide chain enters the
ER, oligosaccharyl transferase adds a preformed precursor oligosaccharide consisting
ofN-acetylglucosamine, mannose and glucose and containing a total of 14 sugars
(Hubbard and Robbins 1980, Olden et al. 1980). Three glucose residues and one
mannose residue are then removed by glucosidase and mannosidase while the
glycoprotein remains in the rough ER (Bischoff and Kornfeld 1983, Esmon et al.
1984). If the protein is folded correctly at this stage, it is able to leave the ER. If,
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however, it is incompletely folded then ER glucosyl transferase is able to access the
remaining sugar moieties and add a single terminal glucose residue. This results in
the binding of the chaperones calnexin and calreticulin and the retention of the
protein in the ER (Kearse et al. 1994, Spiro et al. 1996). Co-translational
glycosylation therefore serves to prevent the export of incompletely folded
glycoproteins from the ER and provides the core carbohydrate for N-glycosylation.
Further glycosylation takes place post-translationally in the Golgi apparatus.
N-glycosylation
Modification ofN-linked oligosaccharide in the Golgi apparatus results in 2
broad classes ofN-linked carbohydrates, the complex oligosaccharides and the high-
mannose oligosaccharides (Alberts et al. 2002b). Complex oligosaccharides are
generated by a combination of trimming of the original oligosaccharide added in the
ER and the addition of further sugar residues. In contrast, high-mannose
oligosaccharides have no further sugars added and represent the remains of the
original N-linked oligosaccharide following trimming.
The addition of further sugars to complex oligosaccharides is catalyzed by a
group of enzymes known as the glycosyltransferases. Over one hundred
glycosyltransferases have been identified and the enzymes are classified according to
the type of sugar they transfer (eg. galactosyltransferases, sialyltransferases) (Beyer
et al. 1981, Sadler 1984). Although these enzymes otherwise share little homology,
they are anchored to the membrane of the Golgi apparatus by signal-anchor domains
which orientate their catalytic domains within the lumen (Wickner and Lodish 1985,
Paulson and Colley 1989). Cleavage of the signal anchor has been reported
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(Lammers and Jamieson 1989) and soluble forms of glycosyltransferases have been
purified from milk, serum and other body fluids (Beyer et al. 1981, Sadler 1984).
Glycosyltransferases may therefore also be active extracellularly, although their
primary site of action is the Golgi apparatus.
Whether a given oligosaccharide is processed to a complex or a high-
mannose oligosaccharide depends largely on its position in the protein. If it is
accessible to glycosyltransferases it is likely to be processed and if not, it is likely to
remain in the high-mannose form. The precise structure of the carbohydrate chain
synthesized is dependent on several factors, including protein conformation,
substrate availability and the expression of glycosyltransferases within the cell
(Smith and Baenziger 1988, Paulson and Colley 1989, Yarema and Bertozzi 2001).
Subsequently, N-glycosylation is often incomplete or variable, creating multiple
glycoforms of proteins.
O-glycosylation
O-glycosylation describes the process by which carbohydrate is added to the
hydroxyl groups of the serine or threonine residues of selected proteins. In common
with the extension ofN-linked oligosaccharide chains, this is catalyzed by a series of
glycosyltransferase enzymes (Clausen and Bennett 1996, Ten Hagen et al. 2001)
which are active in the cis-Golgi (Roth et al. 1994, Hirschberg et al. 1998). In
contrast with N-glycosylation however, no specific consensus sequence for O-
glycosylation has been identified and it has been suggested that this may be due to
the fact that multiple O-glycosyltransferases may act directly on the protein sequence
whereas a single oligosaccharyl transferase is involved in initial N-glycosylation in
the ER (Spiro 2002).
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The degree ofO-glycosylation may vary from just a few to 10 or more sugar
residues (Alberts et al. 2002b). Heavy O-glycosylation is observed in proteoglycan
core proteins (Ten Hagen et al. 2001), where carbohydrate side chains are made up
of repeating disaccharide units and which subsequently polymerise forming
glycosaminoglycans (Alberts et al. 2002b). Subcellular processing and secretion of
O-glycosylated proteins is similar to that ofN-glycosylated proteins, with many
proteoglycans targetted to the extracellular matrix or mucus secretions.
Biological importance of glycosylation
Functions of glycosylation
Glycosylation represents a mechanism by which proteins are modified by
non-genomic influences, specifically the glycosyltransferase and sugar milieu of the
cell. The glycoproteins expressed by a cell may therefore be said to reflect its
genomic, proteomic and metabolic status and as described above, a complex series of
pathways have evolved to synthesize oligosaccharide side-chains. Glycosylation
would subsequently be expected to fulfill important biological functions. However,
many of these functions remain uncharacterised.
N-linked oligosaccharides are found in all eukaryotes but not in prokaryotes
(Spiro 2002). This may reflect their role in ensuring correct protein folding and
suggests that they may fulfill functions relevant to higher organisms.
Due to the limited flexibility of carbohydrate side-chains, even a small
oligosaccharide protrudes from the surface of a protein and can limit the approach of
other molecules. For example, glycosylation may render a glycoprotein more
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resistant to protease digestion (van Berkel et al. 1995, Remacle et al. 2006) or
mediate interactions with other proteins. Selectins are a family of cell adhesion
molecules found on leukocytes which recognise and bind mammalian
oligosaccharides bearing fucose and sialic acid such as the sialyl Lex and sialyl LeA
antigens, which are located mainly on the surface of endothelial cells (Varki 1994).
Glycosylation is also important in interactions between extracellular proteins. Many
coagulation and fibrinolytic factors are glycosylated (Spiro 2002) and their
carbohydrate side-chains have been implicated in control of secretion, activity and
plasma clearance (Rudd et al. 1995, Millar and Brown 2006).
Interactions involving carbohydrate moieties may result in signal
transduction. For example, selectin-mediated cell adhesion stimulates leukocyte
involvement in thrombosis, inflammation and leukocyte trafficking (Varki 1994).
The degree of glycosylation has been demonstrated to directly influence signalling
from the receptor Notch. This transmembrane protein is O-glycosylated by the
addition of a single fucose to certain serine, threonine and hydroxylysine residues
(Moloney et al. 2000). In some cell types an N-acetylglucosamine residue is then
added by a separate glycosyltransferase, sensitizing the receptor to activating stimuli
(Bruckner et al. 2000). This glycosylation is important in temporally regulating
Notch signalling during development. Glycosylation is also important in modifying
the effects of cytokines. It has the potential to enhance or inhibit their
multimerisation, binding to other structures (including extracellular matrix molecules
and parasites) and active effects (Tanaka et al. 1993, Lucas et al. 1994, Opdenakker
et al. 1995). N-glycosylation has been demonstrated to decrease cytokine activity and
receptor binding (Cebon et al. 1990, Opdenakker et al. 1995). As noted above,
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glycosylation may be incomplete or variable, and this may result in cytokines
isoforms of differing activity competing for receptor binding (Opdenakker et al.
1995).
Glycosylation in disease
Altered glycosylation has been described in many disease states. In certain
rare genetic conditions primary defects in glycosylation exist and here it is clear that
the disease phenotype is secondary to altered glycosylation (Freeze and Westphal
2001, Schachter 2001). However, in inflammation and neoplasia it is not clear
whether altered glycosylation is a cause or effect of the disease process.
In inflammation, there is increased hepatic production of the acute phase
proteins al acid glycoprotein and al antitrypsin and a concomitant increase in
glycosyltransferase expression is observed (Kim et al. 1972, Lammers and Jamieson
1989). Hepatic glycosyltransferase expression has also been demonstrated to increase
in response to steroids (van et al. 1986, Wang et al. 1989) and it has been suggested
that subsequent changes in coagulation factor and complement glycosylation may
contribute to the inflammatory process.
In neoplasia, aberrant glycosylation has been reported in essentially all types
of experimental and human cancers and many glycosylated epitopes form tumour-
associated antigens (Hakomori 2002). Initially, this may result from oncogenic
transformation and a growing amount of evidence suggests that glycosylation may
subsequently influence tumour progression. Expression of the Neu3 sialidase has
been demonstrated to increase production of lactosylceramide, resulting in the
inhibition of apoptosis through increase Bcl-2 and decreased caspase expression
(Kakugawa et al. 2002). The ganglioside GM3 acts as a substrate in the formation of
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lactosylceramide and a decrease in its concentration may result in a decrease in GM3
- CD9 / CD82 complexes (Ono et al. 1999), which are antimetastatic in colorectal
and bladder cancer cell lines (Ono et al. 2001, Satoh et al. 2001). GM3 also inhibits
epidermal growth factor (EGF) receptor tyrosine kinase activity, and a decrease in
this action may also result in increased cell motility (Bremer et al. 1986).
Other glycosylation pathways contribute to tumour cell invasion and
metastasis. Increased N-linked oligosaccharide branching is commonly seen in
malignancy, enhanced by expression ofGnT-V and inhibited by GnT-III (Schachter
1986). GnT-V is upregulated by the oncogene family Ets (Kang et al. 1996,
Buckhaults et al. 1997), resulting in increased E-cadherin side-chain branching and
subsequently decreased cell to cell adhesion and a prometastatic effect (Yoshimura et
al. 1996). The sialyl Lex antigen has also been implicated in metastasis, with lung
adenocarcinoma cells expressing long-chain sialyl Lex showing higher metastatic
potential in nude mice (Inufusa et al. 1991). Colorectal cancer cell lines transfected
with long-chain sialyl Lex also show preferential adhesion to hepatocytes (Ota et al.
2000). Significantly, both sialyl Lexand sialyl LeA expression have been associated
with decreased postoperative survival (Nakamori et al. 1993, Kannagi 1997).
It is therefore clear that glycosylation ofPIF / dermcidin has the potential to
alter almost any aspect of its function. In particular, it may feasibly affect whether
PIF / dermcidin induces cachexia or functions as a growth or survival factor.
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Growth Factors
A tumour has been defined as 'an abnormal mass of tissue, the growth of
which exceeds and is uncoordinated with that of the normal tissues, and persists in
the same excessive manner after cessation of the stimuli which evoked the change'
(Willis 1934). This definition lead to the hypothesis that tumour cells are
autonomous in terms of exogenous growth control due to the autocrine action of
growth factors (Sporn and Roberts 1985, Weinberg 1985). The first autocrine growth
factor to be implicated in carcinogenesis was platelet-derived growth factor (PDGF).
The B-chain ofPDGF is encoded by the oncogene v-sis, the activation ofwhich
results in PDGF overproduction (Doolittle et al. 1983, Waterfield et al. 1983).
Growth factors may also result in tumour cell proliferation due to the overexpression
of cellular receptors, for example the EGF receptor encoded by the oncogene c-Erb
(Downward et al. 1984), or by excessive amplification of the signal induced by
receptor activation, for example by ras (Gilman 1984).
Through the activation of oncogenic pathways, growth factors may influence
many aspects of cancer biology. As noted above, K-ras has been implicated in
pancreatic cancer progression and chemoresistance (DiGiuseppe et al. 1994b, Ng et
al. 2000). Angiogenesis may be promoted by overproduction ofVEGF (Luo et al.
2001), which also acts as a tumour mitogen. Smad4 mutations may also prevent the
negative effect of TGF-P on tumour growth (Korc 1998).
It is therefore clear that growth factors have unique physiological functions in
addition to inducing tumour cell proliferation. Indeed, almost no molecule is solely
expressed by tumour cells but rather is likely to result in the selection of tumour cells
if its expression is beneficial, either through its primary physiological function or a
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secondary effect. Consistent with this diversity of function, a range of molecules
originally identified through their physiological functions have subsequently been
demonstrated to be growth factors for tumours. These include cytokines,
chemokines, hormones and extracellular matrix molecules. In pancreatic cancer, IL-8
has proliferative and pro-angiogenic effects (Shi et al. 1999), gastrin induces cell
growth and tumorigenesis (Harris et al. 2004) and fibronectin and collagen I and IV
increase proliferation and chemoresistance (Miyamoto et al. 2004).
As would be expected from this diversity of physiological functions, growth factors
show great structural diversity. Indeed, their only common features appear to be
those essential to their extracellular function and interaction with receptors, namely
the correct degree of hydrophobicity and having the necessary signal peptides to
target them to the secretory pathway.
As our knowledge of cancer biology has expanded, it has emerged that
carcinogenesis is influenced by abnormal control of cell death as well as abnormal
regulation of proliferation. Indeed, the proliferation of cells with genetic
abnormalities should perhaps prompt reconsideration of the definition of cancer




The influence of cell death on oncogenesis rose to prominence with the
finding that the product of the wild-type p53 antioncogene induces apoptosis whereas
the product ofmutant p53 does not (Yonish-Rouach et al. 1991). Other oncogenes
were subsequently found to promote cell survival, including ras, which acts via
mitosis activating protein kinase (Bonni et al. 1999, Scheid et al. 1999) and src,
which acts via the STAT family of transcription factors (Shen et al. 2001Wang et al.
2000, Shen et al. 2001). Consistent with their activation of these signalling pathways,
many growth factors have also been found to have pro-survival effects. For example,
PDGF and EGF have been shown to rescue cells from apoptosis through their action
on the ras pathway (Miyamoto and Fox 2000) and insulin-like growth factor
decreases the apoptosis of pancreatic carcinoma cells in response to radiotherapy and
chemotherapy (Min et al. 2003). The joint effects of these factors on growth and
survival may be mediated through the cell cycle. It is at cell cycle checkpoints that
apoptosis is triggered in cells with DNA abnormalities (Wu and Levine 1994, Nelson
and Kastan 1994). Failure of this process has been suggested to be a key event in
oncogenesis which may reflect either the actions of oncogenes, for example c-myc
(Wyllie 1993), or the survival effects of the growth factor milieu (Wyllie 2002).
In addition to protecting cells from intracellular stimuli of apoptosis, tumour
survival factors exist which protect cells from the insults of the hostile tumour
microenvironment. The immune response to cancer involves cell-mediated
cytotoxicity mediated by ligands of the TNF superfamily. Of these, TNF-a, FasL and
TRAIL are most frequently involved in apoptotic signalling (Ashkenazi and Dixit
1999). The actions of these molecules are mediated by a system of soluble and
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membrane bound receptors. These include the decoy receptors (DcR) 1 and 2, which
are membrane bound (Mongkolsapaya et al. 1998, gli-Esposti et al. 1997), and DcR3
and osteoprotegerin, which are secreted proteins (Pitti et al. 1998, Simonet et al.
1997). DcR3 has been demonstrated to block the apoptotic signalling of Fas ligand
and subsequently function as a survival factor in pancreatic, lung and colonic
carcinoma cells (Tsuji et al. 2003, Pitti et al. 1998).
Another stimulus of cell death to which cancer cells are exposed is oxidative
stress. Evidence from recent studies suggests that cancer cells are subject to
increased oxidative stress associated with oncogenic transformation, changes in
metabolism and increased generation of reactive oxygen intermediaries (ROIs)
(Toyokuni et al. 1995, Hileman et al. 2001, Kang and Hamasaki 2003, Behrend et al.
2003). The oncogenes c-myc and ras have been demonstrated to induce the
generation of reactive oxygen species (Vafa et al. 2002, Hlavata et al. 2003).
Mitochondrial metabolism is also altered in cancer cells in that the generation of
superoxide may be increased, although the mechanism of generation is unchanged
(Konstantinov et al. 1987).
The increased ROI production in cancer cells may result in cellular damage
including the promotion of mutations and genomic instability. This may result in cell
death. Several mechanisms have evolved to protect cells from this damage and there
is evidence to suggest that some of these may be altered in cancer. For example,
expression of the antioxidant enzymes superoxide dismutase and glutathiones-
transferase may be increased in tumour cells (Janssen et al. 1999, Kanbagli et al.
2000), although this may partly be a feedback response to the increased levels of
oxidative stress (Storey 1996) which are often inadequately controlled by these
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enzymes (Pelicano et al. 2004). Extracellular stimuli may also influence the cellular
response to oxidative stress and the use of such agents to pre-condition cells to
oxidative stress has been extensively studied in the field of organ transplantation.
Agents with protective, pre-conditioning effects include oxidative stress itself
('ischaemic preconditioning'), steroids and low levels of cytokines such as TNFa
(Chiappa et al. 2004, Teoh et al. 2004). These agents subsequently have the potential
to function as survival factors in neoplasia, in which they are known to be aberrantly
regulated (Aderka et al. 1991, Knapp et al. 1991, Pelicano et al. 2004). Finally, a low
level of oxidative stress has been recognised to transduce signals into cells via the
activation of tyrosine kinases including src and the subsequent stimulation ofMAP
kinases, phospholipase C-y and phophoinositol-3-kinase (Kamata and Hirata 1999,
Otani 2004). In tumour cells these mediators may stimulate cellular proliferation and
motility (Burdon 1995, Dorward et al. 1997, Schimmel and Bauer 2002, Behrend et
al. 2003). The abnormal oxidative stress and oncogenic signalling seen in
malignancy may subsequently influence the balance of redox signalling in favour of
survival and proliferation. Oxidative stress can also be seen to provide a link between
these two important processes of tumour progression. In addition, cells deprived of
growth factors or subjected to radiotherapy or chemotherapy are also subjected to
oxidative stress (Lieberthal et al. 1998, Pandey et al. 2003, Renschler 2004),
suggesting that cells able to survive under conditions of oxidative stress may also be
resistant to these agents
There are therefore several potential mechanisms by which Y-P30 may
improve the survival of tumour cells (Y79 retinoblastoma cells) subjected to
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oxidative stress (Cunningham et al. 1998). This may select for expressing cells and
raises the possibility that pre-existing PIF / DCD expression could predispose to
malignant progression, increased invasion, angiogenesis and an increased risk of
metastasis formation (Hockel and Vaupel 2001).
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Pancreatic cancer
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death
in the Western world, accounting for 2% of all cancers and 5% of all cancer deaths in
the United States and 2.3% of all cancers in Scotland (Jemal et al. 2004, ISD at
www.isdscotland.org). Its aggressive behaviour and anatomical site commonly result
in a late presentation, often when local invasion or distant metastasis have already
occurred. The disease is subsequently almost universally fatal (Greenlee et al. 2000)
with an overall 5 year survival rate of <5% (Kuvshinoff and Bryer 2000, ISD at
www. isdscotland.org).
In localized pancreatic cancer surgery offers the only hope of cure. However,
less than 20% of tumours are resectable by the time of diagnosis and even in patients
with resectable cancers the 5 year survival rate is less than 25% in the best centres
(Neoptolemos and Kerr 1995, Yeo et al. 1995). Indicators ofboth early disease and
metastasis have subsequently been studied in order that patients suitable for surgery
may be identified earlier and that those with incurable disease may be spared
unnecessary operations (Hruban et al. 2000b). Studies of intraductal lesions with cell
proliferation and atypia suggested that some of these lesions may progress to
infiltrating carcinomas and these lesions have been named pancreatic intraepithelial
neoplasia (PanIN) (Brat et al. 1998, Hruban et al. 1999). Several oncogenes have
been found to be activated in PanIN, including K-ras, HER-2/neu, pl6, p53, DPC4
and BRCA2 (DiGiuseppe et al. 1994b, Yamano et al. 2000, Day et al. 1996, Wilentz
et al. 2000, Wilentz et al. 1998, Moskaluk et al. 1997, DiGiuseppe et al. 1994a,
Goggins et al. 2000) which may have effects on tumour growth. A progression model
for the development of malignancy and invasiveness has subsequently been
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suggested (Hruban et al. 2000a). Although the relative difficulty of biopsying the
pancreas renders direct screening of lesions for abnormal expression of these genes
impractical, they may potentially prove useful as therapeutic targets or circulating
markers.
For the majority of patients with unresectable pancreatic cancer there remain
few treatment options. Trials ofmany radiotherapy and chemotherapy regimes as
primary treatments for pancreatic cancer showed little benefit and significant toxicity
(Thomas 1996, Schnall and Macdonald 1996). This resulted in the reservation of
these therapies for those patients who have already undergone surgical resection
(Neoptolemos and Kerr 1995). More recently however, gemcitabine has been
demonstrated to have a marginal survival benefit over conventional fluorouracil
chemotherapy (median survival 5.6 vs 4.4 months, 18% vs 2% 1 year survival)
(Burris, III et al. 1997). Nevertheless, the management of these patients remains
mainly palliative. The investigation of both the mechanisms of resistance to
chemotherapy and the decline in quality and length of life in patients with
irresectable pancreatic cancer therefore seems important.
Several mechanisms have been implicated in the resistance of pancreatic
cancer to chemotherapy. The majority of cytotoxic agents act by inducing apoptosis
in cells undergoing cycling or protein synthesis. It has subsequently been proposed
that those cancer cells resistant to chemotherapy have low rates of mitosis and
protein synthesis (Stein et al. 2004). A low expression of protein synthesis genes has
been demonstrated in pancreatic cancer and has been shown to correlate with poor 5
year survival (Stein et al. 2004). In contrast, the expression of cell adhesion,
cytoskeletal and ECM genes was found to be positively correlated with a poor 5 year
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survival (Stein et al. 2004). Expression of these genes may favour survival by
decreasing anoikis through strong interactions with the tumour stroma (Plath et al.
2000). Stromal cells have also been demonstrated to stimulate chemoresistance in
pancreatic tumour cells by producing nitric oxide leading to the activation of the NF-
kB pathway in tumour cells and subsequent IL-ip secretion (Muerkoster et al. 2004).
Upstream mediators in this pathway may include K-ras and AKT, which have also
been implicated in chemoresistance (Ng et al. 2000, Fahy et al. 2003, Fahy et al.
2004). Several other genes have also been implicated in pancreatic cancer
chemoresistance including p53, cyclin Dl, CEA-CAM 6, MDRI and src (Nio et al.
1998, Kornmann et al. 1998, Duxbury et al. 2004a, Lage and Dietel 2002, Duxbury
et al. 2004b).
It can therefore be seen that molecules affecting tumour growth and survival
appear to play an important role in pancreatic carcinogenesis and it is subsequently
feasible that PIF / dermcidin may contribute to this process. This is supported by
previous studies demonstrating that PIF appears to play a role in the development of
cachexia in pancreatic cancer (Todorov et al. 1996a, Wigmore et al. 2000). In
mediating cachexia PIF / dermcidin may act in concert with a range of other
mediators to stimulate complex metabolic changes which may, in turn, influence the
expression and function ofPIF / dermcidin.
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Cancer cachexia
Definition and importance of cachexia
The word 'cachexia' originates from the Greek words 'kakos', meaning bad,
and 'hexis', meaning condition. It has been defined as a clinical syndrome of
anorexia, early satiety, changes in taste perception, weight-loss, weakness, anaemia
and oedema (Fearon 1992). Cachexia is classically associated with certain types of
cancer, but may also be seen in other conditions including chronic heart failure,
chronic inflammatory diseases and infective conditions such as the acquired immune
deficiency syndrome (Anker and Sharma 2002, Kotler 2000, Rail and Roubenoff
2004). In cancer, it has been estimated that up to 80% ofpatients will develop
cachexia before death (Dewys et al. 1980). It is commonest in those with pancreatic
or gastric tumours, approximately one third ofwhom have substantial (>10%) weight
loss at the moment of diagnosis and is of higher frequency in patients with solid
tumours, with the exception of breast cancer and sarcomas (Dewys et al. 1980,
Bozzetti et al. 1982).
Duration of survival and quality of life are frequently drastically affected by
cachexia. It has been estimated that cachexia accounts for 22% of deaths in cancer
(Warren 1935). The rate of complications from surgery, radiotherapy and
chemotherapy are increased (Studley 1936, Engelman et al. 1999, Curtis et al. 1995,
Piquet et al. 2002, Dewys et al. 1980). Patients also suffer from the process itself,
with weakness, chronic nausea and anorexia all contributing to a decrease in the
quality of life in what may be a few short months until death (Stone et al. 2000,
Vigano et al. 2004). This inevitably instigates psychological distress in the patient




Patients with cancer cachexia frequently have a decreased nutritional intake
which may be due to a variety of factors. Some of these may be specific to the site of
the tumour, for example, gastrointestinal obstruction, nausea and constipation in
tumours of the gastrointestinal tract. In pancreatic cancer malabsorption may also
occur (Perez et al. 1983) as the tumour results in loss of pancreatic exocrine function.
However, even when these problems are adequately treated an adequate oral intake
may remain difficult to establish due to effects including changes in taste, poor
appetite and early satiety (Fearon 1992). These effects do not appear to be specific to
the site of the tumour, and may also be seen in many patients with inflammatory and
infective illnesses. As such, they may represent an influence of either the tumour
itself or the host response to disease on the drive to eat.
In simple starvation patients undergo a physiological response whereby
energy expenditure is reduced, protein is conserved and fat becomes the primary
energy source through the generation of fatty acids and ketone bodies (Grande et al.
1958, Leibel et al. 1995). It has been suggested that in cancer cachexia this response
is altered or absent, resulting in an increased energy expenditure and continued
protein loss (Brennan 1977). This may also affect the pattern of tissue loss observed
in cancer cachexia, in which visceral protein is conserved at the expense of muscle
protein (Heymsfield and McManus 1985, Fearon and Preston 1990).
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Many mediators contribute to both the metabolic response to starvation and
the drive to eat including hypothalamic control, inflammatory cytokines and the
leptin system. The potential roles of these mediators in cachexia are discussed below.
Hypermetabolism
Studies of resting energy expenditure in cancer patients have shown a
variation from less than 60% to more than 150% of predicted values (Bozzetti et al.
1980, MacFie et al. 1982, Knox et al. 1983, Dempsey et al. 1984, Hansell et al.
1986a, Hyltander et al. 1991, Fredrix et al. 1991). This may be influenced by tumour
type, as patients with cancers more frequently associated with cachexia (including
pancreas and lung) more commonly have an elevated resting energy expenditure
(Fredrix et al. 1991, Staal-van den Brekel AJ et al. 1994, Falconer et al. 1994) and
course of disease, as studies of carcinosarcoma-bearing rats have suggested that the
animals go through an initial hypermetabolic phase then become briefly
normometabolic prior to passing into a preterminal hypometabolic phase (Zylicz et
al. 1990). Unchecked hypermetabolism would inevitably deplete body reserves and it
has been suggested that there is a compensatory fall in physical activity, maintaining
a constant total energy expenditure in spite of the increase in resting energy
expenditure. This decrease in activity may be reflected in a reduction in the quality of
life as the disease progresses, until eventually decompensation occurs and tissue
depletion contributes to cachexia-related mortality. Clearly, it is likely that the
change from hypermetabolism to hypometabolism reflects the influence ofmore than
one process on the net metabolic rate.
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Substrate metabolism
The metabolism ofmany major nutrients including glucose, fat and protein
has been shown to be altered in cancer cachexia.
Many cachectic patients exhibit relative glucose intolerance and insulin
resistance (Rohdenburg et al. 1919, Waterhouse 1974, Holroyde et al. 1975,
Lundholm et al. 1978, Chlebowski et al. 1982, Holroyde et al. 1984, Eden et al.
1984, Shaw and Wolfe 1987, Copeland et al. 1987). This results in an increased rate
of glucose production and recycling via lactate which may have an energy cost of up
to 260kcal per day (Eden et al. 1984). The subsequent rise in plasma glucose
concentration may benefit solid tumours, which gain most of their energy from the
anaerobic metabolism of glucose (WARBURG 1956, Zu and Guppy 2004).
Certainly, alterations in glucose metabolism may become more pronounced with the
progress of the disease (Chlebowski et al. 1982, Shaw and Wolfe 1987).
The primary alteration in fat metabolism in cancer cachexia is an increase in
the fat oxidation rate (Hansell et al. 1986b). This results in a pronounced loss of
adipose tissue (Heymsfield and McManus 1985, Fearon and Preston 1990), which
appears to be due to a decrease in lipogenesis rather than an increase in lipolysis
(Jeevanandam et al. 1986). This has been ascribed partly to reduced levels of
lipoprotein lipase in weight-losing cancer patients (Vlassara et al. 1986). However,
new evidence is emerging to suggest that other factors, such as the lipid-mobilizing
factor, zinc alpha-2 glycoprotein (ZAG) may be involved (Russell et al. 2004, Bing
et al. 2004). Notably, ZAG induces lipolysis, and confirmation of its involvement in
human cachexia may prompt reassessment of the role of lipolysis in adipose tissue
loss.
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Protein metabolism is markedly affected in cancer cachexia. When compared
with starved normal individuals and weight-losing non-cancer patients, patients with
cancer cachexia have been shown to have an increased whole body protein turnover
(Carmichael et al. 1980, Jeevanandam et al. 1984, Fearon et al. 1988, Melville et al.
1990). The differences between these groups support the theory that either the
tumour itself or a host response to the cancer-bearing state may affect protein
metabolism, mirroring theories of anorexia induction (see above). In animal studies,
it has been suggested that tumour cells may use circulating albumin as a source of
albumin for growth (Stehle et al. 1997). In humans, the relative size of tumours is
much smaller and it is therefore less likely that their requirement for nutrients has a
large effect on whole body protein turnover. However, a quantitative effect on
protein catabolism does appear to exist, as turnover has been shown to increase with
the progression of disease (Carmichael et al. 1980). Alterations in host metabolism
include a change in the balance of liver export proteins with increased fibrinogen
synthesis rates (Fearon et al. 1998, Preston et al. 1998). Overall, the increase in
protein cycling has been estimated to have an energy cost of around lOOkcal per day
(Fearon et al. 1988). The net effect of this cycling is a urinary nitrogen loss and a
negative nitrogen balance (Argiles et al. 1999). In mice this is maximal at low levels
ofweight loss and halts at higher levels, consistent with the passage of rats through
hypermetabolic and normometabolic states prior to pre-terminal hypometabolism
(Beck and Tisdale 1989, Zylicz et al. 1990).
The different tissues of the body are affected by the increase in protein
turnover in a highly variable manner. In general, visceral protein is conserved
whereas skeletal muscle is commonly lost. This may result from either decreased
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protein synthesis or increased protein degradation. In humans, the former has been
demonstrated in cancer patients (Dworzak et al. 1998, Emery et al. 1984a). Animal
studies have suggested that this may be secondary to a decrease in RNA synthesis
(Emery et al. 1984b). In contrast, there is no direct evidence that protein breakdown
is involved in human cachexia, although this is difficult to measure in vivo. However,
in rat and mouse systems it has been suggested that the ATP-dependent ubiquitin-
proteasome pathway is involved in proteolysis (Llovera et al. 1994, Llovera et al.
1995, Baracos et al. 1995, Lecker et al. 1999, Lorite et al. 2001). The calcium
dependent and lysosomal pathways do not appear to be involved. On balance, it
seems likely that confirmatory in vivo studies will show a role for proteolysis in
human cachexia.
In the liver, export protein synthesis is deranged and in specific, there appears
to be a loss of feedback control. With regard to albumin, production remains
unchanged despite a drop in the circulating concentration of albumin (Fearon et al.
1998, Preston et al. 1998). In addition, as noted above fibrinogen synthesis increases
and this occurs in the presence of elevated plasma fibrinogen levels.
Inflammatory and acute phase protein responses
There is an increasing body of evidence to suggest that the induction of a
systemic inflammatory response plays an important role in cancer cachexia.
Leukocytosis has been associated with cachexia in human squamous cell carcinomas
(Kato et al. 1999, Yoneda et al. 1991) and may be induced by tumour necrosis factor
(TNF) and granulocyte-colony stimulating factor (G-CSF), cytokines common to
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both inflammation and cachexia (Kato et al. 1999, Tracey et al. 1988). The
subsequent increase in bone marrow activity will have an inevitable energy cost,
although the importance of this in cancer cachexia has yet to be investigated.
There is a substantial amount of data to implicate the acute phase protein
response in the pathogenesis of cachexia. The acute phase protein response
represents a change in the pattern of serum proteins synthesized by the liver and is
reflected in the changes in hepatic protein metabolism described above. It is
characterised by an increase in the serum concentrations of positive acute phase
proteins such as C-reactive protein and fibrinogen and a decrease in the
concentrations of negative acute phase proteins such as albumin. It has been
demonstrated to occur in a significant proportion of patients with pancreatic, lung,
renal and oesophageal tumours (Falconer et al. 1994, Staal-van den Brekel AJ et al.
1995, Blay et al. 1992, Wayman et al. 1997). Furthermore, an acute phase response
has been linked to weight loss in melanoma, lung cancer and pancreatic cancer
(Staal-van den Brekel AJ et al. 1995, Wigmore et al. 1997c, Scott et al. 1996, Flarvie
et al. 1998). In pancreatic cancer, the response has been shown to increase with
disease progression (Falconer et al. 1994) and this may be of clinical importance, as
it has also been shown to be associated with a decreased duration of survival
(Falconer et al. 1995). This is also the case in patients with renal and colorectal
tumours (Blay et al. 1992, Nielsen et al. 2000). In patients with gastrointestinal
tumours an acute phase protein response has been shown to be associated with a
reduced quality of life. The presence of an acute phase protein response in cancer
therefore seems to be closely linked to cachexia and has many of the same effects on
clinical outcome.
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Several effects of the acute phase protein response may stimulate cachexia.
Firstly, it contributes to the increased protein cycling of cachexia described above.
This may be compounded by the other mechanisms acting to induce cachexia. For
instance, anorexia will result in a decreased protein intake resulting in an increase in
muscle protein breakdown to provide amino acids for acute phase protein synthesis.
This in turn may be further exaggerated as there is an imbalance between the amino
acid composition of skeletal muscle and acute phase proteins (Reeds et al. 1994).
Secondly, the acute phase response may induce weight loss through effects of the
positive acute phase proteins as mediators of inflammation. CRP promotes monocyte
extravasation and activation both by increasing the expression of ICAM-1, VCAM
and E-selectin by endothelial cells and by a direct effect (Pasceri et al. 2000,
Mortensen et al. 1976). In doing so, it increases the production of IL-1, TNF and IL-
6, all ofwhich are mediators of cachexia (see below) (Ballou and Lozanski 1992).
Thirdly, the acute phase protein response may promote tumour growth and
progression. It has been suggested that the altered energy substrate metabolism
associated with the acute phase response may result in an increase in available
nutrients for tumour cells (Eden et al. 1984, Flolroyde et al. 1975). ICAM-1
expression by endothelial cells has also been shown to increase tumour cell
adherence, increasing the chance of successful metastasis (Burrows et al. 1991).
Increased tumour burden is associated with an increased cachectic response
(Falconer et al. 1995, Carmichael et al. 1980), which could potentially be mediated
via all of the mechanisms described above.
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Antitumour therapy
Many anticancer therapies have the unfortunate side-effect of contributing to
cachexia. Surgery, particularly on the gastrointestinal tract, may decrease oral intake
in the short term, stimulates the metabolic response to injury and has the potential to
result in complications with long term effects on gastrointestinal function, for
example adhesions or decreased bowel length resulting in the short bowel syndrome.
Chemotherapy also has well recognised anorexigenic and emetic effects and affects
the cells of the gastrointestinal tract resulting in the development of diarrhoea and
food intolerance (Osoba et al. 1994, Parnes et al. 1994). Radiotherapy has also been
demonstrated to cause weight loss (Munshi et al. 2003). These therapies can
therefore be seen to induce some of the mechanisms of cachexia described above.
The induction of common mediators may account for this effect.
Mediators of cachexia
In seeking to explain how the mechanisms of cachexia are induced several
theories have been developed. Initially, it was suggested that a tumour constitutes a
new, metabolically active organ and could therefore induce cachexia through its
metabolic demands. However, in contrast with animal tumours, human tumours are
proportionally small and the presence and severity of cachexia often correlates
poorly with their size. In addition, it cannot easily explain the complex effects on
appetite and substrate metabolism. It was therefore proposed that circulating
mediators may be partly responsible for cachexia. This theory was supported by
parabiotic studies in rats in which cachexia is induced in both the tumour-bearing
animal and the non-tumour bearing animal sharing its circulation. A wide variety of
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factors with an influence on the mechanisms of cachexia have subsequently been
identified.
Cytokines
Several pro-inflammatory cytokines, including tumour necrosis factor a
(TNFa), interleukin-1 (IL-1), interleukin-6 (IL-6), interferon y (IFNy) and ciliary
neurotrophic factor (CNTF) have been implicated in the development of cachexia.
These molecules show variation in the tumours they have been identified in, their in
vivo and in vitro mechanisms of action and in whether they are capable of inducing
cachexia on innoculation into experimental animals or require the presence of tumour
cells.
TNFa was the first cytokine identified as having a pro-cachectic effect and in
this capacity was originally termed 'cachectin' (Beutler et al. 1985a, Beutler et al.
1985b). Administration ofTNFa leads to weight loss, anorexia, increased levels of
glucagon and Cortisol, decreased levels of insulin and insulin resistance, protein and
fat breakdown and an acute phase protein response in animals and humans (Tracey et
al. 1988, Mahony and Tisdale 1988, Moldawer et al. 1988, Charters and Grimble
1989, Goodman 1991, Llovera et al. 1993, Llovera et al. 1997 (all animal refs),
Warren et al. 1987, Selby et al. 1987, Starnes, Jr. et al. 1988, Michie et al. 1988
(human refs)). Flowever, on repeated administration tolerance develops and food
intake and body weight return to normal (Socher et al. 1988a). It is also rare to detect
circulating TNFa in weight-losing patients with cancer (Socher et al. 1988b) and
while anti-TNFa antibodies have been shown to increase food intake in a rodent
model of cachexia (Gelin et al. 1991, Smith and Kluger 1993) they do not abrogate
weight loss. These findings suggest that TNFa has a more subtle effect than first
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thought. Circulating TNFa levels have been shown to exhibit circadian changes, with
increased levels being found in cancer patients at 3am (Muc-Wierzgon et al. 1996).
Soluble TNFa receptors may also influence the response to TNFa, which stimulates
soluble TNFa receptor release masking its own presence and resulting in a
correlation between circulating TNFa receptors and disease stage (Aderka et al.
1991). The effects ofTNFa may similarly be affected by the co-secretion of other
mediators, as transfection ofTNFa into Chinese hamster ovary (CHO) cells results in
the ability to induce cachexia on their implantation into nude mice (Oliff et al. 1987)
yet TNFa is incapable of inducing protein breakdown on in vitro incubation with rat
skeletal muscle (Goodman 1991).
Similar characteristics to those ofTNFa have been attributed to IFNy, which
also has pro-cachectic effects which may be blocked by anti-IFNy antibodies and
which may be induced by transfection into CHO cells and yet are not observed on
administration of IFNy alone (Matthys et al. 1991).
A more direct cachectic effect may be exerted by IL-6. Elevated levels of
circulating IL-6 have been shown to be associated with weight loss and an acute
phase protein response in pancreatic, lymphoma, lung and colorectal cancer patients
(Fearon et al. 1991, Kurzrock et al. 1993, Scott et al. 1996, Wigmore et al. 1997a).
Administration of IL-6 induces weight loss, increased energy expenditure and
increased Cortisol and glucagon concentrations in humans (Stouthard et al. 1996).
Furthermore, treatment with anti-IL6 antibodies has been shown to suppress cachexia
induced by a murine colonic adenocarcinoma (Strassmann et al. 1992). This may
potentially be mediated through the acute phase protein response, which IL-6 has
been demonstrated to induce (Morrone et al. 1988, Castell et al. 1990). However,
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different tumour cell clones producing similar amounts of IL-6 can produce widely
varying degrees ofweight loss (Soda et al. 1995), suggesting that IL-6 acts in
conjunction with other factors. Certainly, IL-6 is not able to induce proteolysis of rat
skeletal muscle directly (Garcia-Martinez et al. 1994). However, transfection studies
have demonstrated that tumour cells overexpressing IL-6 induce weight loss without
increasing IL-1 or TNF levels, suggesting that these are not the mediators involved
(Ohe et al. 1993). Indeed, the pro-cachectic effects of IL-1 may result from its
stimulation of IL-6 secretion (Okusawa et al. 1988, Moldawer et al. 1988, Hellerstein
et al. 1989, Ballmer et al. 1991, Yasumoto et al. 1995) and anti-IL-1 antibodies are
capable of reducing both IL-6 production and weight loss in tumour bearing animals
(Gelin et al. 1991, Oldenburg et al. 1993). IL-6 production and the acute phase
response are also attenuated by anti-IL-1 antibodies in an inflammatory model
(Gershenwald et al. 1990).
It is therefore apparent that cytokines work in combination and may require
the presence of tumour cells to induce cachexia. Other molecules which are produced
by or in response to tumour cells may also act as cofactors in the development of
cachexia.
Neurotransmitters
In common with other physiological processes, the regulation of food intake
is influenced by conscious, subconscious and autonomic input from the central
nervous system. Autonomic control is mediated by the hypothalamus, in which
neuropeptide Y functions as an appetite stimulating neurotransmitter and serotonin
and corticotrophin-releasing factor (CRF) function as appetite suppressants (Kalra et
al. 1991, Heinrichs et al. 1993). In cancer patients, increased levels of tryptophan, the
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precursor of serotonin, have been found and correlate with reduced food intake
(Cangiano et al. 1994). Dysregulation of hypothalamic appetite control in cancer is
also suggested by findings in tumour-bearing rats, in which decreased neuropeptide
Y and increased CRF levels have been found (Inui 1999). Receptor downregulation
may also play a role, as in a similar model, hypothalamic injection of neuropeptide Y
failed to stimulate the appetite of tumour-bearing rats (Chance et al. 1996). In
addition, as with the effects of cytokines neuropetidergic appetite control may be
influenced by the levels of other mediators, in particular the hormone leptin.
Hormones
Dysregulation of secretion of the stress hormones adrenaline, glucagon,
hydrocortisone and Cortisol may contribute to cancer cachexia. Administration of
these hormones produces features of cachexia including glucose intolerance, protein
loss, an acute phase protein response and energy expenditure (Bessey et al. 1984,
Watters et al. 1986). In humans with cancer associated weight loss increases in
Cortisol and glucagon levels have been demonstrated (Schaur et al. 1979, Burt et al.
1983, Knapp et al. 1991). In tumour-bearing animals, large differences in hormone
levels may also be observed, although the pattern of response appears to vary
depending on which cell line is implanted (Besedovsky et al. 1985). Cortisol and
glucagon may also modify the acute phase response (Baumann and Gauldie 1994).
The latter two characteristics echo those described above for IFNy and IL-6, which
may also influence Cortisol levels (Spath-Schwalbe et al. 1989, Steensberg et al.
2003).
Anabolic hormones may also be dysregulated in cancer cachexia. The
secretion of insulin in response to a rise in glucose has been shown to be decreased in
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a group of patients with colorectal cancer (Holroyde et al. 1984). In pancreatic cancer
insulin resistance has also been described, and appears to be due to an influence of
the tumour on normal pancreatic tissue production of islet amyloid polypeptide
(amylin) which reduces insulin sensitivity and glycogen synthesis (Schwarts et al.
1978, Gullo et al. 1993, Permert et al. 1994, Ding et al. 1998). In itself, amylin is also
capable of inducing anorexia and weight loss in rats (Arnelo et al. 1996). Insulin also
affects the acute phase protein response, stimulating albumin production and
decreasing fibrinogen synthesis (De et al. 1993). However, it has been suggested that
the anabolic effect of insulin on skeletal muscle is not affected in cancer (Newman et
al. 1991) and it is increasingly recognised that it is changes in the cortisokinsulin
ratio which may result in the catabolism of peripheral tissues (Fearon et al. 1998).
Other hormones may also play a role in cancer cachexia. For example, leptin
is produced by fat, suppresses appetite and increases energy expenditure (Zhang et
al. 1994). Leptin levels are elevated in some models of inflammation and may be
influenced by IL-ip and TNFa (Grunfeld et al. 1996, Sarraf et al. 1997, Zumbach et
al. 1997, Faggioni et al. 1998). However, studies have demonstrated that leptin levels
are altered in only some patients with cancer cachexia and it has been suggested that
levels are not abnormal in weight-losing patients with pancreatic cancer (Simons et
al. 1997, Brown et al. 2001, Dulger et al. 2004, Tessitore et al. 2004). This
evidence suggests that hormones such as this could potentially act as co-factors in the




Prostaglandins may be involved in cachexia both as humoural mediators and
in signal transduction (Strelkov et al. 1989, Tessitore et al. 1993, Smith and Tisdale
2003). Circulating levels of prostaglandin E2 and have been found to be elevated in a
rat model of cachexia and rat hepatoma cells have been demonstrated to induce
muscle protein loss by the production of this prostaglandin (Strelkov et al. 1989,
Tessitore et al. 1993). In signal transduction, prostaglandin generation appears to be a
major step in the initiation of skeletal muscle proteolysis (Thompson and Palmer
1998). Prostaglandins are also involved in the mediation of the effects of some pro-
cachectic cytokines such as TNFa and IL-1 (Okusawa et al. 1988, Hellerstein et al.
1989, Uehara et al. 1989, Rothwell 1992, Kozak et al. 1997). Inhibitors of
prostaglandin synthesis are capable of preventing the catabolic effect of serum from
mice with cancer cachexia (Smith and Tisdale 1993) and muscle proteolysis in
tumour-bearing rats (Strelkov et al. 1989).
Tumour-derived mediators
With the establishment of animal models of cancer cachexia it became
apparent that the serum of tumour-bearing animals was itself capable of inducing
cachexia in normal animals. The subsequent screening of sera for fractions with
cachectic activity lead to the isolation of cachexia-associated proteins which were
previously unidentified and which were therefore labelled as tumour-specific
cachectic mediators. These include lipid mobilizing factor (LMF) and proteolysis
inducing factor (PIF). Lipid mobilising factor was originally described in a murine
tumour model and has subsequently been found in the urine ofweight-losing cancer
patients (Hirai et al. 1997, Hirai et al. 1998). It is capable of inducing triglyceride
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hydrolysis in adipose tissue through a cyclic AMP-mediated process by interaction
with a (33-adrenoreceptor (Sanders and Tisdale 2004, Russell et al. 2004). Recently
however, production ofLMF has also been shown to take place in normal white
adipose tissue and to be upregulated by the presence of cachexia-inducing tumours in
mice (Bing et al. 2004). Furthermore, sequencing ofLMF showed it to be identical to
zinc a2 glycoprotein (ZAG). Interestingly, ZAG is known to have a role as an acute
phase protein.
As noted above, proteolysis inducing factor was also originally isolated from
a murine cachexia-inducing tumour and was subsequently identified in the urines of
weight losing patients with cancer but not weight losing patients with other
pathologies (Todorov et al. 1996a, Todorov et al. 1996b). Its production may
subsequently be a cause of the cachectic process, consistent with its induction of
muscle proteolysis and alterations in hepatic gene expression (Todorov et al. 1997,
Watchorn et al. 2001), a result of positive effects on tumour cell growth and survival
or the result of induction by another mediator of cachexia.
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Summary and aims
Proteolysis inducing factor is a unique molecule with defined in vitro
metabolic functions which are relevant to cancer cachexia. Its structure, expression
pattern and function as a growth and survival factor are less well characterised. A
more complete understanding of these features has the potential to increase our
understanding of tumour progression and survival and how these processes may be
linked with the development of cachexia.
The work presented in this thesis seeks to explore -
1. The in vitro and in vivo expression patterns of proteolysis inducing factor.
Specifically, the expression ofPIF mRNA by cell lines and pancreatic
carcinoma tissue and the relationship of expression to nutritional
status and survival (chapters 3, 7 and 8).
2. The role of proteolysis inducing factor as a growth and survival factor in
tumour cells.
In particular, the effects of in vitro PIF expression and synthetic PIF
peptides on cellular, immunological and molecular biological markers
of proliferation and apoptosis (chapters 5 and 6).
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3. The influence of the structural features ofPIF known to be involved in the
induction of cachexia and the importance of the PIF homologues Y-P30 and
dermcidin in the role ofPIF as a growth and survival factor.
In specific, the effect of removing potentially glycosylated amino
acids and preventing the production of specific peptide products on
the in vitro system used to assess the role ofPIF as a growth and
survival factor.
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2. Materials and methods
Cell culture
Cell lines
The HuH7, Mia PaCa2, CF-PAC and Panel cell lines were obtained from the
European Collection of Cell Cultures (ECACC, Porton Down, UK).
Culture technique
All cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM-
Gibco-BRL, Paisley, UK) supplemented with 10% fetal calf serum (FCS) (Gibco).
Medium was supplemented with 50 units/ml penicillin, 50pg/ml streptomycin and
2mmol glutamine (all from Gibco). Cells were grown in 25cm2 or 75cm2 flasks
(Corning BV, Schipol-Rijk, the Netherlands).
For passage or use in experiments, cells were harvested from flasks by
removal of all medium and incubation with 1ml of 0.25% trypsin / 0.02% EDTA
(Gibco) per cm2 for 30 seconds. On detachment cells were re-suspended in 10ml of
medium, transferred to a fresh universal and pelleted by centrifugation at 1200g for 5
minutes prior to resuspension in 1ml of medium.
Viable cells were counted using the trypan blue exclusion method. 20pl cell
suspension was added to 20pl trypan blue and 20pl of the resultant mix used to fill
both sides of a multiwell counting chamber. Cells were then counted under the light
microscope.
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For standard passage cells were seeded at a concentration of 1.33xl05/ml in
15ml medium (75cm2 flasks) or 5ml medium (25cm2 flasks). For use in experiments
cells were seeded at the concentrations described in the individual chapters below.
Transfection
The HuH7 cell line was transfected with PIF and PIF mutants in the
mammalian expression vector pcDNA3.1+ using FuGENE-6 (Roche applied science,
Lewes, UK). Prior to transfection the optimum concentration of the selective
antibiotic, Geneticin (Invitrogen, Paisley, UK) was determined. This was performed
by seeding lxlO5 cells per well in 6 well plates and incubating overnight prior to the
addition of 0, 200, 400, 600, 800 or lOOOpg/ml Geneticin. Following approximately
1 week in culture, wells containing 600pg/ml or more showed 100% cell death.
Wells containing 400pg/ml or less contained some surviving cells. The optimum
concentration was taken as the minimum required to kill 100% of cells, ie. 600pg/ml.
For transfection experiments, lxl05 cells per well were seeded in 6 well
plates and incubated overnight. Transfection complexes were then prepared in 0.5ml
microcentrifuge tubes by the dilution of 3pl FuGENE-6 in lOOpl serum-free DMEM
and the addition of 2pg plasmid DNA. The complexes were mixed gently and
incubated for 45 minutes at room temperature. They were then added dropwise to the
cells seeded in 6 well plates. Cells were incubated overnight at 37°C prior to the
addition of 600pg/ml Geneticin. From this point all culture media was supplemented
with 600pg/ml Geneticin. Following 1 week in culture all wells contained only a few
surviving cells. At 2 weeks these had begun to expand into colonies. Cells were then
split into 25cm2 flasks and gown until -90% confluent. Standard culture and passage
techniques were then used.
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Liquid nitrogen storage
For long term storage, aliquots of cells were stored in liquid nitrogen.
Following washing and counting, ~5xl 06 cells were pelleted and resuspended in
sterile dimethylsulfoxide (Sigma) plus 10% FCS. Samples were labelled and frozen
overnight at -70°C prior to transfer to liquid nitrogen. To re-establish culture,
samples were thawed under running warm water then transferred into a universal
using a pastette. 10ml ofDMEM plus 10%FCS was then added slowly, trickling the
medium down the side of the universal. A further 10ml medium was added rapidly.
Cells were pelleted and all medium removed prior to resuspension in 5ml medium
and seeding in a 25cm2 flask.
Induction of oxidative stress
In selected experiments HuH7 cells were subjected to oxidative stress by use
of the enzyme glucose oxidase (Sigma, Dorset, UK). Cells were seeded at the desired
concentration and allowed to settle overnight. Glucose oxidase was then added to the
culture medium directly. Initial experiments were performed to optimize the
concentration and duration of exposure. These suggested that a 2 hour exposure to
75mU/ml glucose oxidase was sufficient to kill approximately 50% of cells. This
level of death facilitates the investigation of treatments which either increase or
decrease cell death and this exposure was therefore adopted as the standard
treatment. Following treatment culture medium was removed and cells were
recovered for 4 hour in normal medium prior to analysis.
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Synthetic PIF peptide treatment
In selected experiments cell were treated with a synthetic PIF peptide
(Albachem) custom synthesised to contain the 30 amino acids of the PIF core. The
peptide had the sequence YDPEAASAPGSGNPCHEASAAQKENAGEDP and was
of greater than 95% purity. Stock peptide was made up at a concentration of





RNA from cultured cells was prepared according to the Trizol method (Life
Technologies, Paisley, UK). Certified RNAse-free pipette tips and microcentrifuge
tubes were used at all times. Culture medium was aspirated from adherent cells
(HuH7, Mia PaCa2, CF-PAC and Panel cell lines) and cells lysed directly by the
addition of 1ml Trizol reagent per cm2 of culture flask area and lifting with a cell
scraper. 1.25ml aliquots of each sample were then transferred to 1.5ml
microcentrifuge tubes and incubated for 5 minutes at 21°C. Phase separation was
then carried out by addition of 0.2ml chloroform per 1ml Trizol (ie. 0.25ml per
1.25ml aliquot of sample), vigorous shaking for 15 seconds to mix and centrifugation
at 12000g for 15 minutes at 4°C. The aqueous phase was transferred to a fresh
microcentrifuge tube. RNA was then precipitated by incubation of supernatants for
49
10 minutes at 21°C with 0.5ml isopropanol per 1ml Trizol used followed by
centrifugation at 12000g for 10 minutes at 4°C. Supernatant was removed from the
resultant RNA pellets which were then washed in 1ml of 75% ethanol (Sigma) per
1ml Trizol used by brief vortexing and centrifugation at 7500G for 5 minutes at 4°C.
The ethanol was removed and the RNA pellet dissolved in 50pl ofRNAse-free water
(Promega). Samples which had been aliquoted into separate microcentrifuge tubes
following Trizol treatment were reunited by sequential suspension in the same 50pl
ofwater. RNA was dissolved by incubation for 10 minutes at 55°C.
Paraffin block RNA isolation protocol
RNA was prepared from laser-capture microdissection (LCMD) samples with
a Paraffin-block RNA isolation kit (Ambion, Huntingdon, UK) using a modification
of the manufacturer's protocol. Laser capture microdissection caps with adherent
cells were placed on 0.5ml RNAse-free microcentrifuge tubes containing lOOpl
proteinase K digestion buffer and 5pi proteinase K. The tubes were then inverted and
incubated in a hybridisation oven for 90 minutes at 45°C with regular vortexing.
Samples were then transferred to 1.5ml RNAse-free microcentrifuge tubes and 600pl
RNA extraction buffer was added to each. Tubes were then vortexed 5 times for 5
seconds each time and incubated at room temperature for 5 minutes. 700gl acid
phenol:chloroform was added to each tube and samples were again vortexed 5 times
for 5 seconds each time. Tubes were then spun at 13 OOOrpm for 5 minutes at room
temperature and the aqueous upper phase transferred to a fresh microcentrifuge tube.
Glycogen was then added to a final concentration of250pg/ml and RNA was
precipitated with 1 volume of isopropanol. Samples were mixed thoroughly and
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incubated at -20°C for at least 30 minutes (usually overnight) then spun at 13 OOOrpm
for 15 minutes at 4°C. Supernatant was carefully decanted from the resultant RNA /
glycogen pellet which was then washed by the addition of 500pl 75% ethanol,
vortexing briefly and spinning at 13 OOOrpm for 5 minutes at 4°C. Ethanol was then
carefully pipetted off and pellets air dried then resuspended in lOpl nuclease-free
water (Promega). RNA samples not immediately used in experiments were stored at -
70°C.
RNEasy RNA preparation protocol
RNA was prepared from frozen tissue samples using rotor-stator
homogenisation and an RNEasy Mini kit (Qiagen, Crawley, UK) according to the
manufacturer's instructions. Tissue samples of approximately 3mm3 (30-35mg) were
cut from frozen specimens of frozen normal and malignant pancreatic tissue which
had been mounted in OCT (see below). Samples were immediately placed in 600pl
buffer RLT in 5ml bijous and homogenised with a rotor-stator for 30 seconds at full
speed or until completely homogenised. Samples were then transferred to RNAse-
free 1.5ml microcentrifuge tubes and centrifuged for 3 minutes at 13 OOOrpm.
Supernatants were transferred into fresh 1.5ml microcentrifuge tubes and 1 volume
(600pl) of 70% ethanol was added and mixed by pipetting. 700gl of sample was then
applied to an RNEasy mini column placed in a 2ml collection tube and centrifuged
for 15 seconds at 8 OOOg. Flow-through was discarded. RNA was then subjected to
either on-column DNAse digestion (see below) or an additional wash by the
application of 700pl buffer RW1 and centrifugation for 15 seconds at 8 OOOg. Flow
through was discarded and the columns transferred to new collection tubes. 500pl
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buffer RPE was then added, columns centrifiiged for 15 seconds at 8 OOOg and flow
through again discarded. This step was repeated once and tubes were then spun again
for 1 minute at 13 OOOrpm to eliminate any possible buffer RPE carryover. Columns
were then transferred to fresh RNAse-free 1.5ml microcentrifuge tubes and RNA
eluted by the application of 30pl RNAse-free water and centrifugation for 1 minute
at 8 OOOg. To increase RNA concentration, the eluate was re-applied to the column
and the final centrifugation step repeated.
DNAse I treatment
Treatment ofRNA in solution
RNA in RNAse-free water prepared using the Trizol method or the paraffin
block RNA isolation kit was DNAse I treated using RQ1 DNAse (Promega)
according to the manufacturer's instructions. lOpl reactions were set up containing
8pl RNA, lpl RQ1 DNAse buffer and lpl RQ1 DNAse. These samples were then
incubated for 30 minutes at 37°C. lpl stop solution was then added and samples
incubated for 10 minutes at 65°C.
On-column digestion of RNEasy-prepared RNA
RNA prepared using the RNEasy Mini kit was DNAse I treated using an on-
column RNAse-free DNAse set (Qiagen) according to the manufacturer's
instructions. Following application ofRNA samples to RNEasy mini columns (see
above), 350pl buffer RW1 was pipetted onto the columns and samples centrifuged
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for 15 seconds at 8 OOOg. Flow through was discarded. lOpl ofDNAse I stock
solution was then diluted in 70pl buffer RDD and applied to each column for 15
minutes at room temperature. 350pl buffer RW1 was then added and columns were
centrifuged for 15 seconds at 8 OOOg. Flow through was discarded and the RNEasy
RNA preparation protocol was continued as described above.
Assessment of RNA quality
Spectrophotometry
The concentration ofRNA samples was assessed by spectrophotometry using
a Thermo spectronic Biomate 5 spectrophotometer (Thermo electron corporation,
West Palm Beach, FL, USA) and Vision 32 VI.25 analysis software, lpl of sample
was diluted 1 in 50 in distilled water. 50gl of distilled water only was used to blank
the spectrophotometer. RNA concentration was calculated from the ratio of
absorbance at 260nm to absorbance at 280nm.
Agilent capillary electrophoresis
For use in real-time PCR experiments, RNA quality was assessed using an
Agilent 2100 Bioanalyzer (Agilent technologies, South Queensferry, UK) with either
an RNA 6000 Nano or Pico LabChip Kits according to the manufacturer's
instructions. All reagents were stored at 4°C and equilibrated to room temperature
for 30 minutes prior to use. For Nano chips, gel was first prepared by centrifugation
of 550pl RNA 6000 Nano gel matrix in a spin filter for 10 minutes at 1 500g. 65pl
aliquots of gel were then placed in 0.5ml microcentrifuge tubes and used within 4
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weeks. The gel-dye mix was prepared by vortexing the Nano dye concentrate for 10
seconds, centrifuging briefly and then adding lpl of dye concentrate to a 65 pi aliquot
of gel. This mix was then vortexed, centrifuged at 13 OOOg for 10 minutes at room
temperature and pipetted as indicated into a new RNA chip held in the chip priming
station. The station was then closed and the plunger depressed until it was held by
the clip. After 30 seconds, the clip was removed and a further 9pl of gel-dye mix
pipetted into the indicated wells. 5pl ofRNA 6000 marker was then added to the
ladder well and all sample wells, lpl ofRNA 6000 ladder was added to the ladder
well. 1 pi of sample was then added to each sample well and the chip was vortexed
for 1 minute at 2400rpm prior to analysis on the bioanalyzer.
For Pico chips, the gel matrix and gel-dye mix were prepared using RNA
6000 Pico gel matrix and dye concentrate and loaded into the RNA 6000 Pico chip as
described above for Nano chips. 9pl ofRNA 6000 Pico conditioning solution was
then pipetted into the well marked CS and 5 pi ofRNA 6000 Pico marker pipetted
into all sample wells and the ladder well, lpl of ladder solution was then added to the
ladder well and 1 pi of sample added to each sample well. The chip was then
vortexed for 1 minute at 2400rpm and analyzed on the bioanalyzer
Exclusion of genomic DNA contamination
Following DNAse I treatment, samples were screened for remaining genomic
DNA by PCR for the housekeeping gene, cytochrome B. Standard 25pi reactions
containing 1 pi DNAse-treated RNA were made up as described below. All samples
were cycled as described for 35 cycles with an annealing temperature of 56°C.
Positive and negative controls of purified genomic DNA and nuclease-free water
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were used in every case. Samples were run on 1.4% agarose gels, stained with
ethidium bromide and visualized under UV illumination.
Reverse transcription
Reverse transcription was performed using AMV reverse transcriptase
(Promega) according to the manufacturer's instructions. A reaction mixture sufficient
to provide 20.5|_tl per RNA sample was prepared. This consisted of 8|ol 25mM
MgCh, 4pl reverse transcription lOx buffer, 4pl dNTP mixture, 2|ol oligo(dT)i5
primer, 1.5p.l AMV reverse transcriptase (high concentration) and lp.1 recombinant
RNasin ribonuclease inhibitor. 20pi of this mix was then added to 20ptl of sample
RNA and mixed by centrifugation. Samples were then incubated in a thermal cycler
(PHC-3, Techne) for 1 hour at 42°C followed by 5 minutes at 99°C.
Polymerase chain reaction
Reaction constituents
Polymerase chain reaction (PCR) was performed using a modification of the
Promega PCR amplification protocol. A reaction mixture was prepared containing
0.75(0.1 25mM MgCh, 2.5(0.1 taq poly lOx buffer and 2.5pl dNTPs (all from Promega)
per sample. This mixture was then aliquoted into thin-walled 0.75ml PCR
microcentrifuge tubes at a volume of 5.75(0.1 per tube. 2.5(0.1 of both forward and
reverse primer solutions at a concentration of lOmM were then added to each tube
followed by lpl of target cDNA. Positive and negative controls for the gene of
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interest, consisting of purified cDNA or plasmid and nuclease-free water
respectively, were used in every case. Finally, lpl oftaq polymerase diluted 1 in 5 in
nuclease-free water was added to each tube and the total volume made up to 25pl
with nuclease-free water. Samples were mixed by centrifugation at 4000rpm for 10
seconds.
Thermal cycling
Samples were run on a thermal cycler (PHC-3, Techne). For most primers a
standard program was used. This consisted of 94°C for 5 minutes, 72°C for 5
minutes then 35 cycles of 94°C for 20 seconds, 55°C for 20 seconds followed by
72°C for 30 seconds.
Agarose gel electrophoresis
Following thermal cycling 15pl of each sample was run on an agarose gel.
Gels were prepared by adding 1.4g of electrophoresis-grade agarose (Seakem
agarose, Flowgen, Ashby de la Zouch, UK) in 100ml lxTAE buffer and dissolving
by microwaving for two 30 second bursts. Gels were cooled to below 65°C and 5pi
ethidium bromide (Sigma) added prior to pouring into levelled gel reservoirs and the
insertion of 10 or 20 well combs. One sample of 5 pi of molecular weight marker was
run on every gel. lpl loading dye (Promega) was added to samples and markers and
mixed by centrifugation at 13 OOOrpm for 30 seconds. Combs were removed and gels
submersed in IxTAE buffer. Samples were then pipetted into the wells of the gel and
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run at 70V for 45 minutes, or until the dye front neared the end of the gel. Gels were
removed from gel tanks and visualized under UV illumination.
Real-time PCR
Real-time PCR was performed using an ABI Prism thermal cycler (Applied
Biosystems, Warrington, UK) according to the manufacturer's instructions. DNAse
treated RNA samples were assessed for quality and reverse transcribed as described
above. 25pl real-time PCR reactions were then set up containing 12.5pl master mix,
1,25pl anti-18S ribosomal RNA primer-probe mix, 7pl anti-PIF primer-probe mix
(90pl forward primer, 90pl reverse primer, 300pl TAMRA probe and 1520pl
nuclease-free water in 2ml)(table)(all from Applied Biosystems), 1.75pl nuclease-
free water (Promega) and 2.5pi of sample cDNA. All samples were run in duplicate
and positive (MiaPaCa2 cDNA) and negative (nuclease-free water) controls were run
on each plate. Samples were then pipetted into the wells of a 96-well real-time PCR
plate (Applied Biosystems) and the wells sealed with the supplied strips of caps. The
plate was centrifuged at 500rpm for 5 minutes then inserted into the thermal cycler.
VIC was selected as internal standard, FAM as unknown and sample volume as 25 pi.
Plates were then run on a standard 40 cycle program. Results were analysed by
calculating the ratio ofmean cycle count value for PIF positivity to the mean cycle
count for 18S positivity for each sample and comparing this with the ratio calculated
for the positive control. Samples requiring more than 23 cycles before threshold for
VIC positivity was reached or more than 36 cycles before threshold for FAM
positivity was reached were discarded.
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Protein purification
Preparation of cell lysates
For preparation of protein lysates, cells were seeded in 25cm2 flasks and
grown to 90% confluency prior to protein preparation using radio-
immunoprecipitation assay (RIPA) buffer (lxPBS, 1% Nonidet P-40 (BDH
Chemicals, Poole, UK), 0.5% sodium deoxycholate and 0.1% SDS). One protease
inhibitor tablet (Roche) was added to each 10ml ofRIPA prior to use. Medium was
removed and cells washed with sterile PBS. 500pl RIPA buffer was then added to
each well and cells scraped thoroughly from the flask bottom. Lysates were then
transferred to 1,5ml microcentrifuge tubes and passed several times through a 21G
needle. Tubes were then centrifuged at 10 OOOg for 10 minutes at 4°C. The resultant
protein supernatant was transferred to a fresh microcentrifuge tube for protein assay
and pellets were discarded.
Protein assay
Protein assays were performed according to the method ofLowry (1951)
using a Dc protein quantification kit (Biorad). AJ reagent was first prepared by the
addition of 5pi solution S to 3ml solution A and dissolving by incubation at 37°C.
All samples were prepared and assayed in a 96-well plate. A standard curve was
prepared by performing 4 serial 1 in 2 dilutions of 20pl of the 1.45mg/ml protein
standard supplied in 20pl RIPA buffer. Samples were diluted 1 in 5 by the addition
of 4pl sample to 16pl RIPA buffer. 5pl per well of standards and samples was then
pipetted into the assay wells of the 96-well plate in triplicate. 25 pi AJ and 200pl
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reagent B were then added to each well and plates were shaken for 15 minutes at
room temperature. Protein concentrations were determined from absorbance at 750
nm using a Dynex Technologies MRX-II plate reader and Assayzap interpretation
software.
Western blotting
NuPAGE gel electrophoresis and transfer
In selected experiments protein samples were run on 10-well 4-12% pre-cast
NuPAGE Bis-Tris gels using an XCell SureLock mini-cell and XCell II blot module
(Invitrogen) according to the manufacturer's protocol. Gels were carefully removed
from packaging and mounted in the XCell SureLock mini-cell. lxMOPS buffer was
then added to both the anode and cathode compartments making sure to cover the
tops of sample wells. 20pg of each protein sample (approximately lOpl) was then
diluted with sufficient 5x Laemmli sample buffer (LSB) to give a final concentration
of lx LSB (approximately 2.5pl). Samples were then incubated for 5 minutes at
95°C. The gel was then loaded with 5pl ofMultimark molecular weight markers
(Invitrogen) in the first lane and the full sample volumes in subsequent lanes. Gels
were run at 100V for 1 hour or until the dye front neared the end of the gel.
Protein was transferred from NuPAGE gels to PVDF membrane (Invitrogen)
by wet blotting in the XCell SureLock mini-cell. Gels were carefully removed from
gel plates and wells trimmed off. Two double layers ofWhatman paper and a sheet
ofPVDF membrane were then cut to size and soaked in lx transfer buffer plus 20%
methanol for 5 minutes at room temperature. Two transfer pads were also soaked. A
sandwich was then constructed consisting of the cathode plate, a blotting pad, a
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double layer ofWhatman paper, the gel, the PVDF membrane, a double layer of
Whatman paper, a further blotting pad and the anode plate. This sandwich was then
inserted vertically into the gel tank, secured with the tension wedge and topped-up
with transfer buffer plus 20% methanol. Electrophoretic transfer was then performed
for 1 hour at 30V.
Polyacrylamide gel electrophoresis and transfer
In selected experiments, protein samples were run on hand-cast
polyacrylamide gels using a Protean II mini-cell and power pack (Biorad). 12.5%
separating gels were prepared by mixing 3.12ml distilled water, 2.5ml 1.5M Tris
(pH8.8), lOOpl 10% SDS and 4.17ml acrylamide / Bis 30% stock (Biorad).
Polymerisation was initiated by the addition of lOpl teramethylethylenediamine
(TEMED) and lOOpl 10% ammonium persulfate (AMPS) (both from Sigma) and the
gel poured between two glass gel plates, one short and one long, held in the pouring
rack, to approximately 1,5cm below the top of the short plate. The top of the gel was
covered with isobutanol (Sigma) to obtain a level, meniscus-free surface and the gel
was allowed to set. 4% loading gels were then prepared by mixing 5.98ml distilled
water, 2.5ml 1.5M Tris (pH8.8), lOOpl 10% SDS and 1.3ml acrylamide / Bis 30%
stock (Biorad) and polymerizing with 20pl TEMED and lOOpl 10% AMPS.
Isobutanol was washed from the separating gel with distilled water and the loading
gel poured on to the top of the short plate. A comb with the desired number ofwells
(usually 10) was then inserted and the loading gel was allowed to set.
To run, gels were placed in running racks in the gel tank and cathode and
anode compartments filled with lx running buffer (). lOpg of sample per well was
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run on polyacrylamide gels. All samples were pre-incubated with LSB and loaded
together with molecular weight markers as described above for NuPAGE gels. Gels
were run at 100V for 1 hour or until the dye front neared the end of the gel.
Protein was transferred from polyacrylamide gels to nitrocellulose membrane
by semi-dry blotting using an LKB Bromma 2117 Multiphor II electrophoresis unit.
Gels were carefully removed from gel plates, the loading wells trimmed off and 4
sheets of blotting paper (Amersham) and one sheet of nitrocellulose (Biorad) cut to
the size of the remaining gel. A sandwich was then constructed containing, from
bottom up, a double layer of blotting paper soaked in transfer buffer (lx stock of
5.86g glycine, 11.625g Tris, 0.75g SDS and 400ml methanol made up to 21 with
distilled water), the nitrocellulose, also soaked in transfer buffer, the gel and a further
double layer of blotting paper soaked in transfer buffer. The cathode and anode
plates of the blotter were wet with transfer buffer and the sandwich placed between
them. Electrophoretic transfer was then performed for 1 hour at 100V.
Staining procedure
Following transfer, both PVDF and nitrocellulose membranes were stained
by the same method. Membranes were removed from transfer sandwiches, placed in
a pyrex dish and stained with Ponceau red (Sigma) for 1 minute with rocking. They
were then washed with lxTBS to clarify lanes and molecular weight markers, which
were marked with a pencil. Membranes were then blocked with 5% Marvel in TBS
for 1 hour with rocking. Blocking solution was discarded and the primary antibody,
diluted appropriately in 10ml blocking solution, was applied to the membranes for 1
hour at room temperature (or overnight at 4°C) with rocking. Membranes were then
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washed 3 times, for 5 minutes each time, with 0.05% Tween 20 (Sigma) in lxTBS.
The secondary antibody, diluted appropriately in blocking solution, was then applied
for 1 hour at room temperature with rocking. Membranes were washed 3 times, twice
as before in 0.05% Tween 20 in lxTBS and once for 5 minutes in lxTBS.
Western blots were visualized with an Enhanced Chemiluminescence (ECL)
kit (Amersham Biosciences, Chalfont St Giles, UK) according to the manufacturer's
instructions. Membranes were first applied to a piece of card wrapped in Saran wrap
and taken to the dark room. 1ml each of the 2 ECL reagents was then mixed in a
bijou tube and applied to the membranes for 1 minute. This solution was then
carefully blotted off and the mounting card was taped to a film cassette. A further
piece of Saran wrap was used to cover the membranes and, under safe lighting, a
piece of film was inserted into the cassette. Exposure was routinely performed for 15,
30, 60 and 300 seconds and film developed using an Amersham Hyperprocessor
automated developer.
Immunoprecipitation
Immunoprecipitation was performed using the mouse monoclonal anti-
glycosylated PIF antibody and anti- pan-mouse Ig-labelled magnetic beads
(Dynabeads - Dynal Biotech, Bromborough, UK) according to the manufacturer's
instructions. lOOpl of beads were first pipetted into a 1ml round-bottomed screw-cap
tube and washed 3 times by applying 1ml ofPBS plus cations (Sigma), inverting to
mix and using a magnet to hold beads at the base of the tube while removing the
PBS. 500pl of antibody and 500pl PBS plus cations was the added and tubes were
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incubated for 30 minutes at 4°C with rotation. Following a further 3 washes with
PBS, 50|ig protein was added and tubes were incubated for 2 hours at 4°C with
rotation. Beads were then washed 5 times as before and transferred to a clean 0.5ml
microcentrifuge tube. 30pl of lxLSB was then added to each tube and antibody-
antigen complexes were released by incubation at 95°C for 5 minutes. Samples were
run on pre-cast NuPAGE tris-tricine gels as described above. Gels were then stained
with Gelcode (Pierce, Rockford, IL, USA) according to the manufacturer's
instructions. First, gels were transferred to pyrex dishes and washed with deionized
water 3 times for 15 minutes with rocking. Gels were then stained by incubation with
20ml Gelcode Blue Stain reagent for 1 hour with rocking. Gels were destained
overnight with deionized water and visualized directly.
Plasmid techniques
Plasmids
The mammalian expression vectors pcDNA3.1+ and pcDNA3.1+V5-His
(Invitrogen) were used. Both contain a multiple cloning site (MCS) under the control
of a constitutive CMV promoter (figure 2.1). The pcDNA3.1+V5-His vector has an
additional 3' V5-His tag. pcDNA3.1+ vector with PIF directionally cloned into the
MCS using the EcoR-I and BamH-I restriction enzymes was created from
pBluescript PIF (kind gift of Ian Waddell) by James A. Ross. This plasmid, termed
pcDNA3.1+PIF, contained the full length PIF cDNA with a 5' GCCGCC Kozak
vertebrate translation initiation sequence (Kozak 1987).
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PIF cDNA
Hani I I (5630) EccR I (225)
/





SV40 early promoter & origin
pUC ori SV40 poly A
Figure 2.1. pcDNA3.1(+)PIF showing the foll-length PIF / dermcidin DNA cloned
into the multiple cloning site.
Transformation
For routine plasmid growth, vectors were transformed into 'One shot' TOP 10
chemically competent e.coli (Invitrogen) using a modification of the manufacturer's
protocol. Cells were stored at -70°C and defrosted on ice immediately prior to use.
1 pig purified plasmid (approximately lpi) was then added to a minimum of 16.67pl
(1/3 vial) e.coli and mixed gently prior to incubation on ice for 5 minutes. Cells were
then heat shocked for 30 seconds at 42°C in a water bath and returned immediately
to ice. 250(4.1 of room temperature SOC medium was added and the samples shaken
horizontally at 200rpm for 1 hour at 37°C. 50pl of neat, 1 in 10 and 1 in 100
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dilutions of each sample were then plated on Luria-Bertrani (LB)(Sigma) agar plates
containing 50pg/ml ampicillin (Sigma) and incubated overnight at 37°C.
Analysis of colonies
Selected colonies from LB plates were analysed by PCR. Standard PCR
reactions containing a forward primer to the T7 promoter region and the 4730 PIF
reverse primer were prepared. Each colony was then harvested with the stick end of a
microbiological loop and inoculated into the PCR reaction. Colonies were
simultaneously inoculated into 3ml LB mini-broths containing 50pg/ml ampicillin.
PCR reactions were cycled and run on agarose gels as standard. Mini-broths were
incubated overnight at 37°C with shaking at 220rpm. Mini-broths which showed
growth and corresponded to PCR reactions that produced the correct size of band for
the insert were selected for plasmid preparation and large-scale culture.
Plasmid mini-prep
Plasmid DNA was prepared from 3ml e.coli broths suing alkaline lysis. 1.5ml
of broth was placed in a 1.5ml sterile microcentrifuge tube and centrifuged at 13
OOOrpm for 2 minutes at 4°C. Supernatant was removed and the pellet resuspended in
1 OOpil Tris-EDTA (TE) buffer (pH 8, lOmmol Tris-HCl, lmmol EDTA) (Sigma).
200p.l of fresh NaOH / SDS solution (20pl lOMNaOH, lOOp.1 10% SDS and 880pl
sterile water in 1ml), 150pil potassium acetate solution (60ml of 5M potassium
acetate, 11.5ml glacial acetic acid and 28.5ml sterile water in 100ml) and 400pl
phenol/chloroform were then added. Samples were vortexed well and spun at 13
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OOOrpm for 5 minutes at 4°C. The upper phase was transferred into a new
microcentrifuge tube. 200pl of isopropanol (Sigma) was added and mixed by
inversion prior to spinning at 13 OOOrpm for 10 minutes at 4°C. Supernatant was
removed and the pellet washed with lOOpl cold 70% ethanol by mixing and
centrifugation at 13 OOOrpm for 2 minutes. The ethanol was then removed and the
pellet air-dried prior to redissolving in 20pl ofTE buffer containing RNAse (Gentra
Systems, Flowgen, Ashby de la Zouch, UK)(lpl of 10mg/ml RNAse per 100p.l TE).
Samples were finally dissolved by incubation at 37°C for 5 minutes. The molecular
weight of purified plasmids was assessed by running lpl ofmini-prep on a standard
agarose gel. The integrity of the insert sequence was determined by direct
sequencing.
Large scale culture and maxi-prep
For use in experiments plasmids were grown in 250ml LB broths and purified
using an Endofree plasmid maxi kit (Qiagen) according to the manufacturer's
instructions. 250ml broths were prepared by the dilution of 1ml mini-broth
containing e.coli with the desired plasmid into 249ml ofLB medium containing
50pg/ml ampicillin. These maxi-broths were cultured overnight at 37°C with shaking
at 220rpm. Bacteria were then pelleted by centrifugation at 6000g in an
ultracentrifuge fitted with a Sorvall GSA rotor for 15 minutes at 4°C. The
supernatants were discarded and pellets lysed by resuspension in 10ml buffer Pl.
10ml of buffer P2 was added and samples were mixed thoroughly by inverting 6
times then incubated for 5 minutes at room temperature. 10ml ofbuffer P3 was then
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added to the lysate and samples mixed by inverting 6 times. The lysate was then
poured into the barrel of a prepared Qiafilter cartridge and incubated at room
temperature for 10 minutes. The plunger was inserted into the cartridge and samples
were filtered into 50ml tubes. 2.5ml ofbuffer ERwas added, mixed by inverting the
tube 10 times and samples were incubated for 30 minutes on ice. During this
incubation, a Qiagen-tip 500 was equilibrated by adding 10ml buffer QBT and
allowing the tip to empty by gravity flow. The filtered lysate was then applied to the
tip and allowed to flow through. The tip was then washed twice with 30ml of buffer
QC and plasmid DNA eluted into a 40ml round-bottomed ultracentrifuge tube with
15ml buffer QN. DNA was then precipitated by adding 10.5ml isopropanol (Sigma),
mixing and centrifuging at 15 OOOg for 30 minutes at 4°C. The supernatant was
carefully decanted and the resultant DNA pellet washed by vortexing with 5ml 70%
ethanol in diethylpyrocarbonate (DEPC) treated water and centrifuging at 15 OOOg
for 10 minutes at 4°C. The ethanol was then removed and the pellet air-dried before
redissolution in 500pl nuclease-free water (Promega).
DNA concentration was assessed by spectrophotometry. Quality was
controlled by isopropanol precipitation and agarose gel electrophoresis of samples
removed from the initial filtered lysate, the Qiagen-tip filtrate, the buffer QC washes
and the DNA eluate.
Directional cloning
For experiments to analyse the subcellular localisation ofPIF the full-length
cDNA was excised from pcDNA3.1+PIF and directionally cloned into
pcDNA3.1+V5-His. First, lpg of pcDNA3.1+PIF was subjected to restriction
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digestion with EcoRI and BamHI (Promega). This was performed in a 20pl reaction
containing 2pl lOx restriction enzyme reaction buffer appropriate to the enzymes
used (Multicore buffer, Promega), lpl EcoRI, lpl BamHI, lpg pcDNA3.1+PIF
(approximately lpl) and nuclease-free water to make up to 20pl. Reactions were then
incubated overnight at 37°C and run on an agarose gel as described above.
Simultaneous double EcoRI / BamHI digestion of the empty pcDNA3. l+V5His
vector was performed. In order to ensure the PIF insert was in frame with the V5His
epitope on insertion, pcDNA3.1+V5His vector A was used. Both digest reactions
were then run on an agarose gel and bands corresponding to the 418bp PIF excision
fragment and the 5479bp pcDNA3. l+V5HisA digestion product excised under UV
illumination using a clean scalpel, placed in 1.5ml microcentrifuge tubes and
weighed.
DNA was extracted from agarose gel slices using a Wizard SV gel and PCR
clean-up kit (Promega) according to the manufacturer's instructions. lOpl membrane
binding solution per lOmg gel slice was added and samples vortexed and incubated
at 50-65°C until the agarose was completely dissolved. An SV minicolumn was then
inserted into a collection tube, the dissolved gel mixture applied and the column
incubated for 1 minute at room temperature prior to centrifiigation for 1 minute at 10
OOOg. Flow through was discarded and the column reinserted into the collection tube.
700pl membrane wash solution, to which 95% ethanol had been added as indicated,
was then applied and columns centrifiiged for 1 minute at 10 OOOg. Flow through was
discarded and the column washed again by the addition of 500pl membrane wash
solution and centrifugation for 5 minutes at 10 OOOg. Minicolumns were then placed
in clean 1.5ml microcentrifuge tubes and 30pl nuclease-free water applied for 1
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minute at room temperature. DNA was then eluted by centrifugation for 1 minute at
10 OOOg and quantified by spectrophotometry.
Ligation reactions were performed using T4 DNA ligase (Promega)
according to the manufacturer's instructions. Three reactions containing 1:3, 1:1 and
3:1 molar ratios of vector to insert were used. Ligation mix was prepared using 1 pi
lOx ligation buffer, 0.2pl T4 DNA ligase and 4.8pl nuclease-free water per reaction.
2pl of vector DNA and 2gl of insert DNA, diluted to give the desired molar ratios
using 1 Ong insert DNA, were then added to 6pl reaction mix to give a total reaction
volume of lOpl. Samples were then incubated overnight at 15°C in a thermal cycler
(Techne) and the full lOpl used to transform TOP 10 e.coli as described above.
Following mini-prep, the orientation and sequence of the PIF insert was confirmed
using direct sequencing and plasmids grown and prepared for use in experiments by
maxi-prep as described above.
Site-directed mutagenesis
Site-directed mutagenesis was performed using a Quikchange II site-directed
mutagenesis kit according to the manufacturer's instructions (figure 2.2) (Stratagene,
Amsterdam, the Netherlands). Forward and reverse mutagenic primers containing the
desired mutation in a central location were designed to meet the recommendations of
the kit (25-45bp length, Tm >78°C, 10-15bp flanking mutation and GC content
>40%) and purchased from a commercial supplier (TAGN, Newcastle, UK).
Sample reactions containing 5pl lOx reaction buffer, lOng pcDNA3.1+PIF
plasmid template, 125ng forward primer, 125ng reverse primer, lpl dNTP mix and
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nuclease-free water to a final volume of 50(j.l were made up in 0.5ml thin-walled
microcentrifuge tubes. 1 pi PfuUltra DNA polymerase was then added. Samples were
cycled in an Express thermal cycler (Thermo-Hybaid, Middlesex, UK) for one cycle
of 30 seconds at 95°C and sixteen cycles of 95°C for 30 seconds, 55°C for 1 minute
and 68°C for 7 minutes. Samples were then cooled on ice for 2 minutes prior to
digestion with 1 pi Dpnl at 37°C for 1 hour.




3. Digest with Dpnl
Methylated parental vector
I I






Figure 2.2. Site directed mutagenesis procedure.
Only the unmethylated, mutated daughter vector is saved from Dpnl digestion and
subsequently able to transform e. coli.
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Samples were transformed into XLl-Blue supercompetent e.coli. 50pl
aliquots of supercompetent cells were transferred into pre-chilled Falcon 2059 tubes
(BD Biosciences, Oxford, UK). 4pl of sample was then added and the transformation
reaction mixed gently and incubated for 30 minutes on ice. Reactions were then heat
pulsed for 45 seconds at 42°C and placed on ice for 2 minutes. 0.5ml ofNZY+ broth
(Gibco), preheated to 42°C, was added and reactions were incubated at 37°C for 1
hour with shaking at 240rpm. lOOpl cells were then plated on LB agar plates
containing 50pg/ml ampicillin (Sigma) and incubated at 37°C for 16 hours. Colonies
were analysed by PCR and inoculated into 3ml LB broths containing 50pg/ml
ampicillin. Plasmids were prepared from broths grown from colonies containing the
correct band on PCR by standard mini-prep technique and the sequence of the
mutation was confirmed by direct sequencing. The plasmids containing the desired
mutations were then used to transform TOPIO e.coli, grown in large scale culture and
purified by maxi-prep and as described above.
In vitro translation
In vitro translation was performed by coupled transcription and translation
using T7 RNA polymerase and rabbit reticulocyte lysate (Promega) according to the
manufacturer's instructions. Radioisotopes used were 35S methionine (10mCi/ml),
14C leucine (0.5mCi/ml) and 35S cysteine (10mCi/ml) (ICN Pharmaceuticals Ltd,
Basingstoke, UK). Reagents were rapidly thawed from storage at -70°C by hand-
warming and placed on ice. Reactions were then set up containing 12.5pl rabbit
reticulocyte lysate, 0.5pl TNT buffer, 0.5pil RNAsin (Promega), 0.5gl T7 RNA
polymerase, 2pl radiolabeled amino acid, 0.5pl amino acids minus the radiolabel
71
used, 1 pg plasmid DNA (approximately lpl) and nuclease-free water to 25pi. In
selected reactions 1.2pl canine pancreatic microsomal membranes (CPMM)
(Promega) were also used. Samples were incubated for 45 minutes at 30°C. 7.5pl of
sample was then removed, mixed with 7.5pi 2x Laemmli sample buffer and
incubated for 5 minutes at 95°C. Samples were spun at 13 OOOrpm for 2 minutes and
supernatants removed from the precipitated haemin to fresh microcentrifuge tubes.
Samples were run on 10-well, pre-cast 10-20% tris-tricine gels (Biorad,
Hemel Hempstead, UK) using Protean II mini-electrophoresis equipment (Biorad).
Gels were carefully removed from packaging, inserted into the mounting rack and a
reservoir for the anode buffer was created with a second gel (if required) or a buffer
dam. Sufficient cathode buffer (lOOmM Tris / lOOmM Tricine / 0.1% SDS) to cover
the wells was then poured into the reservoir. The anode buffer (200mM Tris, pH
8.9) was poured into the exterior of the gel tank to cover the electrode. 5 pi of
Multimark molecular weight markers (Invitrogen) were loaded into the first lane of
each gel. 15 pi of sample per well was loaded. Gels were run at 70V for 2 hours or
until the dye front neared the end of the gel. Gels were then removed from the gel
tank and mounting plates and placed in a pyrex dish.
Gels were visualized by fluorography and autoradiography. All steps were
performed at room temperature with rocking. Gels were stained for 15 minutes with
Coomassie blue then destained with destain (40% methanol, 10% glacial acetic acid,
50% distilled water) for 30 minutes. Dehydration was then performed by 3, hour long
incubations in dimethyl sulfoxide (DMSO). A fluor was added to gels by incubation
for 1 hour 22% 2, 5-diphenyl oxazole (PPO)(Fisons, Manchester, UK) in DMSO.
Gels were then rehydrated by incubation in distilled water for 3 hours with 3 changes
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ofwater over this period. They were then removed from the pyrex dish and
sandwiched between a double layer ofblotting paper soaked in distilled water and
Saran wrap prior to drying with heat on a vacuum drier for 1 hour. Sandwiches were
then taken to the dark room, taped to a film cassette and a piece ofGRI AX film
(Genetic Research Instrumentation, Braintree, UK) applied. Cassettes were
transferred to the -70°C freezer. Exposure times varied from 16 hours to several
weeks. Film was developed using an Amersham Hyperprocessor developing
machine.
MTT assays
For the assessment of cell survival by methylthiazolyldiphenyl-tetrazolium
bromide (MTT) (Sigma) assay cells were plated in 96 well plates (Gibco) at 1.5xl04
cells per well and cultured overnight prior to treatment with glucose oxidase. Each
sample was plated in sextuplicate. Following recovery, lOpl of 5mg/ml MTT was
added to each well and plates were incubated for 4 hours at 37°C. lOOpl per well of
10%SDS, pH 3.0 was then added and plates were incubated overnight at 37°C prior
to reading at 570nm on a Dynex Technologies MRX-II plate reader.
The coefficient of variation over the range of absorbances studied was <1.3%.
Flow cytometry
For use flow cytometry experiments HuH7 cells were seeded in 6 well plates
at lxl06 per well and allowed to settle overnight. Following glucose oxidase
treatment cells and their culture medium were harvested using trypsin / EDTA then
stained and analysed as described below.
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Annexin V staining
Annexin V / propidium iodide (PI) flow cytometry was performed using a
Bender Medsystems kit according to the manufacturer's instructions (Bender
Medsystems, Vienna, Austria). Following harvesting, cells were pelleted and washed
twice in annexin binding buffer by resuspension and centrifugation for 5 minutes at
450g. Cells were then resuspended in annexin binding buffer at a concentration of
2x106/ml and split into 2 groups. The first group was not treated with annexin V and
served as a negative control. 195 pi aliquots of the second group were pipetted into
flow cytometry tubes and 5pi annexin V-FITC was added. Tubes were vortexed and
incubated for 1 Ominutes, at room temperature, in the dark. Cells were then washed
and resuspended in 190pl annexin binding buffer. lOpl of propidium iodide solution
was added to tubes from both groups of cells immediately prior to flow cytometric
analysis.
The coefficient of variation for the assay over the range measured was 27%.
BOB78 staining
Flow cytometry using the BOB78 antibody, which binds a surface marker of
apoptotic cells, was performed as previously described (Flart et al. 2000). Following
harvesting, cells were pelleted and washed twice in PBS by resuspension and
centrifugation for 5 minutes at 450g. Cells were then resuspended in PBS at a
concentration of lxl06/ml and split into two groups, one of 2-5x106 and one of 6-
8xl06. These samples were then blocked by incubation with 20% normal rabbit
74
serum (Diagnostics Scotland, Carluke, Scotland) in PBS for 20 minutes at room
temperature. The first group of cells was treated with 5 pi of negative control mouse
lgM (DakoCytomation, Ely, UK) at 1 in 100 in PBS. The second group was treated
with 5pl lof BOB78 antibody at 1 in 100 in PBS. Both groups were incubated for 30
minutes at room temperature and washed by the addition of 1ml PBS/1% BSA and
centrifugation for 5 minutes at 450g. Cells were then resuspended in 50pl PBS/1%
BSA and 50pl of 1% sheep anti-mouse IgG FITC conjugate (Dako) in PBS was
added to each tube. Cells were then incubated for 30 minutes at room temperature
and washed as before in 1ml PBS/1% BSA. Negative control cells were analysed
immediately. 5pi of propidium iodide was added to BOB78-treated cells before
analysis.
The coefficient of variation for the assays over the range measured was 26%.
Anti-cleaved caspase 3 staining
Cleaved caspase 3 flow cytometry was performed using an anti-cleaved
caspase-3 (Aspl75) (5A1) rabbit monoclonal antibody (Cell Signaling, Hitchin, UK)
and control rabbit IgG antibody (Dako) according to the manufacturer's instructions.
Following harvesting, cells were pelleted, resuspended in 700pl PBS and fixed by
the addition of 300pl formaldehyde and incubation for 10 minutes at 37°C. Cells
were then chilled on ice for one minute. Cells were permeabilized by the addition of
9ml ice-cold 100% methanol and vortexing prior to incubation for 30 minutes on ice.
For staining, lxlO6 cells per tube were aliquoted into assay tubes. 3ml
PBS/1%BSA was then added to each tube and cells rinsed by centrifugation for 5
minutes at 450g. This step was repeated once then cells were blocked by
resuspension in 100pi 20% normal goat serum (Dako) in PBS and incubation for 20
75
minutes at room temperature. 2pl of anti-cleaved caspase 3 antibody or control rabbit
IgG antibody were then added and tubes were incubated for 30 minutes at room
temperature. Cells were then rinsed, again by the addition of 3ml PBS/1%BSA and
centrifugation for 5 minutes at 450g. Cells were then resuspended in 50pl PBS/1%
BSA and 50pl of goat anti-rabbit IgG FITC conjugate (Dako) at 1 in 100 in PBS was
added to each tube. Following a 30 minute incubation at room temperature and a
further wash in 1 ml PBS/1% BSA cells were analysed.
Flow cytometry analysis
Samples were analysed using an Epics XL-MCL flow cytometer (Beckman
Coulter Inc., Miami, USA) and System II acquisition software. Post-acquisition
analysis was performed using Win-MDI 2.8 software (Scripps Research Institute, La
Jolla, USA).
All cells were processed according to forward- and side-scatter. The
coefficient of variation for assays over the range studied was 16%.
Immunocytochemistry
Anti-V5-His immunocytochemistry
For V5-His visualisation cells were treated with 5pM monensin (Sigma) and
visualised using mouse monoclonal anti-V5 antibody (Invitrogen) and a rabbit anti-
mouse FITC-labelled secondary (Dako). Cells were seeded in 8-well chambered
slides at 10 000 cells per well and allowed to settle overnight. Monensin was then
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added at a concentration of 5pM and cells incubated for 12 hours. Medium and
chambers were then removed and the slides washed by immersion in PBS for 5
minutes. A greasepen was used to demarcate wells. Cells were then fixed by
immersion in 3% paraformaldehyde in PBS for 15 minutes at room temperature.
Following a further wash in PBS, permeabilization was performed by the addition of
50pl per well 0.2% Triton X-100 in PBS for 5 minutes. Slides were then washed and
blocked with 50pl per well 20% normal rabbit serum (Dako) in PBS for 30 minutes
at room temperature. 50pl per well of anti-V5 antibody at 1 in 200 in blocking buffer
was then added and slides were incubated for 1 hour at room temperature. Following
a further wash, cells were incubated with 50pl per well of rabbit anti-mouse FITC-
labelled secondary at 1 in 100 in PBS for 30 minutes at room temperature then
washed again. Cells were then stained with 50pl Hoescht 33342 (at 10pg/ml in
distilled water) for 5 minutes at room temperature, washed, mounted in fluorescent
mounting medium (Dako) and visualized by immunofluorescent microscopy.
Cytospins
For assessment of cell death with annexin V, BOB78 and anti-cleaved
caspase 3, cells were seeded at 2xl04 cells per well in 8-well chambered slides and
allowed to settle overnight prior to glucose oxidase treatment. Dead cells were then
harvested from the medium and cytospun onto positively charged slides at 300rpm
for 3 minutes using a Shandon Cytospin 2 centrifuge.
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Annexin V immunocytochemistry
Annexin V staining was performed by incubation of cytospins for 5 minutes
at room temperature in 50pl of annexin binding buffer containing 1.25pl annexin V
and 1,25pl propidium iodide (Bender Medsystems). Slides were then washed by
immersion in PBS for 5 minutes and nuclei stained by incubation with 50pl Hoescht
33342 (at 10pg/ml in distilled water) for 5 minutes at room temperature. Following a
further wash in PBS, cytospins were washed, mounted in fluorescent mounting
medium (Dako) and visualized by immunofluorescent microscopy.
BOB78 immunocytochemistry
BOB78 staining of cytospins was performed by blocking for 1 hour at room
temperature with 50pl of 20% normal rabbit serum (Dako) in PBS then staining for 1
hour at room temperature with BOB78 diluted 1/100 in PBS. Slides were then
washed by immersion in PBS for 5 minutes and incubated at room temperature for
30 minutes with 50pl of secondary rabbit anti-mouse FITC conjugated
immunoglobulins (Dako) diluted 1/100 in PBS. Following another wash in PBS,
cells were fixed by the addition of 50pl 3% paraformaldehyde for 5 minutes then
washed again. Cytospins were then stained with 50pl Hoescht 33342 (at 10pg/ml in
distilled water) for 5 minutes at room temperature, washed, mounted in fluorescent
mounting medium (Dako) and visualized by immunofluorescent microscopy.
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Anti-cleaved caspase 3 immunocytochemistry
Anti-cleaved caspase 3 immunocytochemistry was performed using an anti-
cleaved caspase-3 (Aspl75) (5A1) rabbit monoclonal antibody (Cell Signaling,
Hitchin, UK) according to the manufacturer's instructions. Cytospins were first fixed
by the addition of 50pl 3% paraformaldehyde for 10 minutes at room temperature
then washed 3 times by immersion in tris-buffered saline (TBS) for 5 minutes.
Permeabilization was then performed by the addition of 50pl 0.2% Triton X-100
(Sigma) for 5 minutes at room temperature. Slides were washed in TBS as before
then blocked by incubation with 50pl 20% normal goat serum (Dako) in TBS for 1
hour at room temperature. 50pl of anti-cleaved caspase 3 antibody at 1 in 100 in
1%BSA in TBS was then added to cytospins and incubated overnight at 4°C. Slides
were then washed in TBS as before and incubated with 50pl of secondary goat anti-
rabbit IgG FITC conjugate (Dako) at 1 in 100 in 1%BSA in TBS. Following a further
3 washes in TBS, cytospins were stained with 50pl Hoescht 33342 (at 10pg/ml in
distilled water) for 5 minutes at room temperature, washed again, mounted in
fluorescent mounting medium (Dako) and visualized by immunofluorescent
microscopy.
Immunofluorescent microscopy




BrDU labelling and immunostaining
In experiments investigating cell proliferation, cells were labelled with Cell
Proliferation Labelling Reagent, an aqueous solution of 5-bromo-2'-deoxyuridine and
5-fluoro-2'-deoxyuridine (BrDU) (Amersham) and visualized by
immunocytochemistry using a monoclonal rat anti-BrDU antibody (Oxford
Biotechnology, Kidlington, UK). Cells were seeded in 8-well chambered slides
(Nunc, VWR International, Poole, UK) and cultured overnight under standard
conditions. In experiments in which the synthetic PIF peptide was used, this was
added at the desired concentration and cells cultured for a further 24 hours (see cell
culture section above). BrDU was then added directly to culture medium at a dilution
of 1 in 1000 and cells incubated for a further hour. Culture chambers and medium
were then removed and slides were washed briefly by immersion in PBS prior to
fixation in 80% ethanol overnight at 4°C. Slides were then washed in PBS for 10
minutes and incubated in 5M HC1 for 45 minutes at room temperature. Two further 5
minute PBS washes were performed and the chambers on the slides were demarcated
using a greasepen. Slides were blocked by incubation in 50pl per well of 20%
normal goat serum (Dako) in PBS plus 0.05% Tween-20 for 10 minutes at room
temperature. 50pl of primary antibody at a concentration of 1 in 100 in blocking
solution was then added to each well and slides were incubated for 1 hour at room
temperature. Slides were then washed in PBS 3 times, for 5 minutes each time. 50pl
of goat anti-rat peroxidase-linked secondary antibody (Santa Cruz Biotechnology,
Heidelberg, Germany) at a concentration of 1 in 300 in blocking solution was then
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added to each well and slides were incubated for 30 minutes at room temperature
prior to a further 3 washes in PBS.
DAB peroxidase staining and visualization
Slides were stained using a liquid DAB+ substrate-chromogen system (Dako)
and haematoxylin counterstaining and visualized by light microscopy. 1 drop of
liquid chromogen solution was added to 1 ml of substrate solution and mixed. 50pl
of this mixture was then added to each well and slides were placed on a piece of
white paper and observed for the development ofbrown colour. Once this was seen,
slides were placed in a rack and washed by immersion in distilled water.
Counterstaining with haematoxylin was then performed. A plastic box placed under
the cold tap and continually replenished with running water was used for all wash
steps. Slides were first immersed in haematoxylin for 1-2 minutes then dipped
several times in the bath of running tap water. They were then dipped in 1% acid-
alcohol several times, washed again and dipped in Scott's tap water for 1 minute to
blue. Following a further rinse in tap water, slides were dehydrated by incubation for
5 minutes each in 50, 70, 80, 90 and 100% ethanol then 2 changes of xylene and
mounted with a coverslip using DPX. Cell counts were performed using a light
microscope and graticule to count of > 500 total BrDU positive and negative cells
per well.
The coefficent of variation for the assay over the range measured was 11% in




Full ethical permission from the Local Research and Ethics Committee
(LREC) for Lothian was obtained prior to the recruitment of any patients.
Recruitment
All patients were recruited from the hepatobiliary unit of the Royal Infirmary
ofEdinburgh. Inclusion criteria were suspected pancreatic neoplasia and age over 18.
Exclusion criteria were pre-existing cachexia, active infection and non-pancreatic
neoplasia. Informed consent was obtained 24 hours prior to surgery.
Data collection
Data was collected by patient interview and case-note review. All data was
recorded on a standardised proforma (appendix A). Nutritional data collected
consisted ofweight, serum albumin, serum uric acid and Karnofsky index (appendix
B) (Karnofsky et al. 1948). Prognostic information consisted of patient age, co¬
morbidity, smoking, serum CRP and post-operatively, histology and staging.
Sample collection
Samples ofurine and normal and malignant pancreatic tissues were collected.
Urine samples were collected pre-operatively by mid-stream urine collection and
stored in sterile containers at -20°C until the time of analysis. Tissue samples of
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approximately 1cm3 were harvested from surgical resection specimens (Whipple's)
or core biopsies with the guidance of a consultant pathologist, snap frozen in sterile
containers using liquid nitrogen and stored at -70°C until the time of analysis.
Laser capture microdissection
Mounting and sectioning of tissue
Whole tissue samples were mounted in Tissue-Tek(R) OCTtm (Sakura
Finetek Europe BV, The Netherlands). 8pm frozen sections were then cut using a
Leitz 1720 cryostat. (Leitz, Germany), and 3 sections per sample were mounted on
positively charged slides. Excess OCT was then removed by rinsing in distilled water
and slides stained by submersion for 15-20 seconds in 1% aqueous eosin and washed
again. Slides were then dehydrated in ascending concentrations of alcohol for 1
minute each and cleared in 2 changes of clean xylene for 2 minutes each as described
above under BrDU immunocytochemistry. Slides were finally air-dried and stored in
an airtight container prior to analysis.
Cell capture
Cells were captured using Capsure adhesive-coated caps and a Pixcell II laser
capture microscope (Arcturus) according to the manufacturer's instructions. Under
the guidance of a consultant pathologist, slides were reviewed under the laser capture
microscope. A cap was then inserted into the microscope, placed in contact with the
tissue section and the laser used to capture the entire tumour cell population onto the
cap. This procedure was repeated using a fresh cap to capture normal cells from the
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slide. R.NA was then prepared from both samples using a paraffin block RNA
isolation kit as described above.
Immunohistochemistry
lmmunohistochemistry was performed on sections of normal and tumour
tissues was using mouse monoclonal anti-glycosylated PIF antibody and rabbit
polyclonal anti-PlF-peptide antiserum and a biotin-amplified peroxidase protocol.
Frozen sections were cut as described above under laser capture microdissection.
Endogenous peroxidase activity was then blocked by incubation in 3% hydrogen
peroxide (H2O2) for 10 minutes at room temperature. Slides were washed in distilled
water and transferred to TBS for 5 minutes. They were then wet with distilled water
and placed in a Sequenza slide rack (Ted Pella Inc, Redding, CA, USA), in which all
subsequent steps were performed. 2-3 drops of avidin (Vector Laboratories,
Peterborough, UK) were then applied to each slide for 15 minutes. Slides were
washed with TBS and 2-3 drops of biotin applied for 15 minutes. A further TBS
wash was performed then slides were blocked by the addition of lOOpl per slide of
either 10% normal rabbit serum (Dako) in TBS for experiments using the mouse
monoclonal anti-glycosylated PIF primary or 10% normal swine serum (Dako) in
TBS for experiments using the rabbit polyclonal anti-PIF-peptide primary. After a 30
minute incubation, lOOpl per slide of the primary antibody diluted to the desired
concentration in the appropriate blocking solution was added and slides were
incubated for 1 hour at room temperature. A 10 minute wash with TBS was then
performed. lOOpl per slide of secondary antibody was then added. For experiments
using the mouse monoclonal anti-glycosylated PIF primary, a rabbit anti-mouse
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biotin-linked secondary (Dako) was used. For experiments using the rabbit
polyclonal anti-PIF-peptide primary, a swine anti-rabbit biotin-linked secondary
(Dako) was used. Both secondary antibodies were diluted 1 in 300 in the appropriate
blocking solution. Following a 30 minute incubation at room temperature, the
secondary was washed offwith TBS for 10 minutes. Three drops of
ABComplex/HRP solution prepared as per the manufacturer's instructions (Dako)(l
drop reagent A and 1 drop reagent B in 5ml TBS, pH 7.6) were then added to each
slide and incubated at room temperature for 30 minutes prior to washing with TBS
for 10 minutes. Slides were then developed using a liquid DAB+ substrate-
chromogen system (Dako), haematoxylin counterstained and mounted as described




Urine samples were concentrated using Amicon Ultra 5000 molecular weight
cut-off centrifugal filter columns (Millipore) according to the manufacturer's
instructions. Urine samples were defrosted on ice and 20ml aliquoted into 40ml
round-bottomed ultracentrifuge tubes. Sediment was then removed by
ultracentrifugation for 20 minutes at 16 OOOg and transfer of only the supernatants to
Amicon columns. The columns were then spun for 30 minutes at 4 OOOg and the




Prior to use in experiments, the protein concentration in concentrated samples
was assayed using a Protein Micro-Assay kit (Biorad), based on the method of
Bradford (1976),according to a modification of the manufacturer's instructions. All
samples and standards were prepared and assayed in a 96-well plate (Costar, Cole-
Parmer, London, UK). A standard curve was prepared by performing 4 serial 1 in 2
dilutions of 160pl of the 1.45mg/ml protein standard supplied in distilled water. 40pl
of each sample was then diluted 1 in 5 in distilled water. Standards and samples were
then pipetted into the left-hand, assay wells of the plate in duplicate, adding 80pl per
well. 20pl per well of dye reagent concentrate was then added and the plate placed
on the shaker for 15 minutes. The optical density (OD) at 590nm was then read using
a Dynex Technologies MRX-II plate reader and Assayzap interpretation software.
MALDI-TOF Mass spectrometry
Intact protein analysis
Urine samples were analysed for intact proteins by matrix-assisted laser
desorption ionisation time-of-flight (MALDI-TOF) mass spectrometry using a
Voyager-DE STR mass spectrometer (Applied Biosystems) under the guidance of
the staff at the Wellcome Institute for Cell Biology, King's Buildings, University of
Edinburgh. Samples were diluted to a concentration of lpg/pl in distilled water.
0.5pl per well of each sample was then loaded onto aMALDI plate and 0.5pl of
matrix added immediately. For determination ofwhole mass spectra, a sinapinic acid
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(3,5 dimethyl 4-hydroxycinnamic acid) matrix was used. For analysis of peptide
products of tryptic digests, an alpha-cyano cinnamic acid matrix was used. Plates
were then inserted into the mass spectrometer and samples ionised by targetting with
the laser.
Peptide analysis
One dimensional gel electrophoresis
For determination of specific urinary constituents, urinary proteins were first
separated using 1-dimensional gel electrophoresis. This was performed using 10-well
4-12% pre-cast NuPAGE Bis-Tris gels (Invitrogen) as described above for Western
blotting to run 20pg per well of total urinary protein. Gels were run at 100V until the
dye front neared the end of the gel. Gels were then stained with Gelcode (Pierce) as
described above for immunoprecipitation. Bands of specific molecular weights were
excised using a clean scalpel for each band and placed in clean 1.5ml
microcentrifuge tubes.
Tryptic digest
The protein constituents of specific molecular-weight bands were determined
by tryptic digest and MALDI-TOF mass spectrometry of the resultant peptides. Each
band was first incubated twice in 300pl of200mM ammonium bicarbonate in 50%
acetonitrile (ABC/ACN) for 30 minutes at 30°C. The gel pieces were then incubated
in 300pl of 20mM DTT in ABC/CAN for 1 hour at 30°C and washed 3 times with
300pl ABC/ACN. Cysteines were then alkylated by treatment with lOOpl of freshly-
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made 50mM iodoacetamide (IAA) in ABC/ACN for 20 minutes in the dark. Gel
pieces were then washed 3 times with 500pl ABC/ACN and cut into 2xlmm pieces
with a clean scalpel blade. These samples were then centrifuged for 2 minutes at 13
OOOrpm and covered in acetonitrile until they turned white. Acetonitrile was then
removed and the gel air-dried. Tryptic digest was then performed by adding lpl
trypsin in 1 lOpl of 50mM ammonium bicarbonate and incubating overnight at 32°C.
Samples were then analysed by MALDI-TOF mass spectrometry as described above,
using 2 internal control tryptic peptide peaks of 842.5 and 2211.5 Daltons. Sample
peaks were de-isotoped from these controls and the parental proteins identified by
screening of the resultant mass spectra using the MIS-FIT database.
Statistical analysis
Statistical analysis was carried out using Microsoft Excel. All experiments
comparing the means of 2 samples were analysed using the Student's t test.
Data are presented as the mean with error bars representing the standard error
unless otherwise stated.
Results were considered to be statistically significant with a P value of <0.05.
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Results
3. In vitro expression of proteolysis inducing factor
Summary
It is clear that PIF / dermcidin has diverse biological functions. However,
little is known of the contexts in which they may be important. Previous studies have
suggested that PIF / dermcidin expression may be limited to only a few tissues, but
the expression ofPIF / dermcidin in vitro or at different stages of development
remains unknown. This chapter describes the screening of cell lines and cultured
primary cells at different stages of differentiation and maturity for PIF / dermcidin
mRNA expression.
A variety of cell lines demonstrated PIF / dermcidin expression. Notably, the
pancreatic carcinoma cell lines MiaPaCa2, Panel and CF-PAC consistently showed
strong expression whereas the cell lines HuH7, THP1 and MCF7, which are derived
from tumours not normally associated with cachexia, did not express PIF /
dermcidin.
To assess PIF / dermcidin expression at different stages of differentiation and
maturity, mRNA derived from primary cultures of fetal liver cells and adult
hepatocytes was analysed. Fetal liver cells did not express PIF / dermcidin, in
contrast with adult hepatocytes. However, fetal cells selected for the stem cell
markers CD34 and CD90 did demonstrate PIF / dermcidin expression. In each case
cells were derived from a single organ and confirmation of these results in other
livers will be required.
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To investigate co-translational processing ofPIF / dermcidin, an in vitro
translation system was used to produce radiolabeled polypeptide from the full length
cDNA in the pcDNA3.1+ expression vector. This resulted in a nascent polypeptide
of 1 lkD. An additional, 2.5kD product was formed on the addition of canine
pancreatic microsomal membranes. This is consistent with computer modelling and
suggests the production of a signal peptide which may target PIF / dermcidin to the
secretory pathway. Subcellular localization was then examined by cloning the PIF /
dermcidin cDNA into the pcDNA3.1+ V5 His vector and transiently transfecting
HuH7 cells. Anti-V5 His immunocytochemistry demonstrated staining only after
treatment with monensin, an inhibitor of intracellular protein transport.
These results suggest that PIF / dermcidin expression is more widespread
than previous studies have suggested. In cell lines, this could represent an effect of
transformation or of prolonged culture. It is certainly feasible that expression may be
induced, as non-expressing HuH7 cells are capable of producing PIF / dermcidin
from an expression vector. This might explain why we found adult hepatocytes to
express PIF / dermcidin whereas previous studies have suggested that the liver does
not produce PIF / dermcidin mRNA (Schittek et al. 2001). In cultures of primary




The PIF peptide was originally isolated from lysates of the MAC 16 tumour
using a monoclonal antibody developed to a cachexia-inducing factor present in the
serum of mice (McDevitt et al. 1995, Todorov et al. 1996a, Todorov et al. 1996b).
Using this antibody, it was subsequently possible to detect PIF in the urines of
human patients with pancreatic, hepatic, colonic, ovarian, breast and lung tumours by
Western blotting (Cariuk et al. 1997), although whether PIF was a product of tumour
cells or another cell type was not investigated. More recently, immunohistochemical
studies using the same antibody have suggested that PIF may arise directly from the
tissue of gastrointestinal tumours, specifically colorectal, pancreatic, gastric and bile
duct carcinomas (Cabal-Manzano et al. 2001). Further weight has been added to this
theory by studies on prostatic carcinoma which demonstrated PIF / dermcidin
expression by tumour cells using in situ hybridization (Wang et al. 2003). Recent
studies have demonstrated that PIF may be produced by stromal cells as well as
tumour cells (Deans et al. 2006).
In non-malignant cells, studies on dermcidin have suggested that expression
may be more restricted. In specific, RT-PCR analysis demonstrated expression in
skin, melanocytic naevi and melanoma tissues but not in 16 other human adult or
fetal tissues (Schittek et al. 2001). These results were supported by the findings of
Porter et al. (2003), who analysed 75 tissues by dot-blot expression array and found
DCD expression only in the pons of the brain. Interestingly, both Schittek and Porter
also suggested that PIF / dermcidin expression was similarly restricted in tumours,
Schittek reporting no expression in several tumour tissues and cell lines and Porter
finding that just 2 of 64 pancreatic carcinomas were positive on
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immunohistochemical tissue array. However, the significance of these findings is
unclear as Schittek did not report which tissues or cells were negative and Porter
used an antibody to amino acids 53-64 of the nascent polypeptide, which may
subsequently fail to recognize the proteolytically-processed and potentially
glycosylated PIF core peptide. Therefore, although expression ofPIF / dermcidin in
normal tissues appears limited, whether it is similarly restricted in tumour tissues and
cell lines remains unclear.
During development, it has been suggested that PIF may play a role in the
formation of skeletal muscle and liver tissues (Watchorn et al. 2001). Support for this
arises from the observation that there is a peak in PIF expression at E8.5 in the
mouse embryo (I. Waddell, unpublished observation). This coincides with the period
ofmaximal skeletal muscle and liver morphogenesis. PIF has been demonstrated to
have effects on cellular function and gene transcription in these tissues (Watchorn et
al. 2001, Whitehouse and Tisdale 2003). In liver cells this includes induction of IL-6,
IL-8 and ICAM expression and syndecan 1 and 2 shedding (Watchorn et al. 2002).
The roles of these molecules in cell adhesion and proliferation (Collins et al. 1995,
Zimmermann and David 1999) therefore suggest that PIF may be involved in
hepatocyte differentiation.
The functions ofPIF / dermcidin as a cancer cachectic factor, neuronal
survival factor and antibiotic peptide suggest that it is likely to be a secretory
product. The dermcidin product DCD-1 is certainly secreted, and was originally
isolated from sweat by high-performance liquid chromatography (Schittek et al.
2001). More recently, four different forms of dermcidin have been discovered (Flad
et al. 2002) and it has been suggested that these may be produced by proteolytic
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processing either intracellular^ or following secretion. Certain features of the
expression pattern of DCD-1 in normal skin also suggests that it is a secretory
product, with in situ hybridization, immunohistochemistry and immunofluorescence
demonstrating expression in only eccrine sweat glands (Schittek et al. 2001).
Immunoelectronmicroscopy further demonstrated that DCD-1 is localized to the
Golgi complex and secretory granules in eccrine cells. In addition, the presence of a
NH-terminus signal peptide sequence is consistent with targeting of the PIF /
dermcidin polypeptide to the secretory pathway (Nielsen et al. 1997).
In order to address the differences in reported PIF / dermcidin expression and
to establish a background pattern of expression and a suitable cell line in which to
study the functional effects ofPIF / dermcidin expression we used RT-PCRto screen
a range of cell types for PIF / dermcidin expression. We further aimed to confirm
both the production of a signal peptide using an in vitro translation system and the
targetting of the nascent polypeptide to the secretory pathway in the cell line selected





RMA was prepared from cell cultures using Trizol (Life Technologies) (cf.
p.49). RNA derived from primary hepatocytes cultures which had been treated with
cyclosporin A, heat-shocked or left untreated was the kind gift of S. Mclnally. RNA
derived from fetal liver cells was the kind gift ofN. Masson. All samples were
DNAse I treated prior to reverse transcription (cf. p.52).
Reverse transcription
Samples were reverse-transcribed in 25pl reactions using AMV reverse
transcriptase and random primers (Promega) (cf. p.55).
PCR
Standard 25 pi reactions with lpl sample and lpl taq polymerase were used
(cf. p.55). All DNAse I treated RNA samples were checked for genomic DNA
contamination by amplification with primers to the housekeeping gene, cytochrome
B. Primer sequences were -
F - GGTTCTCTGGGAGGGAGTGC
R - GACAACACAGTAAGAACCAGG
Primers used for PIF / dermcidin PCR were -
F - CTCGGATCCGCCGCCATGAGGTTCATGACTCTCC
R - CAGAATTCCTGGGTATCATTTCTCAGCT




HuH7, CF-PAC, Mia PaCa2 and Panel cells were cultured at 37°C in a 5%
CO2 in air atmosphere in DMEM plus 10% fetal calf serum, L-glutamine, penicillin
and streptomycin (cf. p.46).
Vectors
For in vitro translation experiments the pcDNA3.1+PIF vector was used. For
transient transfection experiments the full length PIF / dermcidin insert in this vector
was directionally cloned into the pcDNA3.1+V5-His vector (Invitrogen) (cf. p.67).
In vitro translation
In vitro translation was performed using a rabbit reticulocyte system
(Promega) according to the manufacturer's instructions (cf. p.71). Radioisotopes
used were 35S methionine, 14C leucine and 35S cysteine (ICN). In selected
experiments reactions were supplemented with 1.2pl canine pancreatic microsomal
membranes (Promega). Samples were run on 10-20% tris-tricine gels (Biorad) and
visualized by fluorography.
Transfection and cell culture
Plasmids were transiently transfected into the HuH7 cell line (ECACC) using
Fugene (Roche Applied Science) according to the manufacturer's instructions(cf.
p.47). Cells were cultured for 24 hours under standard conditions in the presence of
600pg/ml G418 (Sigma). For use in immunocytochemistry experiments cells were
seeded in 8-well chambered slides at a concentration of 10 000 cells per well. After
24 hours cells were treated with 5pM monensin for 12 hours before fixation.
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Immunocytochemistry
Following permeabilization cells were probed with anti-V5 His FITC
conjugated antibody (Invitrogen) and visualized by fluorescence microscopy (cf.
p.76). Nuclei were counterstained using Hoescht 33342.
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Results
Determination of RNA and cDNA integrity
All mRNA samples were assayed for the presence of contamination with
genomic DNA by PCR amplification with primers to cytochrome B. When a band
for the cytochrome B gene was observed, indicating genomic contamination, a
smaller sample ofRNA was retreated with DNAse I and reamplified. Elimination of
genomic contamination was achievable in all cases.
cDNA integrity was assessed by PCR with primers to cytochrome B. This
resulted in products of the correct size without exception.
Expression of PIF / dermcidin in cell lines
PCR of cDNA derived from the HuH7 cell line did not demonstrate PIF /
dermcidin expression (figure 3.1). In contrast, the cDNAs from the pancreatic
carcinoma cell lines MiaPaCa2, CF-PAC and Panel all produced strong bands on
PIF / dermcidin PCR (figure 3.1). This result was confirmed in triplicate.
Ml 2 3 4 5





5. Blank (no cDNA)
97
Expression of PIF / dermcidin in primary hepatocytes
cDNA from one preparation of unstimulated primary hepatocytes was
positive for PIF / dermcidin expression (figure 3.2). In contrast, cDNA from
hepatocytes treated with cyclosporin A or heat-shocked was negative for PIF /
dermcidin. A repeat PCR confirmed these results.
Ml 2 3 4 5
Figure 3.2. Expression ofPIF / dermcidin
by cultured primary adult human hepatocytes
1. Untreated
2. Heat shock treated
3. Cyclosporin treated
4. Positive control (CF-PAC cDNA)
5. Negative control (no cDNA)
Expression of PIF / dermcidin by fetal liver cells
PCR of cDNA prepared from a mixed population of cells derived from a
single fetal liver did not demonstrate PIF / dermcidin amplification (figure 3.3). In
contrast, PCR of cells from single livers which had been sorted on the basis of either
CD34 or CD90 expression was positive for PIF / dermcidin expression. This effect
was independent of length of time in culture, which was 13 days for unsorted cells, 2
days for CD34+ cells and 41 days for CD90+ cells. A repeat PCR confirmed these
results.
M 1 2 3 4 5 6
Figure 3.3. Expression ofPIF / dermcidin by fetal liver cells
1. Primary adult hepatocytes
2. Unsorted fetal liver cells
3. CD34+ fetal liver cells
4. CD90+ fetal liver cells
5. Negative control (no cDNA)
6. Positive control (CF-PAC cDNA)
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Production of a signal peptide
Translation of pcDNA3.1+PIF in the presence of35 S methionine gave an
unprocessed product of 1 lkDa (figure 3.4a, repeated twice). Co-translational
processing, in the presence of canine pancreatic microsomal membranes, produced a
cleavage product of approximately 2.5 kDa (figure 3.4b, repeated twice). As the
larger fragment of PIF / dermcidin does not contain any methionine residues
following cleavage, its visualisation must either reflect incomplete cleavage of signal
peptide or a stage between translation and cleavage. Therefore, to assess processing
after this stage reactions were performed in the presence of35S cysteine, as cysteine
residues are present in both the signal peptide and larger fragment. In this experiment
an additional band of approximate molecular weight 14kDa was apparent in all
reactions to which canine pancreatic microsomal membranes had been added (figure
3 .4c, not repeated). No fragment of larger molecular weight could be identified.
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Figure 3.4. In vitro translation of pcDNA3.1(+)PIF.
S methionine label, no canine pancreatic microsomal membranes (CPMM)
S methionine label with CPMM (pi per reaction)








Secretion of PIF / dermcidin by HuH7 cells
HuH7 cells which had been transiently transfected with the pcDNA+V5His
PIF vector demonstrated V5His immunofluorescence only after treatment with
monensin (figure 3.5, not repeated).
DAPI FITC Merge
Figure 3.5. Immunocytochemistry of V5His labelled PIF / dermcidin in monensin
treated HuH7 cells (FITC labelled secondary antibody).
102
Discussion
The finding that primary cultures of human hepatocytes express PIF /
dermcidin was surprising given the previous studies on dermcidin expression
(Schittek et al. 2001, Porter et al. 2003). However, as noted above PIF / dermcidin
expression may have been under-represented in Porter's study due to the use of an
antibody which may not recognise the PIF core peptide. Schittek used commercially
available multiple tissue cDNA arrays to screen for PIF / dermcidin expression, and
would be expected to gain high quality results, but it is not clear from the
manufacturer's information whether all tissues derived from one individual. If this
were the case, it is feasible that individual differences in PIF / dermcidin expression
may have affected the results. A further explanation for the differences may be that
PIF / dermcidin expression is somehow influenced by the processing or culture of
hepatocytes. This procedure involves the harvesting of liver tissue removed during
partial hepatectomy, usually for metastatic cancer, disintegration of the tissue
architecture by collagenase perfusion and culture on type I collagen coated plates
(Wigmore et al. 1997b). The cells are therefore subjected to a range of stresses and
stimuli not encountered physiologically and any or all of these may induce PIF /
dermcidin expression. Confirmatory studies ofPIF / dermcidin expression in
unprocessed liver tissue would help to address this area.
In contrast with adult hepatocytes, PIF / dermcidin expression was not
detected in whole preparations of fetal liver cells. This is consistent with the
dermcidin studies. However, it is difficult to comment on the contrast between this
result and our finding that adult hepatocytes express PIF / dermcidin. Firstly, as
noted above there are caveats regarding potential induction of expression in adult
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hepatocytes. Secondly, it is not possible to cannulate the vessels of the fetal liver and
the preparation subsequently differs from the adult in using tissue homogenization
rather than collagenase perfusion. Fetal liver preparations therefore initially contain a
high number of blood cells, although these are believed to disappear rapidly in
culture (Malhi et al. 2002).
When cDNA was prepared from fetal liver cells selected for the markers
CD34 and CD90, PIF / dermcidin expression was demonstrated. The expression
could not be ascribed to length of time in culture, as both CD34 and CD90 positive
cells were cultured for less time than unsorted preparations prior to RNA preparation.
It is feasible that the process of sorting or of expansion from a small population could
induce expression, although previous studies have demonstrated little qualitative
change in fetal liver cells over prolonged culture periods (Malhi et al. 2002). PIF /
dermcidin expression may therefore potentially mark cells which have expanded
from small populations ofCD34 and CD90 positive cells.
The production of a 2.5kD band on addition of canine pancreatic microsomal
membranes to the in vitro translation system is highly suggestive of signal peptide
production. The other potential proteolytic products ofPIF, Y-P30 and DCD-1, are
too large to produce a band of this size and their formation would be more likely to
require the action of a specific protease. These results are consistent with those of
computer modelling, which rely on sophisticated methods of neural mapping to
identify signal peptides and the site of their cleavage from nascent polypeptides
(Nielsen et al. 1997). Signal peptides control the entry ofvirtually all proteins to the
secretory pathway, both in eukaryotes and prokaryotes (Gierasch 1989, von and
Manoil 1990, Rapoport 1992). Similar targeting ofPIF / dermcidin is therefore likely
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and is consistent with our visualisation ofV5 His-tagged PIF / dermcidin in HuH7
cell only after monensin treatment and also with the localisation ofDCD-1 to the
secretory granules of dark mucous cells in eccrine sweat glands (Schittek et al.
2001). It therefore appears that these malignant cells, which do not endogenously
express PIF / dermcidin, can produce the polypeptide from our expression vector.
The following chapters will examine the links between PIF / dermcidin
mRNA expression, the production of active forms of PEF and its functional effects.
105
4. Generation of PIF / dermcidin mutants
Summary
Previous studies suggest that post-translational modification may have
important effects on PIF function. Deglycosylation of the core peptide at N- and 0-
glycosylated amino acid residues has been shown to remove its ability to induce
muscle proteolysis (Todorov et al. 1997). Proteolytic processing may also be
important in generating the DCD-1 and PIF core peptides from the nascent
polypeptide chain (Cunningham et al. 1998, Flad et al. 2002).
To investigate the effect of these processes we utilized computer modelling to
identify sites in the PIF / dermcidin amino acid sequence which may be subject to
post-translational modification. We then employed site-directed mutagenesis to alter
these residues and stably transfected PIF / dermcidin into HuH7 hepatic carcinoma
cells.
Cleavage of the signal peptide which may target PIF / dermcidin to the
secretory pathway was predicted by Signal P. A search for N-glycosylation sites did
not reveal any typical consensus sequences but found one atypical sequence at N32.
O-glycosylation was not predicted at any of the 8 serine and threonine residues.
Site-directed mutagenesis was performed on the full-length PIF / dermcidin
cDNA in the pcDNA3.1+PIF vector using a Quikchange II kit. To study N-
glycosylation, the two codons coding for asparagine residues were converted to code
for glutamines both singly and in combination. To generate mutants coding only for
the PIF core peptide, STOP codons were introduced immediately 5' to the sequences
coding for the signal peptide and the PIF core peptide (Y-P30). All mutations were
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confirmed by direct sequencing prior to large scale culture and purification using an
Endofree plasmid maxi kit.
On stable transfection into HuH7 cells, analysis ofPIF / dermcidin expression
by PCR, Western blotting and immunoprecipitation suggested that endogenous
expression was induced as a side-effect of prolonged culture. However, Western
blotting for neomycin phosphotransferase demonstrated expression only in




By assessing the available structural data on PIF and its homologues, Y-P30
and dermcidin, it is possible to construct a model of the parental polypeptide. When
originally purified from the MAC 16 tumour, glycosylated PIF was found to have an
amino-terminal sequence of YDPEAASAPGSGDPSHEASA (Todorov et al. 1996a).
Two years later, the sequence of the Y-P30 peptide, which had been purified from
the supernatants of oxidatively stressed neuronal cells, was found to share close
homology with that ofPIF and extended the carboxyl terminus sequence by a further
9 amino acids (figure l.l)(Cunningham et al. 1998). This was followed by the
identification of the cDNA for Y-P30 (Cunningham et al. 2002). With a coding
sequence of 330bp, this had a predicted peptide product of 110 amino acids and
encoded the PIF core peptide and Y-P30 from amino acids 20 to 50, immediately
after the signal peptide. Another product of the cDNA came to light with the
discovery of dermcidin (Schittek et al. 2001). This study isolated a 46 amino acid
peptide termed DCD-1 from human sweat, the sequence ofwhich was 100%
homologous with the predicted 3' translation product of the Y-P30 cDNA. The
cDNA for dermcidin was also isolated and showed 100% homology with that ofY-
P30. Independently, our collaborators had also identified the cDNA for PIF /
dermcidin by screening a cDNA database for sequences which when translated,
produced peptides with homology to the known amino terminus sequence ofPIF
(Waddell et al., unpublished observation).
These studies therefore confirm that PIF, Y-P30 and DCD-1 arise from the
same gene, dermcidin. In the polypeptide produced by this gene the signal peptide is
sequentially followed by the PIF core / Y-P30, a pro-peptide component and the
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DCD-1 peptide (figurel.l). In order that these separate peptides can be produced, it
therefore seems likely that proteolytic processing of the nascent polypeptide must
occur. The identification of four additional forms ofDCD-1 in sweat further supports
this (Flad et al. 2002). In determining which peptide is produced, proteolytic
processing may subsequently control the function PIF / dermcidin serves in any
particular cell.
Other features ofPIF / dermcidin's structure may also have important effects
on its function. The original description ofPIF determined its sequence from two
species of molecular weight 24kD and 69 kD isolated by affinity chromatography,
the latter ofwhich also contained albumin and which were both found to contain
carbohydrate (Todorov et al. 1996a). Subsequent analyses suggested that PIF is both
N- and O- glycosylated, with one N-linked carbohydrate chain of lOkD and one 0-
linked chain of 6kD attached to the central peptide core of 4kD (Todorov et al. 1997,
Todorov et al. 1999). Removal of these carbohydrate chains with peptide-N-
glycosidase F and O-glycosidase also removed the ability ofPIF to induce
proteolysis in isolated mouse gastrocnemius muscle (Todorov et al. 1997). In the
case of Y-P30, it has also been suggested that phosphatase activity may be involved
in the peptide's effect (Cunningham et al. 1998). The central part of the Y-P30
sequence shares homology with the calcineurin phosphatase domain and the peptide
has been demonstrated to have phosphatase activity in vitro (Cunningham et al.
1998).
In order to investigate the relationship between these structural characteristics
and the function ofPIF / dermcidin we aimed to alter crucial codons in the PIF
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cDNA using site-directed mutagenesis and transfect these mutants into the HuH7 cell




N- and O-glycosylation were modelled using Net N-Glyc
(http://www.cbs.dtu.dlc/services/NetNGlyc/) and Net O-Glyc
(http://www.cbs.dtu.dk/services/NetOGlyc/) respectively. Cleavage of the signal
peptide was modelled using Signal P (http://www.cbs.dtu.dk/services/SignalP/).
Site-directed mutagenesis
Site-directed mutagenesis was performed on the full-length PIF / dermcidin
cDNA in pcDNA3.1+PIF using a Quikchange II kit (Stratagene). The modification
of the manufacturer's protocol described in materials and methods (p.69) was used in
every case.
Primers
Primers used were all designed using the Quikchange primer design tool
(Stratagene, http://labtools.stratagene.com/) to optimize Tm to approximately 78°C.











ProP STOP F TGCAGGTGAAGACCCATAGTTAGCCAGACAGGCAC
ProP STOP R GTGCCTGTCTGGCTAACTATGGGTCTTCACCTGCA
Y-P30 STOP F CTGGTCTGTGCCTAGGATCCAGAGGCC
Y-P30 STOP R GGCCTCTGGATCCTAGGCACAGACCAG
Plasmid culture and preparation
Following mutagenesis cycling plasmids were transformed into XL-1 Blue
supercompetent e.coli which were cultured overnight in 3ml LB broths at 37°C with
agitation (cf. p.64). Plasmids were then prepared by alkaline lysis of 1ml of broth (cf.
p.65) and mutations confirmed by direct sequencing. The remaining broth was then
added to 250ml ofLB broth and cultured overnight at 37°C with agitation (cf. p.66).
Plasmid DNA for use in experiments was then prepared with an Endofree plasmid
maxi kit (Qiagen) according to the manufacturer's instructions (cf. p.66).
DNA sequencing
All plasmid sequencing was performed by Nicola Wrobel of the MRC centre
for cardiovascular research, Centre for Inflammation Research, University of
Edinburgh.
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Transfection and cell culture
HuH7 cells were stably transfected with empty, native PIF / dermcidin and
mutant PIF / dermcidin vectors as described in materials and methods (p.47).
Following selection, cells were cultured under standard conditions in the presence of
600pg/ml G418.
RT-PCR
RNA was prepared from transfected cells using Trizol and DNAse I treated
as described in materials and methods (pp.49 and 52). Samples were reverse-
transcribed in standard 25 pi reactions using AMV reverse transcriptase and random
primers (Promega) (cf. p.55). PCR was then performed in standard 25pl reactions
with 1 pi sample and 1 pi tciq polymerase (cf. p.55). All DNAse I treated RNA
samples were also checked for genomic DNA contamination by amplification with
primers to the housekeeping gene, cytochrome B. Primer sequences were -
F - GGTTCTCTGGGAGGGAGTGC
R - GACAACACAGTAAGAACCAGG
Primers used for PIF / dermcidin PCR were -
F - CTCGGATCCGCCGCCATGAGGTTCATGACTCTCC
R - CAGAATTCCTGGGTATCATTTCTCAGCT
All reactions underwent 35 cycles with a 56°C annealing temperature.
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Western blotting
Protein was prepared from transfected HuH7 cells using RIPA buffer and
quantified using the Bradford method as described in materials and methods (p.58).
Western blotting was performed as described in materials and methods (p.59) using
lOpg of sample per well.
For PIF / dermcidin blotting, 4-12% pre-cast NuPAGE Bis-Tris gels in
MOPS buffer (Invitrogen) were used. The primary antibody was polyclonal rabbit
antisera raised to a synthetic peptide corresponding to the sequence ofPIF /
dermcidin with the highest predicted antigenicity (sequence
HEASAAQKENAGEDPC) (Sigma) at 1 in 1000 in blocking solution. A goat anti-
rabbit peroxidase linked secondary antibody (Santa Cruz) at 1 in 5000 in blocking
solution and an ECL kit (Amersham biosciences) were used for visualization.
For neomycin phosphotransferase blotting, standard 12.5% polyacrylamide
gels were used and protein transferred to nitrocellulose. The primary antibody was
anti-neomycin phosphotransferase (Upstate) at 1 pg/ml in blocking solution. Blots
were visualized using secondary goat anti-mouse peroxidase linked antibody (Santa
Cruz) at 1 in 5000 in blocking solution and an ECL kit (Amersham).
Immunoprecipitation
Immunoprecipitation was performed using Dynabeads as described in
materials and methods (p.62). The antibody used was mouse monoclonal anti-PIF
antibody (McDevitt et al. 1995). Samples were run on a 4-12% pre-cast NuPAGE
Bis-Tris gel in MOPS buffer (Invitrogen). Gels were stained with Gelcode (Pierce)
and destained in deionized water.
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Results
Computer modelling of PIF / dermcidin
Net-O-Glyc did not reveal any amino acids reaching the threshold for O-
glycosylation. There were no typical consensus N-glycosylation sites in the PIF /
dermcidin polypeptide. However, a search with Net-N-Glyc for atypical
glycosylation sites revealed a consensus sequence at N32 with a potential of 0.77.
Signal P predicted cleavage of a signal peptide between amino acids 16 and
17. This peptide would be expected to target PIF / dermcidin to the secretory
pathway.
Generation of PIF / dermcidin mutants
Studies ofMAC-16 and urine-derived PIF suggest heavy glycosylation at
both asparagines 32 and asparagines 44 and at least one serine / threonine residue
(Todorov et al. 1997). This contrasts with the results of computer searches. The
calcineurin-like phosphatase domain has been suggested to lie at amino acids 12 to
17 of Y-P30, ie. amino acids 31 to 38 of the full length polypeptide (Cunningham et
al. 1998). Mutants were therefore generated to convert both N residues to glutamines
both singly and in combination, to truncate the core peptide by moving the point at
which the signal peptide is cleaved to lengthen the signal peptide, truncate the
polypeptide chain through the introduction of STOP codons at the start of the core
peptide and propeptide and to replace the most conserved and functionally important
residue of the calcineurin-like domain (Rusnak and Mertz 2000), H35, to asparagine.
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5 pi of each mutagenesis reaction was run on a confirmatory gel following
Dpn-I digestion. This demonstrated bands corresponding to linear and supercoiled
plasmid as expected. Transformation into supercompetent XL-1 Blue e. coli resulted
in 10 to 100 colonies. This was below the expected efficiency of the Quikchange kit.
The majority of colonies grew when transferred to 3ml minibroths. When plasmids
were prepared by miniprep and analysed by direct sequencing the majority were also
found to contain the desired mutation. No replication errors were noted.
Large scale culture
Innoculation of minibroths into 250ml maxibroths resulted in satisfactory
growth in each case. Preparation of plasmids with the Endofree kit produced
approximately 500pg of purified plasmid which was dissolved in 500pl of
endotoxin-free TE buffer giving a final concentration of 1 pg/pl. Isopropanol
precipitated samples from each stage of the preparation process were run on agarose
gels as a quality control and revealed satisfactory preparation in each case.
Confirmation of PIF / dermcidin expression in transfected cells
PIF / dermcidin PCR of cDNA from cells transfected with PIF / dermcidin-
containing vectors demonstrated PIF / dermcidin expression in every case (figure
4.1). Flowever, expression was also demonstrated in cells transfected with empty
pcDNA3. l(+).The PCR was repeated 3 times with the same result. This result was
validated by sequencing of the empty vector, confirming that it was free from PIF /
dermcidin contamination and by repeating the whole transfection experiment with
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fresh HuH7 cells, excluding the possibility of inadvertent mixing of cells during
passage. Following prolonged passage, PIF / dermcidin expression also became
evident in untransfected FIuH7 cells (figure 4.1). PCR of the DNAse-treated RNA
from which the cDNAs were prepared did not produce bands for PIF / dermcidin,
suggesting that contamination with genomic DNA containing the integrated PIF
cDNA had not occurred (experiment repeated once).
M 123456789
Figure 4.1. PIF / dermcidin PCR of cDNA derived from cells transfected
with pcDNA3.1+ containing the PIF / dermcidin cDNA
1. Empty pcDNA3.1(+) transfected cells
2. pcDNA3.1(+) PIF transfected cells
3. pcDNA3.1 (+) Mutcleav transfected cells
4. pcDNA3.1(+) N32Q transfected cells
5. pcDNA3.1 (+) N44Q transfected cells
6. pcDNA3.1(+) N32Q N44Q transfected cells
7. Untransfected HuH7 cells
8. Positive control (CF-PAC cDNA)
9. Negative control (no cDNA)
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To confirm the production ofPIF / dermcidin protein Western blotting of
transfected cell lysates was performed. Probing with rabbit polyclonal antisera to the
PIF / dermcidin peptide revealed bands of molecular weight 66kD in all cell lysates
(figure 4.2, experiment repeated twice, transfection also repeated). Again, these
bands were present in untransfected HuH7 cells and cells transfected with the empty
pcDNA3.1(+) vector. In cells containing the mutant PIF / dermcidin vectors
pcDNA3.1(+)PIF N32Q, pcDNA3.1(+)PIF N44Q and pcDNA3.1(+)PIF
N32QN44Q, which would not be expected to produce N-glycosylated PIF, no
difference in molecular weight was apparent.
Figure 4.2. Western blot of transfected HuH7 cell lysates using




4. pcDNA3.1 (+) PIF N32Q
5. pcDNA3.1 (+) PIF N44Q
6. pcDNA3.1(+) PIF N32Q N44Q
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To exclude non-detection of glycosylated PIF due to the antibody being
directed to the PIF core peptide, immunoprecipitation using the mouse monoclonal
antibody demonstrated to bind to glycosylated PIF (Todorov et al. 1997) was
undertaken. Again, bands ofweight 66kD were detected in each cell lysate (figure
4.3, experiment repeated once).
1 2 3 4 5 6
66kD—
Figure 4.3. Immunoprecipitation of transfected HuH7 cell
lysates using mouse monoclonal anti-glycosylated PIF
antibody. Transfected vector -
1. None (untransfected)
2. Empty pcDNA3.1(+)
3. pcDNA3 .1(+) PIF
4. pcDNA3.1(+) PIF N32Q
5. pcDNA3.1(+) PIF N44Q
6. pcDNA3.1(+) PIF N32Q N44Q
119
We hypothesized that these results could represent either non-specific binding
of either antibody or, as suggested by the results ofPCR ofHuH7 cells cultured for
prolonged periods (figure 4.1), the induction ofPIF expression by the culture
environment. In pcDNA3.1+ the CMV promoter drives expression of both the
antibiotic resistance gene, neomycin phosphotransferase and the insert, in this case
the P1F / dermcidin cDNA. Therefore, in order to confirm function of the CMV
promoter in transfected HuH7 cells we performed Western blotting for neomycin
phosphotransferase. This demonstrated expression of the 30kD protein neomycin
phosphotransferase II in all cells transfected with pcDNA3.1+, including those
transfected with the empty vector, but not in untransfected cells (figure 4.4, not
repeated).
Figure 4.4. Anti-neomycin phosphotransferase Western ofPIF /
dermcidin-transfected cells
1. Empty pcDNA3.1 (+) transfected cells
2. pcDNA3.1(+) PIF transfected cells
3. pcDNA3.1 (+) Mutcleav transfected cells
4. pcDNA3.1 (+) N32Q transfected cells
5. pcDNA3.1 (+) N44Q transfected cells
6. pcDNA3.1(+) N32Q N44Q transfected cells
7. Untransfected HuH7 cells
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Discussion
We have successfully used the technique of site-directed mutagenesis to alter
codons of the PIF / dermcidin cDNA. The mutations introduced were carefully
designed both to facilitate this process and to create amino acid substitutions which
would affect the structure of the polypeptide. In the case ofN-glycosylation,
substitution of asparagine with glutamine is a widely accepted technique to prevent
carbohydrate addition (Choi et al. 2003, Li et al. 2004b, Wujek et al. 2004).
Similarly, the use of STOP codons is an established and effective method of
sequentially truncating proteins (Revilla et al. 1999, Rebrin et al. 2001). Finally, in
the case of the calcineurin-like phosphatase domain of the PIF core peptide, the
histidine at position 35 corresponds to the most highly conserved amino acid in
calcineurin itself, in which substitution with asparagine results in a significant
reduction in phosphatase activity (Mertz et al. 1997). All of these mutations would
therefore be expected to have significant effects on the functions ofPIF. However,
confirming their production from the pcDNA3.1+ vector in the HuH7 cell system did
not prove straightforward.
When assessed by RT-PCR, HuH7 cells did not appear to express PIF /
dermcidin (cf. chapter 3). We were therefore surprised to find the presence ofPIF /
dermcidin cDNA following prolonged passage or transfection with empty
pcDNA3.1+. The stronger bands seen following transfection further suggest that an
additional stimulus may be acting on the transfected cells. In the case of prolonged
passage, several factors might influence expression. Firstly, repeated oxidative stress
may induce PIF / dermcidin and is the only factor known to stimulate PIF /
dermcidin expression (Cunningham et al. 1998). It would be expected to affect cells
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in culture at several stages, for example when nutrients are depleted pre-passage or
during the process of trypsinisation. The mechanism of induction is unclear, but
examination of the putative PIF / dermcidin promoter reveals ample scope for
transcriptional regulation. We identified this region from the human genome
mapping project and found 127 binding sites for 27 different transcription factors in
the 2000 base pairs immediately upstream of the transcriptional start site. These
included binding sites for c-Jun, which is known to be induced by oxidative stress via
a Rafl-dependent pathway (Chakraborti and Chakraborti 1998) and whose activity is
redox regulated (Hwang et al. 2004).
Transcriptional regulation may also be affected by cell senescence, a second
factor which may contribute to PIF / dermcidin expression following prolonged
passage. Senescence is known to affect the transcriptional activity ofE2F-1 and p53
(Dimri et al. 1994, Tsou et al. 1996, Itahana et al. 2001), both ofwhich have
predicted binding sites in the PIF / dermcidin promoter. Alternatively, the effect of
senescence on cell signalling, including alterations in cellular redox status, could
potentially affect PIF / dermcidin expression (Esposito et al. 2004).
In the case of transfected cells, PIF / dermcidin expression could also be
induced by either antibiotic selection or the presence of the plasmid. The antibiotic
used, G418, acts by inhibiting protein synthesis and is inactivated by the plasmid-
encoded enzyme neomycin phosphotransferase. However, it is feasible that either of
these molecules or their product may have additional effects on gene expression,
although there are no descriptions of such an effect in the literature. Similarly, the
production of proteins from the plasmid or the process of integration with the
genome could also potentially influence gene expression.
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The induction of endogenous PIF / dermcidin is therefore certainly feasible
and as we had extensively validated this experimentally, we sought to confirm
production ofmutant PIF / dermcidin from the transfected vector. Unfortunately,
Western blotting for PIF / dermcidin demonstrated bands of uniform molecular
weight in all transfectants including those transfected with N-glycosylation mutant
PIF / dermcidin. Of these, the double mutant would certainly not be expected to carry
any N-linked carbohydrate and would therefore be predicted to be lOkD lighter than
native, glycosylated PIF (Todorov et al. 1997). As the rabbit-polyclonal anti-PIF /
dermcidin antibody used was developed to an unglycosylated peptide fragment of
PIF / dermcidin it may not bind to glycosylated PEF. However, this possibility was
excluded by the detection of the same molecular weight bands by
immunoprecipitation using the anti-glycosylated PIF mouse monoclonal antibody
(McDevitt et al. 1995). The weight of this band, at 66kD, is suggestive that if the
antibodies are indeed detecting PIF they are detecting the albumin-bound form
(Todorov et al. 1996a). Albumin is known to be secreted by HuH7 cells
(Nakabayashi et al. 1982) and its association with endogenous PIF as well as mutant,
vector-derived PIF could mask the small differences in molecular weight the
mutations would be expected to produce.
In order to confirm the function of the CMV promoter, the component of the
pcDNA3 .1+ vector that drives expression in mammalian cells and to avoid the
problems of immunological detection of native and mutant PIF / dermcidin, we
examined the production of neomycin phosphotransferase in HuH7 cells. As
expected, this revealed expression in only transfected cells. This confirms successful
transfection of empty, native PIF / dermcidin and mutant vectors and demonstrates
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that the CMV promoter functions in HuH7 cells. This suggests that the native and
mutant PIF / dermcidin inserts in pcDNA3.1+, under the control of the same
promoter, are also likely to be expressed. In light of this, the fact that the problems
with immunological detection ofPIF / dermcidin could also occur in any other cell
system used for transfection and the possibility of assessing vector expression by in
vitro translation, it was decided to proceed with functional studies of transfected
HuH7 cells ensuring that every experiment was appropriately controlled and that any
difference detected could subsequently only be attributed to overexpression of the
transfected sequence from the CMV promoter.
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5. Analysis of the survival-promoting effect of proteolysis inducing
factor
Summary
Proteolysis inducing factor shares the same peptide core sequence as the Y-
P30 survival peptide but differs in being heavily N-glycosylated. In this chapter we
describe our investigation of whether PIF functions as a survival factor in non-
neuronal cells and the influence ofmutating the potentially glycosylated asparagine
residues on this effect. These aims were achieved by analyzing the survival ofHuH7
cells, stably transfected with either native or mutant PIF / dermcidin vectors,
following the induction of oxidative stress.
Oxidative stress was induced by treatment with glucose oxidase. Survival was
assessed by MTT assay and examination of annexin V, BOB78 and anti-cleaved
caspase 3 staining by flow cytometry and immunocytochemistry. The molecular
weights of plasmid peptides products were additionally assessed by in vifro
translation.
On the induction of oxidative stress PIF / dermcidin was observed to increase
survival by 26% when assessed by MTT assay (not significant) and 42% when
assessed by forward- and side-scatter on flow cytometry (P<0.01). The mode of
death was necrosis, as assessed by annexin V, BOB78 and cleaved caspase 3
staining. Mutation of both asparagine residues in combination removed the protective
effect ofPIF / dermcidin but mutation of either N32Q or N44Q singly had no
significant effect. In vitro translation did not reveal any difference in the molecular
weights ofPIF / dermcidin produced from native or mutant vectors.
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These results demonstrate that PIF / dermcidin is capable of functioning as a
survival factor in non-neuronal, transformed cells. This effect does not appear to
require the N-glycosylation essential for muscle proteolysis but is inhibited by




The first clue to the potential physiological function of the PIF peptide core
came with the discovery of Y-P30 (Cunningham et al. 1998). This 30 amino acid
peptide was purified from the medium ofY79 human retinoblastoma and the FIN33.1
mouse hippocampal cell lines following their exposure to hydrogen peroxide (H2O2).
N-terminus sequencing ofY-P30 revealed a high degree of homology with PIF, as
discussed in chapter 1. However, Y-P30 did not appear to be glycosylated and was
capable of protecting cells from oxidative stress. Specifically, when either purified or
synthetic, full-length Y-P30 were applied to differentiated HN33.1 cells (ie.
multipolar cells with cell processes), both survival and differentiation following
treatment with H2O2 were improved (Cunningham et al. 1998). This finding was
supported by in vivo work, demonstrating a reduction in pyramidal neuron loss and
microglial infiltration in lesions of rat cerebral cortices treated with Y-P30
(Cunningham et al. 1998). More recently, the identification of the cDNA encoding
Y-P30 facilitated transfection ofHN33.1 cells, producing Y-P30 overexpressing cells
(Cunningham et al. 2002). These similarly demonstrated improved survival and
differentiation following stress with H2O2, incubation with activated macrophages
and xenografting into the brains of immunocompetent rats, as assessed by
microscopy and counting (Cunningham et al. 2002).
The function ofY-P30 as a survival factor therefore appears to confer a
selective advantage on overexpressing neuronal cells both in vitro and in vivo. If this
function were also to be active in tumour cells, it could help to explain the
development of cachexia as cells would be selected for PIF expression. The
metabolism and microenvironment of a tumour frequently results in the exposure of
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cells to high levels of oxidative stress. (Spitz et al. 2000, Das 2002, Raghunand et al.
2003). This may induce death in susceptible cells and lead to genomic instability and
drug resistance in those that survive, resulting in the positive selection and
progression of resistant cells (Pelicano et al. 2004). A survival benefit ofPIF /
dermcidin expression may therefore have significant implications.
We subsequently aimed to determine whether PIF / dermcidin expression
might contribute to the survival of tumour cells under conditions of oxidative stress.
Furthermore, we sought to investigate whether there was a direct link between the
function of PIF / dermcidin as a survival factor and its induction of muscle
proteolysis, for which N-glycosylation is essential (Todorov et al. 1997). These aims
were addressed by studying the survival ofHuH7 cells transfected with native and
mutant PIF / dermcidin-containing vectors under conditions of oxidative stress.
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Materials and methods
Induction of oxidative stress
Cells were plated in 96 well plates (Gibco) at 1.5xl04 per well, 6 well plates
(Gibco) at 1 xl 06 per well or 8-well chambered slides at 2x104 per well and cultured
overnight prior to the induction of oxidative stress by the addition of 75mU/ml
glucose oxidase (Sigma) for 2 hours (cf. pp.46 and 48). Medium was then replaced
and cells incubated under standard conditions for 4 hours.
MTT assays
The survival of cells in 96 well plates was assessed by MTT assay (cf. p.73).
10pi of 5mg/ml MTT was added to each well and incubated for 4 hours at 37°C.
lOOpl per well of 10%SDS, pH 3.0 was then added and plates were incubated
overnight at 37°C prior to reading at 570nm on an Assayzap plate reader.
Flow Cytometry
Cells grown in 6 well plates were analysed by flow cytometry (cf. p.73).
Following glucose oxidase treatment cells and their culture medium were harvested,
pelleted and washed twice by resuspension in PBS and centrifugation at 1500xG for
5 minutes. Annexin V / PI flow cytometry was performed using a Bender
Medsystems kit according to the manufacturer's instructions (Bender Medsystems).
Cleaved caspase 3 flow cytometry was performed using the cleaved caspase-3
(Asp 175) (5A1) rabbit monoclonal antibody (Cell Signaling) according to the
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manufacturer's instructions. Flow cytometry using the BOB78 antibody at 1 in 100
and control antibody, also of IgM isotype (Sigma), was performed as described
previously (Hart et al. 2000). The secondary antibody used was sheep anti-mouse
IgG FITC (Dako, Ely, UK). Samples were analysed using a Coulter Epics XL flow
cytometer.
Immunocytochemistry
For immunocytochemistry experiments (cf. p.76) cells cultured in 8-well
chambered slides were used. For the assessment of cell death with annexin V,
BOB78 and anti-cleaved caspase 3, cells were treated with glucose oxidase and dead
cells harvested from the medium. These were then cytospun onto positively charged
slides at 300rpm for 3 minutes.
Annexin V staining was performed by incubation of cytospins for 5 minutes
at room temperature in 50pl of annexin binding buffer containing 1.25 pi annexin V
and 1,25pl propidium iodide (Bender Medsystems).
BOB78 staining was performed by blocking for 1 hour at room temperature
in 20% rabbit serum then staining for 1 hour at room temperature with BOB78
diluted 1/100 in PBS. Slides were washed in PBS then incubated at room
temperature for 30 minutes with secondary rabbit anti mouse FITC conjugated
immunoglobulins (Dako) diluted 1/100 in PBS. Cells were fixed in 3%
paraformaldehyde for 5 minutes and mounted in fluorescent mounting medium




In vitro translation was performed using a rabbit reticulocyte system (Promega)
according to the manufacturer's instructions (cf. p.71). Samples were labelled with
35S cysteine (ICN). In selected experiments reactions were supplemented with 1.2pl
canine pancreatic microsomal membranes (Promega). Samples were run on 10-20%
tris-tricine gels (Biorad) and visualized by fluorography.
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Results
Analysis of HuH7 cell response to oxidative stress with glucose oxidase
In order to assess the effect of glucose oxidase empty vector-transfected cells
were analysed. Treatment for 2 hours with 75mU/ml glucose oxidase resulted in a
decrease in survival of 66% on MTT assay (figure 5.1a). This was significant



















































Figure 5.1. Effect of glucose oxidase on sham transfected HuH7 cells.
a. MTT assay, b. Forward vs side-scatter, untreated and c. glucose oxidase treated, d.
Quantification of live and dead gates.
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On flow cytometry, glucose oxidase treatment resulted in a characteristic
change in the forward- and side-scatter of cells suggesting an increase in cell death
(figure 5.1b, c). 82% of untreated cells were gated as live and 18% as dead (figure
5.1 d). Glucose oxidase treatment decreased the live gate to 29%, a 65% reduction
(figure 5.1 d). There was a commensurate increase in the dead gate to 71%. This
effect was significant (Student's 1 test, P<0.05, 3 repeats). Analysis of the annexin V
staining patterns of dead-gated cells revealed that untreated, 7% stained with annexin
only, 17% with PI only, 31% with both and 45% with neither (figure 5.2). When
treated with glucose oxidase, 20% stained with annexin only, 8% with PI only, 58%
with both and 14% with neither. These differences were not significant despite 3
repeats of the experiment.
70
Non PI+ Ann+ Pl+/Ann+
staining
Staining
Figure 5.2. Effect of glucose oxidase treatment on annexin / propidium iodide
staining of sham transfected HuH7 cells.
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On staining of dead-gated cells with the BOB78 antibody, a surface marker of
apoptosis (Hart et al. 2000), 1% stained with BOB78 only in the untreated sample,
22% with PI only, 7% with both and 70% with neither (figure 5.3). On glucose
oxidase treatment, 10% stained with BOB78 only, 20% with PI only, 36% with both
and 33% with neither. These differences were not significant despite 3 repeats of the
experiment. Dead-gated HuH7 cells did not stain for cleaved caspase 3. These data
suggested that glucose oxidase induced necrosis ofHuH7 cells. This was supported
by the results of immunocytochemistry with both annexin V and BOB78 (figure














Figure 5.3. Effect of glucose oxidase treatment on BOB78 / propidium iodide
staining of sham transfected HuH7 cells
□ Untreated
□ 75mU GO




Figure 5.4. Effect of glucose oxidase on cell morphology and staining patterns.
Annexin V / propidium iodide, b. BOB78 / propidium iodide.
Effect of PIF / dermcidin on the response ofHuH7 cells to oxidative stress
Following glucose oxidase treatment the mean survival ofHuH7 cells as
assessed by MTT assay was increased from 34% to 43% by transfection of the PIF /
dermcidin-containing vector, a survival benefit of 26% (figure 5.5a). However,
despite 5 repeats of the experiment this difference did not reach significance. On
flow cytometry, forward- and side-scatter gating demonstrated an increase in live-
gated cells from 26% to 37% following PIF / dermcidin transfection, a survival

































Figure 5.5, Effect ofPIF / dermcidin transfection on survival following glucose
oxidase treatment, a. MTT assay, b. Flow cytometry, forward and side scatter.
***P<0.01.
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Analysis of the dead-gated cells revealed a largely unchanged pattern of
annexin V staining following PIF / dermcidin transfection without glucose oxidase
treatment. However, on glucose oxidase treatment, PIF / dermcidin transfected cells
demonstrated a further decrease in the small proportion of dead cells staining with
annexin only in favour of double annexin / PI staining (figure 5.6a), although this
was not significant (3 repeats). BOB78 staining was also affected, with a decrease in
total (BOB78 alone or double BOB78 / PI) staining (figure 5.6b). No staining of















































Figure 5.6. Effect ofPIF / dermcidin transfection on flow cytometric staining
patterns following glucose oxidase treatment, a. Annexin V / propidium iodide, b.
BOB78 / propidium iodide.
137
Effect of site-directed mutagenesis of asparagine residues
As previous studies have reported heavy N-glycosylation of the PIF peptide
(Todorov et al. 1997), we substituted glutamine for each of the two asparagine
residues in the PIF / dermcidin polypeptide sequence, both singly and in
combination. In vitro translation of these mutant vectors with 35S-cysteine resulted in
products of identical molecular weight to wild-type PIF / dermcidin (figure 5.7).
When transfected into HuH7 cells, the single mutations N32Q and N44Q conferred
the same survival benefit as wild-type PIF / dermcidin as assessed by the MTT assay
(figure 5.5a). However, on flow cytometry the N32Q mutation abrogated the effect
on cell survival, whereas the N44Q mutation had no effect (figure 5.5b). Double
mutation ofN32 and N44 removed the ability ofPIF / dermcidin to protect cells as
assessed by both MTT assay and flow cytometry (figure 5.5a, b). Although these
differences were replicated 3 times they did not reach statistical significance. No
difference in the annexin V and BOB78 staining patterns between N32Q, N44Q and
PIF / dermcidin or N32Q N44Q and sham transfectants was observed.
Vector PIF N32Q N44Q N32Q N44Q
CPMM - +
14kD —
Figure 5.7. In vitro translation ofPIF / dermcidin asparagine mutants.
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Discussion
Previous studies have shown that glucose oxidase induces necrosis in hepatic
cells through the generation of a constant dose ofH202 and subsequently free oxygen
radicals (Lemasters 1999). In HuH7 cells we also found that cell death occurred
almost exclusively by necrosis. In particular, there was no activation of cleaved
caspase 3, a mediator common to both the receptor-activated and intrinsic pathways
of apoptosis which is known to be functional in HuH7 cells (Ashkenazi and Dixit
1998, Feng and Kaplowitz 2002). The low level of annexin staining in comparison
with double annexin / PI staining on both flow cytometry and immunocytochemistry
was also consistent with necrotic cell death. In addition, BOB78 staining showed a
similar pattern of changes to annexin V. We have previously demonstrated that
BOB78 antigen translocation to an intact plasma membrane is an indicator of
apoptosis (Hart et al. 2000). Further repeats will help improve the reproducibility of
annexin V and BOB78 flow cytometry.
In the glucose oxidase system, we demonstrated a highly significant survival
benefit ofPIF / dermcidin expression using forward and side scatter gated flow
cytometry. On MTT assay a similar but non-significant effect was observed. Shifts
from cell necrosis to apoptosis are known to occur in primary hepatocytes, where
inhibition of caspases converts apoptotic to necrotic cell death in the presence of an
overwhelming death stimulus from staurosporine (Feng and Kaplowitz 2002).
However, this did not occur in the HuH7 cells, as cleaved caspase 3 was not
activated. In addition, although not significant the main changes in annexin V
staining PIF / dermcidin transfection were a fall in annexin-only and a rise in double
annexin / PI staining, likely to be due to the increased proportional effect of live cells
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falling into the dead gate. PIF / dermcidin therefore appears to improve survival by
decreasing necrosis. The mechanisms by which this occurs remain to be determined.
We attempted to correlate the ability ofPIF / dermcidin to promote survival
with structural mutations designed to alter N-glycosylation. Previous studies have
suggested heavy N-glycosylation of up to lOkD, possibly at one site in the 24kD
moiety (Todorov et al. 1997). Treatment ofPIF with peptide N-glycosidase F
destroys its antigenic and cachexia-inducing properties (Todorov et al. 1997).
However, when we eliminated either of the 2 N-glycosylation sites at N32 and N44
singly, no significant effect on the survival benefits ofPIF / dermcidin expression
was observed. In contrast, mutation of both sites in combination appeared to inhibit
the survival-promoting effect of wild-type PIF / dermcidin. None of the mutations
altered the molecular weight ofPIF / dermcidin produced by in vitro translation.
These results are interesting as they appear to suggest that in a cell free translation
system, PIF / dermcidin is not substantially glycosylated at either N-residue. This is
feasible as neither site contains a typical consensus N-glycosylation sequence,
although N32 has characteristics of an atypical site (Welply et al. 1983, Sato et al.
2000). The loss of protection on mutation of both asparagine residues therefore
suggests that either one of the sites must be glycosylated for this effect or that the
double mutation interferes with function in another way, for example by structural
modification which alters receptor binding. In light of the lack of consensus
glycosylation sites or glycosylation in the in viiro translation system, the latter
explanation seems more likely. In addition, there is no evidence that the Y-P30 /
DSEP molecule is glycosylated (Cunningham et al. 1998, Cunningham et al. 2000).
Interestingly, the phosphatase domain identified in Y-P30 as similar to the similar to
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that of calcineurin lies between N32 and N44 (Cunningham et al. 1998, Cunningham
et al. 2000). X-ray crystallography has shown that asparagine residues contribute to
this domain in calcineurin (Rusnak and Mertz 2000). It is therefore feasible that loss
of both N residues but not one alone is sufficient to impair such phosphatase activity.
Further structural studies will be help to determine whether it is indeed this domain
which is responsible for PIF / dermcidin's survival effect.
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6. Analysis of the induction of cell proliferation by proteolysis
inducing factor
Summary
It has been suggested that DCD acts as a growth factor in breast cancer cells
(Porter et al. 2003). In their study, Porter et al. stably transfected an alkaline
phosphatase tagged CDC construct into the 2INT breast carcinoma cell line and
observed an increase in cell numbers at 1,3,5 and 7 days following seeding. This
raises several questions. Firstly, which peptide induces proliferation, DCD or PIF /
Y-P30, secondly, can the increase in cell numbers be ascribed to an increase in cell
cycling and thirdly, is proliferation also induced in other cell types and particularly in
HuH7 cells, which do not express PIF / dermcidin endogenously.
To address these questions we utilized two approaches. Firstly, the
proliferation ofHuH7 cells stably transfected with wild-type and mutant PIF /
dermcidin vectors was assessed. Secondly, a synthetic PIF peptide was used to treat
HuH7 cells. Cell cycling was quantified by direct counting of cells labelled with
bromodeoxyuridine (BrDU) and visualized by immunocytochemistry.
Cells stably transfected with wild-type PIF / dermcidin had a higher rate of
proliferation than cells transfected with empty vector (P<0.02). This increase in
proliferation was inhibited by mutation introducing a STOP codon immediately
following the signal peptide sequence but not by mutation introducing a STOP codon
immediately 3' to the sequence encoding the PIF peptide (P<0.02). Mutation of the
residue corresponding to the most highly conserved amino acid in the calcineurin
phosphatase domain, histidine 35, to asparagine also prevented PIF / dermcidin
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induced cell proliferation. Treatment of cells with the synthetic PIF peptide resulted
in significant HuH7 cell proliferation with a bell-shaped dose-response curve
(P<0.05 at peak).
These results suggest that the PIF core peptide is sufficient to induce cell
proliferation and that the phosphatase domain may be involved in mediating this
effect. These findings confirm the potential ofPIF to act as an oncogene, promoting
the selection of clones with the capacity to induce cachexia.
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Introduction
The first direct evidence that PIF / dermcidin might stimulate cell
proliferation came from an investigation into the effect ofDSEP overexpression in
neural cells (Cunningham et al. 2002). Here, it was found that overexpression
decreased the ability of all-/ra/?.v-retinoic acid to slow cell proliferation. Just under
three times more overexpressing cells than sham transfectants were counted at 3 days
post treatment. More recently, transfection of dermcidin (essentially the same cDNA
as DSEP) has been demonstrated to increase cell numbers in breast cancer cell lines
(Porter et al. 2003). In this study, increased numbers of 21NT breast cancer cells
were observed at 5 and 7 days when stably transfected with a full-length DCD-
containing construct as opposed to the empty vector. In both the DSEP and DCD
studies the full length cDNA was used, and it is therefore not clear whether it is the
Y-P30, DCD-1 or another peptide that induces proliferation. Both studies also
demonstrated an improvement in cell survival following oxidative stress, but the
increase in numbers remains more likely to be accounted for by increased
proliferation than by decreased death as the cells were not stressed in proliferation
assays.
Several features ofPIF / dermcidin's structure and the signalling pathways it
induces are consistent with a proliferative effect. Structural analysis of the PIF
polypeptide has demonstrated cleavage of a signal peptide and targetting to the
secretory pathway (chapter 3). An extracellular action is consistent with a role as a
growth factor and therefore an oncogene (Porter et al. 2003). How this may be
mediated is unclear. The central sequence of the PIF core peptide has homology with
the phosphatase of calcineurin (Cunningham et al. 1998), but although calcineurin
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may result in T-cell activation (Bommireddy et al. 2003), it may inhibit proliferation
in neoplastic cells via cdk-4 dephosphorylation (Baksh et al. 2000). However, PIF /
dermcidin may have different targets to those calcineurin and it is feasible that
dephosphorylation of these targets may result in cell proliferation. There is evidence
that calreticulin and low- and high-affinity receptors in 21NT cells, breast cancer
tissue and human brain all interact with PIF / dermcidin (Cunningham et al. 2000,
Porter et al. 2003). It has also been suggested that there exists a membrane receptor
for PIF on skeletal muscle (Smith and Tisdale 2003, Waddell et al, unpublished
observation). It subsequently appears feasible that different receptors may exist for
glycosylated and unglycosylated PIF. It is likely that at least one of these receptors
has significant functional effects as several signal transduction pathways have been
shown to respond to PIF.
Perhaps the PIF-induced pathway with the most significant proliferative
effects is that ofNF-kB. PIF has been demonstrated to induce activation ofNF-kB in
hepatic cells (Watchorn et al. 2001). NF-kB induces proliferation in a variety of cell
types including pancreatic carcinoma and hepatic cells (Kirillova et al. 1999, Liptay
et al. 2003, Li et al. 2004a, Yao et al. 2004). In addition, the STAT3 transcription
factor is also known to be activated by PIF treatment. STAT3 has also been
demonstrated to be involved in the proliferation of pancreatic carcinoma and hepatic
cells (Kirillova et al. 1999, Kountouras et al. 2001, Scholz et al. 2003). Upstream of
transcriptional regulation, PIF has been shown to induce signalling in skeletal muscle
via the release of arachidonic acid and its conversion to 15(6)-
hydroxyeicosatetranoic acid (15(6)-HETE). 15(S)-HETE has been demonstrated to
induce the proliferation of leukaemia cells (Postoak et al. 1990). In skeletal muscle, it
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has been proposed that 15(S)-HETE leads to activation of the ubiquitin-proteasome
pathway and this may also have pro-proliferative effects in pancreatic cancer (Shah
et al. 2001). It can therefore be seen that many of the signal transduction pathways
putatively activated by PIF / dermcidin have the potential to induce cell proliferation.
In this chapter we describe our investigation of two aspects ofPIF /
dermcidin's effect on cell proliferation. Firstly, we have aimed to confirm
definitively that cell cycling was responsible for the increases in cell numbers found
in other studies. In order to achieve this, we utilized bromodeoxyuridine staining.
This technique labels newly formed DNA allowing cells in S-phase of the cell cycle
to be identified with an anti-BrDU antibody on immunocytochemistry.
Secondly, we sought to determine the portion of the PIF / dermcidin
polypeptide responsible for the induction of cell proliferation. Two approaches were
used, the synthesis of a peptide containing the full-length PIF core / Y-P30 sequence
and the analysis of the proliferative effects of truncation mutants generated by the
introduction of STOP codons into the PIF / dermcidin cDNA sequence. Mutants
containing the asparagine to glutamine substitutions N32Q, N44Q and N32QN44Q
and the histidine to asparagine substitution H35N were also examined to investigate




PIF / dermcidin mutants
PIF / dermcidin mutants were created by site-directed mutagenesis of the
pcDNA3.1+PIF vector and transfected into HuH7 cells as described in materials and
methods (cf. pp.69 & 47). The vectors used in experiments were empty vector
(pcDNA3.1+), native pcDNA3.1+PIF, pcDNA3.1+PIF ProP STOP, pcDNA3.1+PIF
Y-P30 STOP, pcDNA3.1+PIF H35N, pcDNA3.1+PIF N32Q, pcDNA3.1+PIF N44Q
and pcDNA3.1+PIF N32QN44Q.
Synthetic PIF peptide
A 30 amino acid peptide incorporating the lull length PIF core / Y-P30
sequence was designed (cf. p.49). The full sequence was -
YDPEAASAPGSGNPCHEASAAQKENAGEDP. Custom synthesized peptide of
>95% purity was purchased from Albachem.
Cell culture
The HuH7 cell line was cultured under standard conditions as described in
materials and methods (cf. p.46). For use in experiments, cells were seeded in 8-well
chambered slides at a density of 10 000 per well and allowed to settle overnight. In
experiments using the synthetic peptide, peptide was added at a range of
concentrations and cells cultured under standard conditions for a further 24 hours
prior to BrDU immunocytochemistry.
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For experiments using the mutant PIF / dermcidin vectors cells were stably
transfected as described above. Following seeding and overnight incubation BrDU
immunocytochemistry was performed.
BrDU labelling and immunocytochemistry
Following a 1 hour incubation in BrDU (Proliferating cell labelling reagent,
Amersham) cells were fixed in 80% ethanol and subjected to standard BrDU
immunocytochemistry as described in materials and methods (cf. p.79). Cells were
then counted under direct vision using a graticule. Each sample was plated in 3
chambers and at least 500 cells per chamber were counted and marked as positive or
negative. Experiments were performed in triplicate.
Assessment of transfectants
In order to assess PIF / dermcidin expression in transfected cells, Western
blots of cell lysates were performed as described in materials and methods (cf. p.59).
The primary antibody used was polyclonal anti-PIF / dermcidin rabbit antisera
(Sigma). Blots were visualized with a goat anti-rabbit peroxidase-linked secondary
antibody (Santa Cruz) and an ECL kit (Amersham).
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Results
Assessment of cell proliferation in transfected HuH7 cells
In experiments examining the effects of transfection of vectors containing
native PIF / dermcidin, the truncation mutants ProP STOP and Y-P30 STOP or the
H35N mutation, BrDU immunocytochemistry resulted in readily distinguishable
positive and negative nuclear staining (figure 6.1).
Figure 6.1. BrDU staining of pcDNA3.1(+) transfected HuH7 cells.
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Stable transfection of the PIF / dermcidin-containing vector resulted in a 20%
increase in cells positive for BrDU in comparison with transfection of the empty
vector (figure 6.2). This was significant (Student's / test, P<0.02, 8 repeats). The
effect was abrogated by the H35N and Y-P30 STOP mutants but not by the ProP
STOP mutant, transfection ofwhich also resulted in a significant increase in cell































Figure 6.2. Effect of pcDNA3.1(+) insert on proportion of transfected HuH7 cells
staining for BrDU, truncation mutants. **P<0.02.
In experiments examining the effects of the asparagine mutations N32Q,
N44Q and N32QN44Q and the Mutcleav mutation, no difference in cell morphology
was observed on BrDU staining. In these experiments, cells transfected with the
native PIF / dermcidin-containing vector demonstrated a 14% increase in
proliferation over controls (figure 6.3). This was increased to 24% in cells
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transfected with the N32Q mutant vector (significant at P<0.05, Student's 1 test, 3
repeats). Cells transfected with the N44Q vector showed no significant difference in
proliferation in comparison with those transfected with native PIF / dermcidin,
demonstrating an increase in proliferation of 15% above control. TheN32QN44Q
and Mutcleav vectors had intermediate effects on cell proliferation with transfected
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Figure 6.3. Effect of pcDNA3.1(+) insert on proportion of transfected HuH7 cells
staining for BrDU, asparagine mutants and mutcleav. *P<0.05.
Assessment of PIF / dermcidin expression in transfectants
The assessment ofPIF / dermcidin expression in cells transfected with the
N32Q, N44Q, N32QN44Q and Mutcleav vectors has been described in chapter 4.
Western blotting of lysates from cells transfected with the ProP STOP, Y-P30 STOP








Induction of cell proliferation by a synthetic PIF peptide
When HuH7 cells were treated with the synthetic PIF peptide there was no
identifiable change in cell morphology. Cell counts for BrDU positivity revealed that
the peptide increased cell proliferation (figure 6.4). The response had a bell-shaped
dose-response curve and produced a maximum increase of 14% at a peptide
concentration of 1 Ong/ml (significant at P<0.05, Student's t test, 8 repeats)
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The results of transfection experiments suggest that PIF / dermcidin
expression induces cell proliferation. At 20%, the magnitude of the increase is
significant as this represents the increase in the proportion of cycling cells following
a 24 hour incubation, which would therefore be expected to have an exponential
effect on cell numbers over time. This is consistent with the previous studies on the
proliferative effects of DSEP (Cunningham et al. 2002, Porter et al. 2003).
Furthermore, the increased proportion of cells in S phase revealed by
bromodeoxyuridine staining suggests that PIF / dermcidin may act by increasing
entry to the cell cycle rather than decreasing apoptosis or inducing population
expansion by another mechanism. Such an effect could potentially be mediated at the
Gi-S checkpoint.
The effect of introducing STOP codons prior to the DCD-1 and Y-P30
sequences (ProP STOP and Y-P30 STOP mutants respectively) suggests that the PIF
core / Y-P30 sequence is required for the induction of cell proliferation. When the
sequence 3' to Y-P30 including the propeptide and DCD-1 coding areas (ProP
STOP) was knocked out there was little effect on PIF / dermcidin-induced
proliferation but this was abrogated by further truncation, removing the Y-P30
sequence. As discussed above, the CMV promoter is active in HuH7 cells and the
appropriate use of controls means that the only factor which should be able to
account for the differences in proliferation observed is the difference in vector
sequence introduced by site-directed mutagenesis. In addition, experiments using the
synthetic PIF peptide demonstrate that the PIF core peptide is sufficient to induce
proliferation. The bell-shaped dose-response curve is characteristic of biological
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responses to several cytokines and growth factors including IFN-y, IL-6, IL-8, TNF-
a and IL-1 (Talmadge et al. 1987, Utsunomiya et al. 1996, Ben-Baruch et al. 1997,
Tsigos et al. 1999). Furthermore, it has been suggested that bell-shaped dose-
response curves may result from the action of an agonist on two separate receptors
(Ashby 1990). It is therefore intriguing to suppose that HuH7 cells may express both
the high- and low-affinity PIF / dermcidin receptors previously reported (Porter et al.
2003), one ofwhich may stimulate proliferation and one which may inhibit it. It is
highly unlikely that the effects are due to any contaminant of the peptide as synthesis
is performed from the constituent amino acids entirely by machine. This eliminates
the potential for endotoxin or any other peptide product ofPIF / dermcidin to induce
the proliferation observed. It is hoped that further studies using the in vitro
translation system will confirm that the STOP codons introduced indeed truncate the
polypeptide, but due to the problems with anti-PIF antibodies (cf chapter 7) and the
requirement for separate antibodies to detect the product of each mutant vector, one
ofwhich potentially produces only a ubiquitous signal peptide, it does not seem
feasible to confirm the truncations in HuH7 cells.
The finding that PIF / dermcidin induced cell proliferation is prevented by the
N32QN44Q and H35N mutations further supports the role of the PIF core in the
induction of proliferation, as both of these mutations lie within it. These mutations
also lie within the calcineurin phosphatase-like domain (Cunningham et al. 1998).
Histidine is the most highly conserved amino acid across the calcineurin-like family
of phosphatases (Rusnak and Mertz 2000) and its removal has been demonstrated to
cause a significant decrease in enzyme activity (Zhuo et al. 1994, Mertz et al. 1997).
It is therefore feasible that its replacement with asparagine in the FI35N mutant
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reduces phosphatase activity. The effect of the N32QN44Q mutant is less clear. As
described above, this mutation was designed to prevent N-glycosylation ofPIF, but
we have been unable to demonstrate this in HuH7 cells. However, the single
mutations N32Q and N44Q did not affect PIF / dermcidin-induced cell proliferation.
In the calcineurin phosphatase domain, the role of asparagine residues has not been
investigated, although they are a conserved part of the active phosphatase site
(Rusnak and Mertz 2000). It is therefore feasible that mutation of both asparagines
disrupts the phosphatase site but mutation of either alone is insufficient to do so. One
way to test this hypothesis would be to extend the studies of para-nitrophenyl
phosphate cleavage by Y-P30 performed by Cunningham et al. (1998). In particular,
it would be possible to synthesize peptides containing the H35N and N32QN44Q
mutations and compare their ability to induce proliferation with that of the native
peptide. These studies will cast further light on the mechanism which allows PIF /
dermcidin to act as an oncogene (Porter et al. 2003).
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7. Investigation of urinary PIF expression and proteomic profiles
Summary
In previous studies, detection of urinary PIF has been the gold standard for
identification of PIF production and is the measure which has been correlated with
weight loss. We therefore set out to investigate the link between the presence of
urinary PIF and PIF production in patients with pancreatic carcinoma. However,
during the course of our studies, other workers in our laboratory demonstrated that
the anti-PIF antibody used in Western blotting of urines also recognizes CD59, a
ubiquitous cellular marker of epithelial lineage. We therefore sought an alternative
method of identifying urinary PIF. This lead to the development of matrix-assisted
laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry for urine
analysis.
Nineteen patients undergoing surgery for pancreatic carcinoma were recruited
and nutritional and prognostic information was collected. Urine and tissue samples
were obtained immediately prior to and during surgery respectively. For mass
spectrometry, urine was concentrated by a factor of 100 using an ultracentrifugation
filter cell. Samples were analysed by matrix-assisted laser desorption-ionisation
time-of-flight mass spectrometry using a Voyager-DE STR mass spectrometer. In
order to identify specific urinary proteins, concentrated urines were run on
polyacrylamide gels and bands excised and subjected to tryptic digest. Peaks
obtained from these bands on mass spectrometry were compared with those of
known and predicted tryptic digest products using the MIS-FIT database.
Full mass profiles of the urine samples revealed peaks at 23 500, 9 750 and 6
200 which were not present in urines from 4 non-matched healthy male volunteers
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aged between 25 and 30 years. There was no significant link between the presence of
any band and weight loss or duration of survival. When samples were run on
polyacrylamide gels, protein bands did not correspond exactly to these peaks but
were identifiable at 15, 23, 30 and 40kD. Tryptic digests of these bands identified in
them mitogen-activated protein kinase kinase kinase 3,) and APC-binding protein
EB1, which have not previously been reported in normal urine and immunoglobulin
light chain, keratin, a-1 microglobulin and mannose binding lectin-associated serine
protease-2 related protein, which have previously been found in normal urine. PIF
was not identified.
Mass spectrometry is a promising technique for the analysis of urine. The
identification of cachexia-associated factors may in future provide a method of
screening patients for early nutritional intervention. Further studies of the statistical
significance of these factors and refinements in MALDI-TOF technique have the
potential to yield great advances in this field.
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Introduction
Following the discovery ofPIF, the importance of urinary PIF as a nutritional
indicator in pancreatic cancer was one of the main areas addressed by researchers,
establishing the clinical relevance of the molecule. As discussed in chapter 1, in
humans PIF was first isolated from the urines of patients with carcinoma of the
pancreas, in whom an association with weight loss was reported (Todorov et al.
1996a). The same study demonstrated PIF in the urines of patients with carcinomas
of the lung, breast, ovary and one patient with T-cell lymphoma. Taken with the lack
of PIF in the urines of non-weight losing pancreatic carcinoma patients or those of
patients with weight loss due to major burns, multiple injuries or surgery-associated
catabolism and sepsis, this suggested that the presence ofurinary PIF was specific to
the cachectic state in malignancy and was not restricted to a particular type of cancer.
Subsequent studies examined the nutritional status ofPIF-positive patients
with pancreatic carcinoma in more detail. Urinary PIF was demonstrated in 80% of
patients with pancreatic carcinoma and this group was found to have a significantly
greater total weight loss and rate ofweight loss than patients whose urine did not
contain PIF (Wigmore et al. 2000). In addition, the presence ofPIF was independent
of serum CRP concentration, the acute-phase response and survival (Wigmore et al.
2000), suggesting that it is not a by-product of the inflammatory response to
malignancy, although it remains possible that PIF may be produced by the liver or
another tissue as part of another response to malignancy.
In this study, we sought to determine urinary PIF levels in patients with
pancreatic carcinoma as part of their nutritional assessment prior to the determination
of tumour PIF production (cf. chapter 8). As described above, a monoclonal antibody
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to a cachexia-inducing factor present in the serum of mice was originally used to
purify PIF from the MAC 16 tumour (McDevitt et al. 1995, Todorov et al. 1996a,
Todorov et al. 1996b). Subsequently, the same antibody was used to purify PIF from
the urines ofweight-losing patients with pancreatic carcinoma (Cariuk et al. 1997)
and Western blotting became the standard technique for PIF detection (Todorov et al.
1996a, Todorov et al. 1996b, Wigmore et al. 2000). The Western blotting technique
used was straightforward, concentrating urines by ammonium sulphate precipitation
then running 5gg protein per well on a 15% polyacrylamide gel prior to transfer to
nitrocellulose and probing using the antibody described, which had been biotinylated
(Wigmore et al. 2000). However, a high degree of urine concentration was required,
and it was not possible to isolate PIF from plasma due to the higher overall and
relative protein concentrations.
When workers in our laboratory attempted to identify PIF in urine samples
which had previously been found to be positive a band ofmolecular weight 24kD
could not be identified. Instead, a 21kD band was found. When excised and
sequenced, this was identified as CD59, a ubiquitous cellular marker of epithelial
lineage which is also N-glycosylated (Venneker and Asghar 1992). It was therefore
concluded that although PIF may previously have been found using this antibody, in
our hands it did not provide the necessary specificity, potentially due to a cross-
reaction with a common carbohydrate antigen on CD59. We subsequently sought a
new assay to meet several criteria. Firstly, it should be suitable for the analysis of
urine in order to validate earlier studies. Secondly, it should provide definitive and
reproducible protein identification. Thirdly, it should be fast, as a high number of
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specimens were to be analysed. Having considered these criteria, we settled on the
technique of mass spectrometry.
Mass spectrometry, and in specific, matrix-assisted laser desorption
ionisation-time-of-flight (MALDI-TOF) mass spectrometry, is an enormously
sensitive technique which allows the determination of the precise mass of a protein
or of peptides derived from it by enzymatic or chemical cleavage. The latter provides
a unique 'fingerprint' for each protein which can subsequently be identified by
screening against databases in which the masses of all proteins and their predicted
peptide fragments are held. In MALDI-TOF mass spectrometry this is achieved by
mixing samples with an organic acid and drying them onto a metal slide. The
samples are then targeted with a laser, resulting in their conversion to an ionized gas
in which each protein or peptide contains at least one positive charge. They are then
accelerated through an electric field towards a detector. The time taken to reach the
detector is dependant on the mass and charge of the sample, allowing determination
of the precise mass from ions with one positive charge. This technique is capable of
identifying proteins from samples in the nanogram range with an error rate of <1 in
106.
Mass spectrometry has been used extensively in the field of proteomics, the
attempt to characterise all of the proteins encoded in an organism's genome including
their post-translational modifications. However, in each organism, different cells
express different sets of proteins which may be influenced by the conditions the cell
is subject to. Examination of these proteomes is facilitated by mass spectrometry and
can provide a valuable insight into disease by identifying differences in the proteins
expressed by normal and abnormal cells. In cancer, MALDI-TOF mass spectrometry
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has been used to identify proteins which are differentially expressed by tumour cells
in comparison with normal cells (Chen et al. 2004, Kreunin et al. 2004). These
proteins have the potential to function as biomarkers which could be of great clinical
benefit and to this end mass spectrometry for the detection of proteins in bodily
fluids, including plasma and urine, has been investigated (Ostergaard et al. 1997,
Vlahou et al. 2001, Koomen et al. 2004).
In urine, protein may be present in the absence of systemic or renal disease.
MALDI-TOF mass spectrometry has identified 67 forms of 47 different proteins in
normal urine (Thongboonkerd et al. 2002). In systemic disease it is generally
increases in plasma protein loading which result in the presence of abnormal proteins
in the urine (Nedelkov and Nelson 2001). Frequently found proteins include cystatin
C, (3-2 microglobulin, urinary protein 1 and retinol binding protein.
The techniques used to prepare urine for protein analysis are straightforward
and allow for the processing of multiple samples simultaneously. We therefore
sought to develop MALDI-TOF mass spectrometry to examine the urines of patients
with pancreatic cancer for changes in the total protein profile and the presence of




Patients undergoing surgery for suspected pancreatic carcinoma were
recruited from the hepatobiliary unit of the department of surgery, Royal Infirmary of
Edinburgh (cf. p.81). Full ethical permission was obtained from the Local Research
and Ethics Committee (LREC) for Lothian. Informed consent was obtained from
every patient (appendix C). Information pertaining to the diagnosis of malignancy,
nutritional status and prognosis was collected as described in materials and methods
and recorded on a standardised proforma (appendix A).
Control urine samples were obtained from four healthy male laboratory
workers aged between 25 and 30 years.
Urine samples
200ml pre-operative mid-stream urine (MSU) samples were obtained and
stored at -20°C.
Concentration of urine
For use in mass spectrometry experiments urine was concentrated using
Amicon Ultra 5000 molecular weight cut-off centrifugal filter columns (Millipore)
according to the manufacturer's instructions (cf. p.85). This resulted in the




The protein concentration in all samples was assayed using a Biorad protein
assay as per the manufacturer's instructions (cf. p.58).
One-dimensional polyacrylamide gel electrophoresis
In experiments to examine the identity of proteins of specific molecular
weights 20pg per well of sample was run on a 4-12% pre-cast NuPAGE Bis-Tris gel
in MOPS buffer (Invitrogen) (cf. p.59). Gels were stained with Gelcode (Pierce) and
destained in deionized water. Bands were then excised with a clean scalpel.
Tryptic digest
Bands from polyacrylamide gels were treated with ammonium bicarbonate
and acetonitrile then subjected to tryptic digest as described in materials and methods
(cf. p. 86).
MALDI-TOF mass spectrometry
For analysis in the mass spectrometer 0.5pl of sample (either tryptic digest or
concentrated urine) was applied to each well of the MALDI plate and 0.5 pi ofmatrix
added (cf. p.86). The matrix used was a-cyano cinnamic acid for tryptic digests and
sinapinic acid for whole urine samples. The plate was then allowed to dry, loaded
into the Voyager-DE1M STR mass spectrometer (Applied Biosystems) and analysed.
Results of tryptic digests were compared with the known and predicted tryptic digest




A total of 19 patients undergoing surgery for pancreatic carcinoma were
recruited over an 18 month period from January 2002 to June 2004 (appendix D).
Tissue and urine samples were obtained from every patient.
Assessment of nutritional status revealed that 16 patients had lost weight
prior to diagnosis, 1 did not know if they had gained or lost weight and 2 patients'
weights had remained stable. The mean percentage weight loss was 8.4% with a
range of 0 to 18%. Three patients remained weight stable. Two of these patients were
the only patients not to describe a decrease in oral intake. One patient described an
increase in intake following the insertion of a biliary stent. All but one patient had
experienced a decrease in performance status as assessed by the Karnofsky index.
Serum albumin was determined in every case and was low in the 2 patients with the
highest weight losses, 12 and 13.15kg. Serum urate was assayed in 14 patients and
was normal in every case.
Prognostic information was collected in every case. At the end of the study,
the mean duration of follow-up was 11 months. Eleven patients had developed
recurrence or metastasis, 5 ofwhom had residual tumour or metastases at the time of
initial surgery. Of the 19 patients recruited, 9 (47.4%) had died by the end of the
study. The mean duration of survival of the deceased patients was 254 days post-
diagnosis. Including patients who were still alive at the end of the study the overall
duration of survival exceeded 323 days. Examination of routine histopathology
reports revealed a variety of tumours consisting of 8 pancreatic adenocarcinomas, 4
cholangiocarcinomas, 2 ampullary tumours, 1 ampullary adenoma, 1 serous
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microcystadenoma of pancreas, 1 tubulovillous adenoma of the ampulla, 1 metastatic
fibrosarcoma and 1 duodenal carcinoma. Of the pancreatic adenocarcinomas, 2 were
staged as pT3N0Mx, 4 as pT3NlMx and 2 as Ml. At the end of the study, none of
the patients with pT3N0Mx tumours, 2 of the patients with pT3NlMx tumours and 1
of the patients with M1 tumours had died. The other tumours were of various stages
(figure). Six of the 19 patients were smokers at the time of surgery and of these, 2
(33.3%) had died by the end of the study. Serum CRP levels were determined in 15
patients and were elevated in 6, ofwhom 2 (33.3%) had died by the end of the study.
There was no statistically significant difference in the duration of survival of
patients with a specific tumour type, patients with a tumour of a more advanced
stage, patients who smoked or patients who had an elevated CRP.
Urinary whole mass spectra
Urine samples from the nineteen patients recruited were concentrated and
their protein content assayed. This revealed a range of concentrations from 102pg/ml
to 4769pg/ml. Samples were diluted to give a concentration of approximately
100pg/ml then run on the mass spectrometer. Satisfactory spectra were obtained for
15 of 19 samples (figure 7.1a), 1 gave a spectrum of intermediate quality and 3
samples did not give satisfactory mass spectra despite the use of alternative matrices
and serial dilutions.
Of the 16 samples analysed, 14 produced peaks at a mass of 6200, 13
produced peaks at a mass of 9100, 16 produced peaks a mass of 9750, 7 produced
peaks a mass of 11730, 4 produced peaks a mass of 13800 and 15 produced peaks at
a mass of 23500. Of these peaks, those at 6200, 9100 and 9750 were seen in the 4
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samples of normal urine analysed (figure 7.1b). Those at 11730, 13800 and 23500
were not seen. There was no significant increase in the mean weight loss of patients
with any specific band in their urine (Student's 1 test).
Voyager Spec #1[BP = 5601.8, 2191]
a
Voyager Spec #1[BP = 1144.7, 10636]
b
Figure 7.1. Whole mass spectra of concentrated urine samples from a. patient with
pancreatic carcinoma and b. normal individual.
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One dimensional gel electrophoresis and tryptic digests
In order to further investigate the protein composition of the peaks identified
on whole mass analysis and to try to identify PIF / dermcidin peptides, patients urine
samples were separated by one-dimensional gel electrophoresis. This resulted in a
characteristic banding pattern (figure 7.2), with bands at 6, 12, 21, 33, -40, -45, -77










Figure 7.2. One-dimensional gel electrophoresis of concentrated urine
samples from 4 patients with pancreatic carcinoma.
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As the molecular weight of glycosylated PIF is believed to be around 24kD
and the predicted molecular weight of the full-length nascent polypeptide is 12kD,
the bands of these molecular weights from 2 patients, one ofwhom was positive for
PIF / dermcidin mRNA by real-time PCR (see following chapter) were excised and
subjected to tryptic digest. MALDI-TOF mass spectrometry of the peptide products
of these digests failed to detect any predicted peptide products ofPIF / dermcidin.
However, a range of other proteins were identified. In patient JG, who was positive
for PIF / dermcidin expression on real-time PCR, the 15kD and 30kD bands were
identified as immunoglobulin kappa light chain (molecular weight 23481 / 23512).
The 40kD band contained keratin (type II cytoskeletal l)(molecular weight
66067Da) and alpha- 1-microglobulin/bikunin precursor (molecular weight
39000Da). The patient did not have an elevated serum urea or creatinine at the time
of urine collection. In patient DB, the 23kD band contained mitogen-activated
protein kinase kinase kinase 3 isoform 1 (molecular weight 74090), immunoglobulin
kappa light chain (molecular weight 29506), APC-binding protein EB1 (molecular
weight 24282) and mannose binding lectin-associated serine protease-2 related
protein (molecular weight 19505). The 33kD band contained immunoglobulin kappa
light chain (molecular weight 23512). Of these proteins, only MEKK3 and APC-
binding protein EB1 have not previously been found in normal urine (Nedelkov and
Nelson 2001, Thongboonkerd et al. 2002, Pisitkun et al. 2004).
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Discussion
The use of mass spectrometry in the investigation of urinary proteomes in
cancer has previously been described for transitional and squamous cell carcinomas
of the urinary tract (Ostergaard et al. 1997, Vlahou et al. 2001). Protein products of
these tumours may directly enter the urine and are subsequently likely to be readily
detectable. In contrast, although the urinary proteome in cancer cachexia has also
been studied (Choudhary et al. 1999a, Choudhary et al. 1999c), the protein peaks
observed on full mass spectra were not definitively identified. Our confirmation of
protein identities using tryptic digest therefore represents the first definitive
characterisation of alterations in the urinary proteome in non-urinary cancer.
Unfortunately, our attempts to correlate urinary PIF excretion with the
nutritional and clinical status of patients with pancreatic carcinoma were
unsuccessful, firstly as it was not possible to recruit sufficient patients in the
available time and secondly due to problems with the immunological detection of
PIF. The finding that the anti-glycosylated PIF antibody also binds CD59 was
disappointing and presented a technical difficulty to our laboratory. This was
addressed mainly by a co-worker, who carefully replicated the published urine
blotting protocols. Advice and training from their authors was obtained but it was not
possible to replicate their results. Indeed, in our hands the only urinary protein found
to bind the antibody was CD59, the identity of which was confirmed beyond
reasonable doubt by protein sequencing. This does not mean that PIF does not bind
under other conditions. As noted above, the antibody was originally used to purify
MAC 16 tumour-derived PIF by affinity chromatography (Todorov et al. 1996a), and
it was from PIF produced by this method that the core peptide sequence and the
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pattern of glycosylation was determined. Unfortunately, none of the published
studies describe confirmatory sequencing of urine-derived PIF.
MALDI-TOF mass spectrometry also failed to identify PIF in the urines we
analysed. As noted above, this technique is capable of detecting tiny amounts of
protein with great accuracy. However, communication with the authors of previous
studies of glycosylated PIF has suggested that it is present at extremely low
concentrations in urine, circa 0.5ng per ml (M. Tisdale, personal communication).
We concentrated our urine samples approximately 100 fold, resulting in a PEF
concentration of 50ng per ml in the 5pi placed on the mass spectrometry plate. This
represents 25pg ofPIF, equivalent to approximately 1 femtomole of the 24kD
species. As this is the very limit of sensitivity of the mass spectrometer used it is
possible that PIF was not detected in our samples as it was present at too low a
concentration. Although further concentration would be possible it would not
increase the low amount ofPIF present in relation to other proteins. While this may
be problematic in Western blotting, it may not be so for mass spectrometry and could
prove worthwhile. Similarly, the low relative abundance ofPIF in plasma might also
prove less problematic for mass spectrometric analysis and plasma analysis could be
revisited.
Post-translational modification and the method by which samples are
prepared from urine may also affect the spectrum of proteins detected by mass
spectrometry (Thongboonkerd et al. 2002). In particular, heavy glycosylation may
render PIF highly adherent, potentially resulting retention on the vessels used in
purification and can also impair the detection of peptides by MALDI-TOF. Heavy
glycosylation may also have contributed to our failure to identify PIF in the gel
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bands analysed as they were not stained with silver stain, which would be expected
to demonstrate carbohydrate epitopes. The bands at 21kD and 1 lkD which were
analysed were chosen as they lay close to the predicted weights of glycosylated and
non-glycosylated PIF / dermcidin. The fact that carbohydrate ions are metastable in
mass spectrometers and therefore subject to degradation prior to detection (Mortz et
al. 1996) and that multiple glycoforms ofPIF may exist (Wirth et al. 2002) may also
have resulted in unexpected molecular weights, further hampering identification.
A combination of the above factors may potentially have resulted in the
failure to detect urinary PIF. Urinary PIF has previously been reported to be present
in up to 80% of urines from weight-losing patients with pancreatic carcinoma
(Wigmore et al. 2000). Our cohort of patients did not differ significantly from those
in these studies and it would seem unlikely that all 19 of our patients were non-PIF
producers. The apparent absence of urinary PIF in our studies therefore appears to
contrast directly with previous work (Todorov et al. 1996a, Wigmore et al. 2000).
However, if urinary PIF is indeed not present in these patients' urines, this would be
in keeping with the results ofMonitto et al. (2004), who have demonstrated that PIF /
dermcidin overexpressing xenografts do not induce cachexia. Furthermore, the
previous study claiming to have detected urinary PIF by mass spectrometry did not
confirm it as a constituent of the identified 24kD urinary peak (Choudhary et al.
1999b). Reconciling these studies and those describing the in vitro pro-cachectic
effects of glycosylated PIF on myotubes and hepatocytes (Smith et al. 1999,
Watchorn et al. 2001) will require further detailed evaluation ofPIF glycosylation.
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8. Assessment of PIF / dermcidin expression in pancreatic carcinoma
tissue
Summary
The source ofPIF previous studies detected in the urine ofweight-losing
patients with pancreatic carcinoma has not been definitively determined. Antigenic
cross-reactivity with PIF isolated from MAC-16 tumours suggests that tumour cells
may produce PIF. However, screening of tissues for dermcidin mRNA demonstrated
expression only in skin and brain (Schittek et al. 2001) and SAGE analysis has not
demonstrated DSEP expression in pancreatic tumours (Porter et al. 2003). This
chapter describes the investigation ofwhether pancreatic tumour cells produce PIF in
vivo.
Samples of pancreatic tumours were obtained from specimens removed
during surgery for pancreatic cancer. PIF / dermcidin expression was then assessed
by analysis ofmRNA and protein production. mRNA was prepared by laser capture
microdissection and tissue homogenization. Following reverse transcription PIF /
dermcidin expression was assessed by both standard and real-time PCR. Production
ofPIF peptide was assessed by immunohistochemistry.
cDNA produced from mRNA prepared by laser capture microdissection was
positive for PIF / dermcidin by standard PCR in both tumour and normal samples.
However, analysis of this mRNA by Agilent capillary electrophoresis suggested it
was not of sufficient quality for quantitative PCR and it did not prove possible to
improve yields through refinements in technique. mRNA derived from homogenized
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tissues was of better quality. However, quantitative PCR identified significant PIF /
dermcidin expression in only one sample and this experiment was not repeated.
Staining of frozen sections with the monoclonal antibody to glycosylated PIF
did not reveal any positivity. Staining with rabbit polyclonal antiserum to the PIF
peptide demonstrated staining of interstitial cells, peripheral nerves, and vascular
smooth muscle cells, but not tumour cells. However, it was not possible to inhibit
this staining with either the antigenic fragment ofPIF to which the antisera was
raised or the full-length Y-P30/PIF synthetic peptide.
The results ofmRNA experiments conflict. On balance, the finding that
mRNA isolated from homogenized tumour was of better quality and that quantitative
PCR is more specific than standard PCR suggests that pancreatic tumours may not
express PIF / dermcidin mRNA, although the development of better RNA
purification and the analysis of larger numbers is required. The results of
immunohistochemistry experiments appear to support the results of real-time PCR,
as although staining was observed it was not inhibited by the antigenic peptide and
may therefore be non-specific. The source ofPIF previously identified in the urines
of patients with pancreatic carcinoma therefore remains unclear.
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Introduction
The most comprehensive study of tumour PIF / dermcidin expression to date
examined production in prostatic carcinoma (Wang et al. 2003). This study
demonstrated the presence ofPIF / dermcidin mRNA in prostatic carcinoma cell
lines, primary prostatic carcinoma and osseous metastases and confirmed by in situ
hybridisation that it was produced by only malignant epithelial cells. Interestingly,
urinary PIF was demonstrated in 9 of 19 cachectic patients but 0 of 19 non-cachectic
patients. However, the correlation between tumour expression ofPIF / dermcidin
mRNA and the presence of urinary PIF was not examined. Another study did
investigate this relationship, assessing PIF expression by immunohistochemistry and
the presence of urinary PIF by Western blotting in patients with gastrointestinal
cancers (Cabal-Manzano et al. 2001). Of the 16 patients examined, 5 showed
granular, cytoplasmic staining of tumour cells which was stronger in less
differentiated tumours. All of these patients were also positive for urinary PIF, in
contrast with patients negative for tumour PIF staining, who were all negative. The
positive tumours arose from the pancreas, colon, liver, lung and oesophagus. These
results strongly argue that tumour cells are the source of urinary PIF. However, the
numbers examined were small and as discussed above, there is now evidence to
suggest that the monoclonal mouse anti-glycosylated PIF antibody used recognises
epitopes of other antigens including CD59 (cf. chapter 7). Indeed, another study
obtained contrasting results with an antibody to the DCD-1 peptide. This gave only 2
positive results on immunohistochemical array examination of 64 pancreatic tumours
(Porter et al. 2003). However, this antibody would not be expected to recognise the
Y-P30 / PIF core peptide which may be present even in the absence ofDCD-1 due to
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proteolytic cleavage. Examination ofPIF / dermcidin mRNA in either of these
studies would have helped to resolve the apparent conflict between their findings, but
this was not performed. In fact, PIF / dermcidin mRNA expression in gastrointestinal
tissues has only once been assessed, and although expression was not found, only
normal tissues and no tumours were examined (Schittek et al. 2001).
We therefore sought to examine the production ofPIF / dermcidin mRNA by
pancreatic tumour cells and correlate this with PIF peptide production. Initially, it
was also planned to correlate these findings with both the clinical status of patients
and the presence of urinary PIF. However, as described in the previous chapter, the




Tumour samples were collected at the time of surgery (cf. p. 82). For patients
undergoing Whipples resections, samples of tumour and normal tissue were removed
from fresh surgical specimens under the guidance of a consultant pathologist. For
patients undergoing palliative bypasses, core biopsies of tumour and normal tissue
were taken intraoperatively by the operating surgeon. All samples were immediately
snap frozen in liquid nitrogen and stored at -70°C prior to analysis.
Laser capture microdissection
Frozen sections were cut from tumour and normal tissue samples, mounted
on charged slides and stained with eosin only. Histology was determined with the
help of a consultant pathologist. Capsure laser capture microdissection caps and a
Pixcell laser capture microscope (Arcturus) were used to generate separate samples
of carcinoma and normal cells as per the manufacturer's instructions (cf. p. 82).
RNA preparation
RNA was prepared from laser-capture microdissected cells using a paraffin
block RNA isolation kit (Ambion) with a modified protocol as described in materials
and methods (cf. p.50).
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For the preparation ofRNA from intact tissue samples tissue a rotor-stator
homogeniser was used for homogenisation. RNA was then extracted using an
RNEasy kit (Qiagen) according to the manufacturer's instructions (cf. p.51).
All samples were DNAse I treated prior to reverse transcription (cf. p.52).
Samples prepared by laser capture microdissection were treated using Promega
DNAse I. Samples prepared by tissue homogenisation and RNEasy column
purification were treated by on-column DNAse digestion as described in materials
and methods.
Assessment of RNA
RNA concentrations were assessed by spectrophotometry. RNA quality in
samples prepared by laser-capture microdissection and direct tissue homogenisation
was assessed by Agilent chip capillary electrophoresis as described in materials and
methods (p.53).
Reverse transcription
Samples were reverse-transcribed in 25 pi reactions using AMV reverse
transcriptase and random primers (Promega) (cf. p.55).
PCR
Standard 25pl reactions with lpl sample and lpl taq polymerase were used
(cf. p.55). All DNAse I treated RNA samples were checked for genomic DNA
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contamination by amplification with primers to the housekeeping gene, cytochrome
B. Primer sequences were -
F - GGTTCTCTGGGAGGGAGTGC
R - GACAACACAGTAAGAACCAGG (TAGN)
Primers used for PIF / dermcidin PCR were -
F - CTCGGATCCGCCGCCATGAGGTTCATGACTCTCC
R - CAGAATTCCTGGGTATCATTTCTCAGCT (TAGN).
All reactions underwent 35 cycles with a 56°C annealing temperature.
Real-time PCR
Real-time PCR was performed using an ABI Prism cycler (Applied
Biosystems) and 25pi reaction volumes as described in materials and methods (p.57).
Samples were run in duplicate using a 18S ribosomal RNA VIC-labelled internal
control and FAM-labelled PIF / dermcidin unknown. 18S primer and probe
sequences were from Applied Biosystems (sequences copyright Applied
Biosystems).






Biotin-amplified DAB immunohistochemistry was performed on frozen
sections as described in materials and methods (p.83). The primary antibodies used
were rabbit polyclonal anti-PIF peptide antiserum (Sigma) and mouse monoclonal
anti-glycosylated PIF monoclonal antibody (cf. McDevitt et al. 1995) at
concentrations of 1 in 1000 and 1 in 100 in blocking solution. The secondary
antibodies used were swine anti-rabbit biotin-linked antibodies and rabbit anti-mouse
biotin-linked antibodies respectively. Secondary antibodies were diluted 1 in 300 in
blocking solution. All sections were counterstained with haematoxylin. Histology
and staining patterns were assessed with the help of a consultant pathologist.
In peptide inhibition experiments, 10mg/ml of either the peptide used to raise
the rabbit antiserum (Sigma) or the full-length synthetic PIF core peptide (Albachem)
were added to the primary antibody prior to its application to tissue sections.
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Results
Investigation of PIF / dermcidin mRNA expression in pancreatic tumour tissue
Using laser capture microdissection, it was possible to separate cells from
areas of tumour and areas of normal pancreas (figure 8.1). PCR of cDNA derived
from these samples was positive for PIF / dermcidin expression in every case (figure
8.2). However, despite our best efforts to ensure tissue was snap-frozen as quickly as
possible and repeated attempts at RMA extraction, analysis ofRNA concentration
revealed extremely low amounts ofRNA in LCMD samples. Analysis ofRNA
quality by Agilent chip capillary electrophoresis also revealed that RNA was of
insufficient quality for real-time PCR experiments (figure 8.3). It was therefore
decided to prepare RNA from gross, matched samples of normal and tumour tissue.
Figure 8.1. Laser capture microdissection, a Slide prior to capture, b Cap with
adherent cells post capture.
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Figure 8.2. PCR ofLCMD-derived cDNA for PIF / dermcidin
expression.
1. Patient 1, normal tissue
2. Patient 1, tumour tissue
3. Patient 2, normal tissue
4. Patient 2, tumour tissue
5. Positive control (CF-PAC cDNA)
6. Blank (no cDNA)
Figure 8.3. Agilent bioanalyzer virtual RNA gel.
1. HuH7-derived RNA showing strong 18S and
28S bands (positive control)
2. Patient 1, LCMD-derived RNA
3. Patient 2, LCMD-derived RNA
4. Patient 1, homogenization-derived RNA
5. Patient 2, homogenization-derived RNA
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Preparation by tissue homogenisation yielded higher amounts ofRNA.
Agilent analysis revealed that the quality of this RNA was significantly better than
that obtained from LCMD (figure 8.3). Standard PCR of cDNA derived from these
samples was positive for cytochrome B in the majority of cases (figure 8.4a). In
contrast, PIF / dermcidin PCR was negative in every case (figure 8.4b). Real-time
PCR of the same samples revealed a satisfactory level ofVIC (28S ribosomal RNA)
positivity (count >23) in only 11 of 28 samples. Only one of the samples positive for
PIF / dermcidin expression on standard PCR, GT-normal, had a VIC count of >23. In
only one of the VIC positive samples, JG-tumour, was the FAM count <36. This
sample had a FAM : VIC ratio of 0.96. These results suggest an undetectable level of
PIF / dermcidin expression in the 10 samples with FAM counts of>36, including
those found positive for PIF / dermcidin on standard PCR, but a relatively high level
of expression in the JG-tumour sample.
These results did not permit statistical analysis. The RNA extraction, reverse
transcription, quality control PCR and real-time PCR procedures were not repeated.
182
Ml 23456789 10 11 12
a
Figure 8.4. PCR of homogenization-derived cDNA from 12 samples of pancreatic
tumour, a. Cytochrome B. b. PIF / dermcidin. Bands in the gel are short and do not
correspond to the 358bp length ofPIF / dermcidin PCR product and are therefore felt
to represent primer artefact.
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Investigation of PIF peptide production in pancreatic tumour tissue
In order to determine whether the production ofPIF peptide mirrored PIF /
dermcidin mRNA expression we investigated tumour PIF production using
immunohistochemistry. Staining of frozen sections with monoclonal anti-
glycosylated PIF antibody revealed no specific staining at concentrations of neat, 1 in
100 or 1 in 1000. Staining of the same sections with the rabbit polyclonal anti-PIF
peptide antiserum gave a characteristic pattern. Positivity was observed in smooth
muscle cells of the walls of small blood vessels, nerve cells and interstitial cells
(figure 8.5a-g). The latter had a fusiform appearance and were considered to be either
myofibroblasts or possibly tissue macrophages or mast cells. Staining of some
epithelial cells was also seen and was localised to what appeared to be secretory
granules. However, no tumour epithelium was positive.
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Figure 8.5. Staining pattern of pancreatic tumours stained with rabbit polyclonal
anti-PIF peptide antiserum, a. Small blood vessel, b. Nerve, c. Interstitial cells, d.
Fusiform cells, e. Epithelial cells, f. Pancreatic tumour tissue.
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In order to test the specificity of the rabbit polyclonal antisera,
immunohistochemistry was repeated on the same sections having pre-incubated the
primary antibody with an excess of either the immunogenic peptide to which it was
raised or the full-length synthetic PIF core peptide. No change in the staining pattern
was observed. In light of these findings, no further immunohistochemistry was
performed with this antiserum.
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Discussion
Our initial results with laser-capture microdissection prepared RNA
suggested that PIF / dermcidin was expressed by both normal and neoplastic cells
from samples of human pancreatic carcinoma. This would have suggested a much
broader expression profile than has previously been described (Schittek et al. 2001,
Porter et al. 2003). However, doubt was cast on this by the fact that the better quality
samples prepared by tissue homogenisation were not positive for PIF / dermcidin
expression on PCR. These samples contained greater amounts ofRNA than the
LCMD samples and should have contained all cell types present in the LCMD
samples. False negatives would therefore seem unlikely and the negative results of
real-time PCR support this. We were also unable to confirm the LCMD sample
results with real-time PCR as the RNA was found to be of insufficient quality.
Therefore, in the absence of further time to improve the LCMD technique, we feel
that tissue homogenisation provided more reliable results and conclude that in the
majority of cases, PIF / dermcidin is expressed in neither normal nor neoplastic
pancreatic tissue. This is consistent with the previous studies of expression (Schittek
et al. 2001, Porter et al. 2003).
In one case, JG, we observed a significant signal for PIF / dermcidin
expression on real-time PCR. This sample was not positive on standard PCR,
although this is a less sensitive assay. The tumour in this case was a ductal
adenocarcinoma of pancreas, and that this may produce PIF / dermcidin is supported
by the findings ofPorter et al. (2003), who as noted above, found expression in 2 of
64 pancreatic adenocarcinomas. However, urine from the same patient was analysed
by tryptic digest and mass spectrometry and PIF was not identified (cf. chapter 7)
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although it cannot be stated categorically that PIF has not entered the urine due to the
possibility that MALD1-TOF analysis may have failed to detect glycosylated PIF.
The initial results of immunohistochemistry with the rabbit polyclonal anti-
P1F peptide antibody were of great interest, as they suggested expression by a variety
of cells. Theoretically, this antisera should recognise only the most antigenic part of
the PIF core peptide. This has no close homologues and the post-streptococcal
glomerular antigen (Yoshizawa et al. 1992), to which it is related, would not be
expected to be found in the patterns observed. Specific staining of other antigens is
therefore unlikely to account for the widespread staining observed. However, as the
antisera is polyclonal, it is feasible that antibodies to other antigens could produce
positive staining. In order to exclude this, we attempted to block specific binding by
incubation with the immunogenic peptide and the full-length PIF core peptide. The
large excess of these peptides would be expected to bind all anti-PIF antibodies in
the antisera, leaving those capable of non-specific binding and allowing the
determination ofPIF expression by analysing the differences between slides stained
in their presence and absence. Unfortunately, no differences were observed,
suggesting that the staining was non-specific. This is consistent with the results of
both RNA analysis and urine mass spectrometry and supports the lack ofPIF /
dermcidin expression in the majority of pancreatic tumours. The lack of staining
observed when the mouse monoclonal anti-PIF antibody was used is also consistent
with these results. Despite the recognition ofCD59 by this antibody, previous studies
suggest that it is also potentially capable of detecting the glycosylated form ofPIF.
Glycosylated PIF would therefore also not appear to be produced by pancreatic
tumours.
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In order to confirm these negative results, careful analysis of positive controls
for both antibodies will be required. In the case of the polyclonal antisera, as it was
obtained from a reliable commercial source it would be hoped that some
immunoreactivity to the innoculated peptide would be present. It may therefore be
possible to detect binding by a simple shift in weight of peptide-bound antibody on a
standard immunoblot. This could also be confirmed by performing tryptic digest and
mass spectrometric analysis of immunoprecipitated, antibody-bound peptide. This
technique could also potentially be used to identify any antigens binding to the
antisera non-specifically. In the case of the mouse monoclonal antisera, a reliable
source of glycosylated PIF would be required as a positive control. Unfortunately,
such a source was not available to us at the time of this study.
Potentially, the staining pattern of slides from the tumour of patient JG,
which was positive for PIF / dermcidin expression on real-time PCR, could also have
demonstrated a positive staining pattern. However, when compared with other slides
no difference could be detected. Staining was also not affected by preincubation of
the antisera with the peptides. IfPIF / dermcidin mRNA is indeed expressed by this
tumour, it would therefore not seem to be converted into a peptide form which is
detectable either by immunohistochemistry with the available antibodies or by mass
spectrometric analysis of urine. This could potentially be due to the production of a
low amount of peptide, which would be consistent with the results ofPCR in which
mRNA was undetectable by standard PCR and at the lower limit of real-time PCR
detection. Further work on the reliable detection ofPIF / dermcidin peptides will be
required to confirm and extend these studies.
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9. Discussion
This thesis has sought to investigate how PIF / dermcidin is involved in cell
survival and growth and how these functions are related to the structural
characteristics of the molecule. We also sought to relate our findings to the in vivo
situation in the context of pancreatic carcinoma and cachexia. The results obtained
provide insight into the potential physiological and pathological roles ofPIF /
dermcidin, with particular reference to neoplasia.
The importance of PIF / dermcidin to cell proliferation
Our finding that PIF / dermcidin induces tumour cell proliferation confirms
its oncogenic potential. Autocrine secretion ofPIF / dermcidin would be expected to
contribute to the autonomous growth of tumour cells. This has been suggested to
occur by the amplification of the dermcidin gene locus in breast cancer (Porter et al.
2003), which may result in overproduction. Alternatively, as with other oncogene
pathways involving secreted products, abnormalities in the receptor system or
signalling pathways could contribute to tumour cell expansion (Downward et al.
1984). Despite the finding of putative PIF receptors by two groups (Porter et al.
2003, Smith and Tisdale 2003), as yet their identity is unknown. Cloning will
facilitate the investigation of their role in neoplasia. Of the signalling pathways
known to be stimulated by glycosylated PIF, there is some evidence that the
proteasome pathway may be involved in the induction of cell proliferation. In
pancreatic cancer, inhibition of the 26S proteasome has been found to inhibit
proliferation, potentially via prevention of p21waf"1 degradation (Shah et al. 2001).
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This serves as a reminder that the ubiquitin-proteasome system is active not just in
muscle tissue but in every cell type and could be activated by ligation of aberrantly
expressed PIF / dermcidin receptors. Were the effect to be similar to the stimulatory
effect of glycosylated PIF on murine myotube proteasomes this could contribute to
the pro-proliferative effects we have observed (Lorite et al. 2001, Whitehouse and
Tisdale 2003). The stimulation of 15(S)-FIETE production seems less likely to
stimulate proliferation, having been demonstrated to inhibit cell growth in colorectal
and prostatic cancer cells (Shappell et al. 1999, Shappell et al. 2001, Chen et al.
2003).
The importance of PIF / dermcidin to cell survival
We have demonstrated that PIF / dermcidin overexpression results in an
increase in cell resistance to oxidative stress. This is in keeping with the results of
previous studies on neuronal cells (Cunningham et al. 1998, Cunningham et al.
2002). We also confirmed that the mode of cell death in our system is necrosis,
which is reduced by PIF / dermcidin expression. In neuronal cells oxidative stress
similarly results in necrotic cell death which may be reduced by preconditioning,
which results in the induction of several antioxidant enzymes (Arthur et al. 2004).
Preconditioning by enzymatic induction is well described in hepatic cells and it is
subsequently feasible that PIF / dermcidin may act in this manner in HuFI7 cells.
Alternatively, PIF / dermcidin expression may protect cells from oxidative stress by
induction of the proteasome system (Smith and Tisdale 2003, Whitehouse and
Tisdale 2003). Proteasome induction has been associated with improved survival of
both neuronal cells and liver cells following oxidative stress (Lee et al. 2004,
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Donohue, Jr. et al. 2004). PIF / dermcidin may therefore potentially work via either
of these systems or by another, as yet unidentified mechanism. Intriguingly, low-
level oxidative stress has been demonstrated to induce the proteasome system, and it
is subsequently feasible that PIF / dermcidin may exert its effects indirectly, via the
induction of oxidative stress. This could also help to explain the down regulation of
PIF / dermcidin expression in adult hepatocytes by the preconditioning agents
cyclosporin and heat-shock, but would require further investigation to be
substantiated.
One final mechanism by which PIF / dermcidin may influence cell necrosis is
via the calcineurin-like phosphatase domain. Cell necrosis is increasingly recognised
as having elements of an ordered pathway which appears to include onset of the
mitochondrial permeability transition (Lemasters et al. 1998, Lemasters 1999). This
transition may be induced by oxidative stress and interestingly, may be blocked by
cyclosporin A. Cyclosporin's inhibition of calcineurin (Rusnak and Mertz 2000)
raises the possibility that this may be the point at which PEF / dermcidin acts on the
necrotic pathway and that phosphatase activity may be involved. This would be
consistent with our finding that mutation of both asparagines was required to inhibit
PIF / dermcidin's survival effects. Similar results with cells transfected with the
H35N PIF / dermcidin mutant would further support this.
An effect of the phosphatase domain on the anti-necrotic properties ofPIF /
dermcidin would suggest some overlap between the survival and proliferative effects
of the molecule, as our results suggest that this domain is required for the
proliferative action ofPIF / dermcidin. In contrast with the proposed
'preconditioning' mechanisms of action, which suggest that PIF / dermcidin may act
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as a modifier of the response to environmental stress rather than as an anti-apoptotic
survival factor, this would be in favour ofPIF / dermcidin acting primarily as a
conventional growth factor, with secondary effects on cell survival via cell cycle
modulation. In support of this, we have already described the pro-proliferative effect
of transfection, and shown changes in the proportion of cycling cells. This may
involve a range of factors such as c-myc and ras which have been demonstrated to
inhibit apoptosis (Wyllie 1993, Bonni et al. 1999, Scheid et al. 1999). In particular,
PIF has been demonstrated to induce STAT-3 activation in hepatic cells (Watchorn
et al. 2001), and this transcription factor family is known to inhibit apoptosis (Shen
et al. 2001Wang et al. 2000, Shen et al. 2001). Investigation of the effects of classical
inducers of apoptosis, for example staurosporine and camptothecin, on PIF /
dermcidin overexpressing cells would help to determine if this influences apoptosis
and subsequently confirm whether cell proliferation and survival are separable
phenomena.
The importance of PIF / dermcidin expression in hepatic cells
Our demonstration ofPIF / dermcidin expression in untreated primary
hepatocytes, CD34 positive fetal liver cells and CD90 positive fetal liver cells but not
in primary hepatocytes treated with cyclosporin or heat-shocked, the HuH7 cells line
or unsorted fetal liver cells suggests that hepatic cells are capable of regulating PIF
expression in different stages of development and following different stimuli. As
discussed above (cf. chapters 3 and 9), it is difficult to propose a single mechanism
or stimulus to account for these differences. However, control will ultimately be
mediated through the PIF / dermcidin promoter. We have begun to study the
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sequence immediately 5' to the dermcidin gene and have discovered 127 putative
binding sites for 21 different transcription factors using computer modelling. The
identification of DNAse 1 hypersensitive sites in fetal and adult hepatocytes
subjected to different stimuli will help identify the transcription factors that regulate
PIF / dermcidin expression.
If PIF / dermcidin expression by cultured primary hepatocytes reflects the in
vivo situation, PIF may have a greater physiological role than previously proposed.
Glycosylated PIF is known to activate the transcription factors NF-kB and STAT3 in
primary hepatocytes and induces IL-6, IL-8 and C-reactive protein production while
decreasing transferrin production (Watchorn et al. 2001). These effects are consistent
with a pro-inflammatory action and may reflect aberrant glycosylation ofPIF in
patients with cachexia but would not be expected to be active in the normal liver.
Alternatively it is possible that the in vivo effect ofPIF is blocked by the action of
another pathway whose influence is lost in vitro.
In our studies, it appears feasible that the ischaemia and oxidative stress to
which hepatocytes are subjected during harvesting might induce PIF / dermcidin
expression in primary cultures. This would be consistent with the inhibition ofPIF /
dermcidin expression by the preconditioning agents cyclosporin and heat-shock. The
potential role of PIF / dermcidin in hepatic preconditioning is subsequently hard to
determine, as it appears to protect cells from oxidative stress and yet its expression is
inhibited by preconditioning agents. One possible explanation is that as discussed
above, PIF / dermcidin does generate a low level of oxidative stress and that
prevention of this stress is part of the protective effect of these preconditioning
agents. Another is that by protecting cells from oxidative stress these agents prevent
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the induction of PIF / dermcidin expression. This would imply that they act
independently ofPIF / dermcidin. Therefore, were PIF / dermcidin to have a direct
effect on the mitochondrial permeability transition, this would not seem to be
required for cyclosporin's inhibition of cell death via this pathway (see above).
Finally, a form of feedback may be involved, with a decrease in phosphatase activity
secondary to cyclosporin inhibition resulting in decreased positive feedback on PIF /
dermcidin expression. In any case, PIF / dermcidin would appear to work via
mechanisms independent of cyclosporin or heat shock. Our finding that it protects
HuH7 cells from oxidative stress subsequently implies that it may prove valuable as
an adjunct to these agents in hepatic pre-conditioning.
We found that PIF / dermcidin mRNA was not expressed by unsorted fetal
liver cells but was produced by those selected for the markers CD34 and CD90.
CD34 is a cell surface glycoprotein originally identified on cells from the immature
human myeloid cell line KG-1 and subsequently demonstrated to be expressed on
haemopoietic stem cells capable of differentiating into either biliary cells or
hepatocytes (Civin et al. 1984, Theise et al. 2000, Lanza et al. 2001, Crosby et al.
2001). CD90 is also a haemopoietic stem cell marker, the expression ofwhich
correlates with liver-specific gene expression and which jointly stains hepatic oval
cells with CD34 (Petersen et al. 1998, Okumoto et al. 2003). The co-expression of
PIF / dermcidin with both of these cluster determinants therefore raises the
possibility that it may be a marker ofbi-potential stem cells. This would be in
keeping with the effects ofPIF on liver cell ICAM-1 and VCAM expression and
syndecan shedding, which have lead to the suggestion of a role in development
(Watchorn et al. 2001, Watchorn et al. 2002). To more firmly establish this role,
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further studies of PIF protein expression and culture from limiting dilutions of
potential stem cells will be required.
The targetting of PIF / dermcidin to the secretory pathway in HuH7 cells
raises the question of why previous studies which have used immunological methods
to detect glycosylated PIF have always required cell lysates, as opposed to
supernatants, for success (Todorov et al. 1996a, Todorov et al. 1999). One
explanation could be that PIF is processed differently in these cells and is retained in
the cytosol. The antibody used in these studies appears to recognise a glycosylated
epitope (Todorov et al. 1997), and glycosylation of the PIF core could be a signal for
intracellular retention. However, this does not explain the finding that in vivo, studies
using the same antibody have demonstrated PIF in urine and suggest that it may be
found, bound to albumin, in serum (Todorov et al. 1996a, Wigmore et al. 2000). This
may be explained were cell lysis to be required for PIF to enter the extracellular
compartment. The alternative hypothesis, that the peptide is somehow secondarily
glycosylated following secretion, does not seem likely given its identification in cell
lysates. Further studies of the antigen specificity of the different antibodies and
careful analysis of glycosylation in different cell types will be help to address these
issues.
The importance of asparagine residues in the PIF / dermcidin
polypeptide
In our in vitro systems, PIF / dermcidin did not appear to be glycosylated.
Use of the anti-glycosylated PIF monoclonal antibody, which also detected CD59,
did not demonstrate any bands with the molecular weight of glycosylated PIF on
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Western blotting or immunoprecipitation. Similarly, the use of rabbit polyclonal anti-
PIF peptide demonstrated only products with molecular weights corresponding to
aggregated or albumin-bound PIF. Furthermore, the asparagine residues of human
PIF do not lie in classical consensus N-glycosylation sites. Despite the possibility
that they may represent atypical or novel glycosylation sites, mutation of both
residues to glutamines also did not affect the molecular weight ofPIF detected by
either Western blotting or in vitro translation. In vivo, we were also unable to detect
glycosylated PIF in the urines ofweight losing patients with pancreatic carcinoma by
Western blotting and neither glycosylated nor unglycosylated PIF / dermcidin were
detectable by MALDI-TOF mass spectrometry. These findings are in agreement with
those ofMonitto et al. (2004), who were unable to demonstrate PIF glycosylation in
a range of cell types and did not find overexpressing cell lines to be pro-cachectic.
Previous studies on Y-P30 have also suggested it is not glycosylated (Cunningham et
al. 1998, Porter et al. 2003). These findings do not exclude the possibility that PIF
glycosylation is detectable under different circumstances, such as in cachexia, for
which glycosylation appears to be required.
The inhibition ofPIF / dermcidin's survival benefits and proliferative effects
by mutation of both asparagine residues suggests that in combination, they are
important to this function. Whether this is due to an effect on the potential
phosphatase domain or on receptor binding is not clear. Studies comparing the
survival and proliferative effects of synthetic peptides containing asparagine to
glutamine substitution with the wild type PIF core peptide and identification of the
PIF receptor will help to clarify the role of these residues.
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The importance of the PIF core peptide to PIF / dermcidin function
Our results demonstrate that the PIF core peptide is sufficient to induce HuH7
cell proliferation. This is consistent with studies showing the proliferative effects of
DSEP transfection, which implied but did not confirm that these were due to the Y-
P30 portion of the molecule (Cunningham et al. 2002, Porter et al. 2003). Potentially
therefore, proteolytic processing of the nascent PIF / dermcidin transcript as
suggested by Schittek et al. (2001) may result in the production of a signal peptide, a
peptide with proliferative effects, an antibiotic peptide and an as yet uncharacterised
'pro-peptide'. Why and how these peptides with such different functions should arise
from the same gene is unclear. In the hypothalamus, the pro-opiomelanocortin
(POMC) polypeptide is cleaved to give rise to several hormones (Chretien and
Seidah 1981). Different forms ofPOMC-derived peptides are secreted depending on
the proteolysis and glycosylation of the full-length precursor and secretion of one
form ofPOMC peptide may occur without the secretion of another (Chretien and
Seidah 1981). It is feasible that the production ofPIF / dermcidin peptides may
similarly be separately regulated. This could explain the previously reported
differences in PIF expression and glycosylation (Todorov et al. 1996a, Monitto et al.
2004). Alternatively, the functions of the PIF / dermcidin peptides may have evolved
to act in concert, potentially in response to an as yet unidentified stimulus. For
example, it is feasible that secretion of anti-bacterial and pro-survival / proliferation
peptides might benefit cells under conditions of oxidative stress in bacterial infection
(Liaudet et al. 2002). Identification of the mechanisms controlling PIF / dermcidin
expression, confirmation that proteolytic processing occurs, identification of the
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proteases responsible and determination of the destinations of the peptides produced
will address these issues.
Several mechanisms may potentially account for the effect of the PIF core
peptide. Firstly, this peptide contains the sequence with homology to the phosphatase
domain of calcineurin and has previously been demonstrated to cleave p-nitrophenyl
phosphate (Cunningham et al. 1998). Our results suggest that this may be important
for the induction of cell proliferation and potentially also for protection from
oxidative stress. However, as calcineurin has not been reported to stimulate cell
proliferation it seems likely that the PIF phosphatase will act on different targets. As
yet, these remain unknown. Secondly, the PIF core peptide may exert its effects
through interactions with calreticulin. It has been suggested that the survival effect of
Y-P30 involves binding to cell surface calreticulin, inducing its translocation to the
cytoplasm and resulting in increased calcium binding and subsequent protection from
reactive oxygen intermediaries (Cunningham et al. 2000). However, what effect this
may have on proliferation in our system is difficult to determine, as calcium has
previously been demonstrated to induce the proliferation of normal hepatocytes but
not malignant cells (Swierenga et al. 1980). Thirdly, the PIF core peptide might
feasibly act by interacting with one of the uncharacterised PIF receptors. Given the
small size of the peptide, it is possible that the H35N and N32QN44Q mutations may
interfere with core peptide binding one of these receptors or alternatively, to
calreticulin or the phosphatase target. Investigation of the biological and phosphatase
activity ofmutation-containing synthetic peptides and their binding patterns will help
elucidate which of these mechanisms are important in cell survival and proliferation.
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Characterisation of the urinary proteome and PIF excretion
Using mass spectrometry, we have demonstrated proteins in the urines of
patients with pancreatic carcinoma which are not present in the urines of healthy
individuals. Although we did not quantify these changes, they are unlikely to be of
the correct order ofmagnitude to affect overall nitrogen balance as nephrotic
syndrome is rare in patients with malignant disease (Lund et al. 1989) and the
proteins found therefore potentially reflect other aspects of the neoplastic process.
Although they may subsequently prove to be important tumour markers, as yet little
is known of their function. This reflects the power of proteomic technology to
identify proteins which may have been sequenced only as part of the human genome
project or described in minimal detail in the literature. However, to identify their
clinical relevance studies with sufficient numbers of patients to prove statistical
significance will be required. Similarly, to identify their possible relevance as
therapeutic targets, conventional scientific assessment of their biological function is
necessary. These caveats are often levelled as criticisms of'fishing expeditions' using
genomic technology. However, changes in the overall patterns of protein expression
may also act as tumour markers and could reflect biological processes of therapeutic
importance. In non-urinary tract cancers changes in the urinary proteome may
potentially be of increased importance as these tumours cannot directly secrete
proteins into urine. Changes in the proteome may therefore reflect not only
abnormalities in renal function but also the presence of abnormal proteins in the
circulation. The urinary proteomes of patients with pancreatic carcinoma therefore
provide a potential insight into the pathophysiologies of cancer and cachexia and
their relationship with renal function.
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We identified two proteins in the urines of patients with pancreatic carcinoma
which have not previously been reported in normal urine, mitogen-activated protein
kinase kinase kinase 3 isoform 1 (MEKK3) and APC-binding protein EB1 (Nedelkov
and Nelson 2001, Thongboonkerd et al. 2002, Pisitkun et al. 2004). EB-1 interacts
directly with the tumour-suppressor APC, linking it to microtubules (Mimori-
Kiyosue et al. 2000). MEKK3 has been demonstrated to inhibit apoptosis through
NE-kB activation and is overexpressed in certain tumours (Samanta et al. 2004). It is
therefore feasible that these proteins may influence progression or cachexia in
pancreatic cancer. Studies of their expression by tumour cells and their effects on
progression and malignancy will help to determine their roles.
The significance of the other proteins we identified in the urines assayed is
difficult to determine. Mannose binding lectin-associated serine protease-2 related
protein (MBP2-RP), immunoglobulin light chains, the alpha-1-
microglobulin/bikunin precursor and keratin have all previously been detected in
normal urine (Nedelkov and Nelson 2001, Thongboonkerd et al. 2002, Pisitkun et al.
2004). However, the passage of these proteins into urine may be altered by disease,
particularly those affecting the kidneys and urinary tract (Ostergaard et al. 1997,
Vlahou et al. 2001, Thongboonkerd 2004). In this respect, al-microblobulin and
bikunin have been investigated extensively as markers of renal function and it has
been suggested that urinary al-microglobulin may be a marker of asymptomatic
renal tubular dysfunction (Yu et al. 1983). Both al-microglobulin and bikunin are
abundant serum glycoproteins (Vetr and Gebhard 1990) and it is therefore feasible
that their presence in urine may be due to an effect of the neoplastic or cachectic
processes on renal function. In favour of cachexia being the relevant pathology are
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the findings that bikunin has negative effects on the malignancy of ovarian
carcinoma and serum al-microglobulin levels do not correlate with the presence of
neoplasia (Takagi et al. 1980, Tanaka et al. 2004). Altered renal function may also
potentially account for the presence ofMBP2-RP, immunoglobulin light chains and
keratin in urine. Certainly, urinary immunoglobulin excretion has been demonstrated
to be elevated in prostatic and renal carcinoma and is thought to reflect glomerular
damage (Hemmingsen and Skaarup 1977, Abdul and Hoosein 1995). In pancreatic
carcinoma the production of immunoglobulins is also known to be both qualitatively
different and greater in comparison with the normal pancreas (Goodale et al. 1979,
Goodale, Jr. et al. 1981, Maacke et al. 2002). Ultimately, changes in urinary protein
excretion may contribute to the negative nitrogen balance of cachexia and could
potentially prove to be an important indicator of the cachectic process. Larger
studies to investigate the significance of this process and the importance of
individual urinary proteins appear warranted.
Implications of PIF / dermcidin - induced cell proliferation and
survival for the development of cachexia
Although the mechanisms by which cachexia develops are increasingly well
understood, little is known of the reasons why tumours produce pro-cachectic
substances. One theory is that production of cachectic factors may bestow a survival
advantage on tumour cells. This would suggest that the metabolic changes of
cachexia develop as a by-product of oversecretion of these molecules. However, it is
feasible that this alteration in metabolism may also benefit the tumour, selecting for
cells which are capable of survival in adverse conditions. In particular, levels of
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oxidative stress are often high within tumours (Pelicano et al. 2004). Subsequently,
P1F / dermcidin expression would again be expected to benefit cells, and a form of
positive feedback loop could develop.
We found that the unglycosylated PIF core peptide is sufficient to induce cell
proliferation and that the survival benefits ofPIF / dermcidin expression do not
require glycosylation. It has previously been suggested that unglycosylated PIF is
unlikely to induce cachexia (Monitto et al. 2004) and it would therefore seem
feasible that the stimulation of cell growth and survival are the primary functions of
the unglycosylated molecule. In contrast, studies of glycosylated PIF suggest that this
form is capable of inducing muscle proteolysis and alterations in hepatic gene
expression (Todorov et al. 1996a, Watchorn et al. 2001) and that glycosylation is
required for the action on muscle (Todorov et al. 1997). Glycosylation subsequently
appears to be a key event which may potentially separate PIF / dermcidin's growth
and survival promoting effects of from its pro-cachectic ones. Differential
glycosylation may also help to explain the difficulties in the immunological detection
ofPIF. We did not find PIF / dermcidin to be glycosylated in either HuH7 cell or our
in vitro translation system and unglycosylated PIF / dermcidin has previously been
demonstrated in neuronal cells and several overexpressing cell lines (Cunningham et
al. 1998, Monitto et al. 2004). In contrast, PIF purified by affinity-chromatography
from the MAC16 cell line and from the urines of patients with pancreatic carcinoma
appears to be glycosylated. Identification of the stage at which PIF becomes
glycosylated may subsequently reveal cellular abnormalities contributing to
cachexia. Tumours are known to exhibit abnormal patterns of glycosylation, which
may change with progression (Kannagi et al. 2004). Interestingly, the PIF core
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peptide lacks consensus sequences for N-glycosylation and would therefore not be
expected to be a target of the principle N-glycosylating enzymes (Welply et al.
1983). Investigation of PIF glycosylation therefore has the potential to reveal novel
cellular biochemistry as well as improve our understanding ofPIF / dermcidin
biology.
The importance of PIF / dermcidin in pancreatic carcinoma
We have demonstrated that PIF / dermcidin is widely expressed in human
pancreatic carcinoma cell lines. In addition, the HuH7 cell line did not exhibit PIF /
dermcidin expression, suggesting an association between cell lines derived from
cachexia-inducing tumours and PIF / dermcidin expression. However, it has
previously been reported that in vivo only 2 of 64 pancreatic tumours demonstrated
PID / dermcidin expression (Porter et al. 2003), and this is consistent with our
findings of a restrictive expression pattern both by immunological and PCR analysis
of tumours and urinary analysis. Furthermore, glycosylation is required for the
induction of muscle proteolysis (Todorov et al. 1997). Subsequently, a direct link
between PIF / dermcidin expression in vitro and the induction of cachexia in vivo
does not appear to exist, although the production ofPIF / dermcidin mRNA would be
necessary for any cachectic effect. The role ofPIF may therefore be restricted to a
subset of carcinomas. In these tumours, PIF may have the potential to influence cell
growth and survival and subsequently progression. Examination of expressing
tumours will help to identify characteristics associated with PIF / dermcidin
expression, for example malignancy and cachexia. Furthermore, it may lead to the
establishment ofPIF / dermcidin's position in the PIN - carcinoma sequence. The low
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frequency of expression observed suggests that it is unlikely to be a central molecule
in this process, but could be important at later stages when the development of
oxidative stress provides a selective pressure for expression. If so, it may be of
relevance to the prognosis of these tumours. Oxidative stress is known to contribute
to the malignancy of cancer (Pelicano et al. 2004). Furthermore, many cancer
therapies function via the induction of oxidative stress (Renschler 2004) and tumour
cell resistance to this may subsequently confer resistance to these agents. PIF /
dermcidin expression may therefore potentially influence the poor clinical outcome
in these patients through effects on tumour progression, resistance to therapy and
development of cachexia.
Oxidative stress may also potentially account for the more widespread in
vitro expression ofPIF / dermcidin. In culture, cells must survive in an altered
nutritional environment and with different oxygenation to in vivo conditions. This
may result in higher levels of oxidative stress (Lluis et al. 2005). As yet, the only
stimulus for PIF / dermcidin expression to be identified is oxidative stress
(Cunningham et al. 1998) and this may therefore stimulate in vitro expression.
Alternatively, another effect of the culture environment may influence expression via
one of the many putative transcription factor binding sites in the PIF / dermcidin
promoter. Elucidating the mechanisms controlling expression may aid in
understanding the differences between in vitro and in vivo expression.
Limitations of the current studies
There were some areas in which it was not possible to fully achieve our aims.
We were technically unable to demonstrate PIF / dermcidin protein production
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immunologically. In vitro, it was possible to confirm expression at the mRNA level
although expression in HuH7 cells appeared to be variable and potentially inducible
in prolonged culture necessitating careful validation of results. We were unable to
detect PIF / dermcidin expression in vivo, possibly due to the difficulty of preparing
high-quality RNA from pancreatic samples but also possibly reflecting the low level
of expression reported by other authors (Porter et al. 2003). We were subsequently
unable to fully relate our laboratory studies to the clinical situation or to resolve the
conflicting evidence from previous studies regarding PIF expression. However, the
technical difficulty we experienced does raise the possibility that the available anti-
PIF antibodies, particularly the monoclonal anti-glycosylated PIF antibody, are not
as reliable as previously thought and that previous work based on this antibody
should perhaps be re-evaluated using new antibodies.
The transfection ofmammalian overexpression vectors is a useful technique
but may produce results which are not relevant to the physiological function of a
gene. The HuH7 cell line has not been characterised for the expression ofPIF /
dermcidin receptors and it is subsequently not possible to say whether its response to
overexpression is either typical or representative of the in vivo situation.
Overexpression vectors result in the unregulated production of large amounts of
mRNA for the gene of interest and feedback or other methods of control of
expression are subsequently not possible. Studies of gene function using this method
are therefore usefully supported by studies using RNAi, transgenic animals and more
traditional methods of promoter and expression analysis.
It was not possible to recruit sufficient patients with pancreatic carcinoma in
the available time to draw statistically significant conclusions regarding their urinary
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proteomic profiles. In addition, the need to develop this technology restricted the
time available to fully analyse all patients' urine samples using mass spectrometry of
tryptic digests. These factors leave several opportunities for the future study of this
promising technique.
Conclusion
Proteolysis inducing factor / dermcidin is a novel molecule with multiple
functions in muscle proteolysis, hepatic metabolism, the innate immune system and
cell survival and proliferation. These functions may be relevant in a range of
physiological and pathological processes including cachexia and neoplasia. This
thesis has described the effect of expression on cell survival and proliferation in a
hepatic carcinoma cell line system. Within the molecule, an important structure for
these effects appears to be the PEF core peptide, which may act through the
calcineurin-like phosphatase domain or potentially via receptor interaction and
effects on oxidative stress and the proteasome. This thesis also attempted to relate
these findings to the role ofPIF / dermcidin in pancreatic carcinoma and cachexia,
although problems with the detection of glycosylated PIF by immunological methods
prevented this aim from being fulfilled. In attempting to develop an alternative
method of detecting urinary PIF / dermcidin MALDI-TOF mass spectrometry
revealed changes in the urinary proteome of patients with pancreatic carcinoma.
Further studies of the in vivo roles of these proteins and ofPIF / dermcidin has the
potential to further improve our understanding of tumorigenesis, cachexia and the
cellular processes which underlie them.
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Appendix A - Patient Data Collection Proforma





Duration of symptoms -
N ame/Addressograph
Date of Diagnosis -
Co-morbidity/PMH -
Current Health (eg URTI) - Smoker




ASA Pre-illness stable weight
Pre-illness BMI
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Head / neck / body




Staging Investigations - CT T N M
Tumour volume
- EUS T N M
- Lap/LUS T N M
- CXR
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Investigations
















Ischaemic time - Whipples - time from transaction of neck to freezing =
Other - time from specimen removal to freezing =
Skeletal muscle taken Y/N
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LCM
Site of cell collection (eg core, rim) -
PCR
mRNA PCR Level















Date of Recurrence -
Date of death -
Cause of death -
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Appendix B - Karnofsky Index
Normal, no complaints 100
Able to carry out normal activities, minor signs of disease 90
Normal activity but with effort 80
Self-caring but unable to carry out normal activity or work 70
Requires occasional assistance but able to care for most needs 60
Requires considerable assistance and frequent medical care 50
Disabled, requires special care and assistance 40
Severely disabled, hospitalization indicated although death not imminent 30




Appendix C - Patient Information Sheet and Consent Form
Transcriptional Regulation of Proteolysis Inducing Factor in Pancreatic Carcinoma
A Study into Weight Loss in Patients with Pancreatic
Cancer
(Version 2)
You are being invited to take part in a research study. Before you decide it is important for you to
understand why the research is being done and what it will involve. Please take time to read the
following information carefully and discuss it with others ifyou wish. Ask us if there is anything
that is not clear or ifyou would like more information. Take time to decide whether or not you
wish to take part.
Thank you for reading this
What is the purpose of the study?
Proteolysis inducing factor (PIF) is a molecule detected in the urine of patients with pancreatic tumours. Its
presence is associated with increased weight loss. PIF is not found in the body normally, and we plan to
confirm that it is produced by tumour cells and investigate why. We will do this by DNA analysis of the
tumour and by analysis of your urine for PIF and other molecules which might cause weight loss or affect
the behaviour of the tumour.
Why have I been chosen?
We plan to look at PIF production in tumours which have been removed surgically. You have been chosen
as we believe you have this type of tumour and your planned treatment is surgery.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still free to
withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision not to
take paid, will not affect the standard of care you receive.
What will happen to me if I take part?
Your treatment will not be altered by taking part in our study. For the experiments we are planning, we
need a sample of your tumour which we will take at the time of surgery. If it is possible to remove the
tumour we will take it to the pathologist who will take the sample for us. If it is not possible to remove the
tumour your surgeon will take an additional biopsy sample (about the size of the head of a matchstick) for
the study. We also need a urine sample before the operation, and access to the results of some of the blood
tests which have been performed.
You should be aware that it will not be possible to return the samples of tumour or urine to you once they
have been taken.
What do I have to do?
We would be grateful if you could pass 200ml (about 1 mug) of urine into the container provided.
Otherwise, your treatment will continue unchanged.
What is the drug or procedure being tested?
We are not testing any drugs or procedures. You will receive treatment for your condition as normal.
What are the side effects of any treatment received when taking part?
Your treatment will proceed as normal and any side effects will be dealt with as normal.
What are the possible disadvantages and risks of taking part?
If we take an additional biopsy sample you will be exposed to the associated risks of bleeding, leakage
from the pancreas and inflammation of the pancreas. If your surgeon is able to remove the tumour the only
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risk is that by removing a part of your tumour we could affect the information gained from it by the
pathologists. To avoid this, all samples will be taken under their guidance.
What are the possible benefits of taking part?
As your treatment will be unchanged, there is no direct benefit to you for taking part. However, you will be
helping research into cancer, and specifically into the reasons why people with cancer lose weight.
What if new information becomes available?
Sometimes during the course of a research project, new information becomes available about the subject
being studied. If this happens your research doctor will tell you about it and discuss with you any changes
in the way your samples will be used. If you decide to continue in the study you will be asked to sign an
updated consent form.
Also, on receiving new information your research doctor may consider it necessary to withdraw you from
the study. He / she will explain the reasons and arrange for your care to continue.
What happens when the research study stops?
Your treatment and follow up will continue as normal.
What if something goes wrong?
If you are harmed by taking part in this research project, there are no special compensation arrangements.
If you are harmed due to someone's negligence, then you may have grounds for a legal action but you may
have to pay for it. Regardless of this, if you wish to complain, or have any concerns about any aspect of the
way you have been approached or treated during the course of this study, the normal National Health
Service complaints mechanisms should be available to you.
Will my taking part in this study be kept confidential?
Yes. All information which is collected about you during the course of the research will be kept strictly
confidential. Any information about you which leaves the hospital/surgery will have your name and address
removed so that you cannot be recognised from it.
If you agree, we will write to your GP and inform them of your involvement in the study.
What will happen to the results of the research study?
We plan to continue the study until 2004. We will then analyze the results and hope to publish them in a
medical journal. You will not be identified in any publication. If you would like a copy of the results,
please contact the lead researcher around December 2004.
Who is organizing and funding the research?
This research is supported by the University of Edinburgh Department of Surgery at the Royal Infirmary of
Edinburgh.
Who has reviewed the study?
The Local Research and Ethics Committee of the Royal Infirmary of Edinburgh.
Contact for further information
If you would like to know more, please contact the lead researcher -
Mi". A. Lowrie
Tissue Injury and Repair Group
Centre for Inflammation Research (6th Floor)




Thank you for talcing part.
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Appendix C - Patient Information Sheet and Consent Form
CONSENT FORM
Transcriptional Regulation of Proteolysis Inducing Factor in Pancreatic
Cancer
A Study into Weight Loss in Patients
with Pancreatic Cancer
Version 2
Name of Researcher: Mr A. Lowrie, Tissue Injury and Repair Group, Centre for
Inflammation Research (6th Floor), School of Clinical Sciences and Community Health,
University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG Tel - 0131
650 2879
Please initial box
1. I confirm that I have read and understand the information sheet dated
for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to
withdraw at any time, without giving any reason, without my medical
care or legal rights being affected.
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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63 M 11 PDA* Resection 500
71 F 4 PDA Resection 112
68 F 7 Serous microcystadenoma Resection >562
50 M 9 Liposarcoma Resection >536
51 F 12 PDA Resection >515
60 M 13 Duodenal carcinoma Resection 171
47 F 5 Ampullary adenocarcinoma Resection >568
52 M 18 Cholangiocarcinoma Resection >447
80 F 10 Ampullary TVA Resection >471
45 M 11 Cholangiocarcinoma Resection 267
65 F 0 Cholangiocarcinoma Resection 341
55 F 0 PDA Bypass 219
74 F 14 PDA Resection 284
52 M 8 Cholangiocarcinoma Resection 254
58 F 13 PDA Bypass 139
77 F 3 PDA Resection >214
45 F 3 Ampullary adenocarcinoma Resection >171
60 F 0 Ampullary adenoma Resection >123
47 M 18 PDA Resection >243
*PDA - Pancreatic ductal adenocarcinoma
Appendix F - Publications arising from work contained in this thesis
Dermcidin expression in hepatic cells improves survival without N-glycosylation but
requires asparagine residues.
Lowrie A. G., Wigmore S. J., Wright D. J., Waddell I., Ross J. A.
British Journal ofCancer, 2006; Jun 5;94(11): 1663-71.
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